#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Default mode network deactivation to smoking cue relative to food cue predicts treatment outcome in nicotine use disorder
#Text=Identifying predictors of treatment outcome for nicotine use disorders (NUD) may help improve efficacy of established treatments, like varenicline.
1-1	0-7	Default	_	
1-2	8-12	mode	_	
1-3	13-20	network	_	
1-4	21-33	deactivation	_	
1-5	34-36	to	_	
1-6	37-44	smoking	_	
1-7	45-48	cue	_	
1-8	49-57	relative	_	
1-9	58-60	to	_	
1-10	61-65	food	_	
1-11	66-69	cue	_	
1-12	70-78	predicts	_	
1-13	79-88	treatment	_	
1-14	89-96	outcome	_	
1-15	97-99	in	_	
1-16	100-108	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[1]	
1-17	109-112	use	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[1]	
1-18	113-121	disorder	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[1]	
1-19	122-133	Identifying	_	
1-20	134-144	predictors	_	
1-21	145-147	of	_	
1-22	148-157	treatment	_	
1-23	158-165	outcome	_	
1-24	166-169	for	_	
1-25	170-178	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[2]	
1-26	179-182	use	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[2]	
1-27	183-192	disorders	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[2]	
1-28	193-194	(	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[2]	
1-29	194-197	NUD	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[2]	
1-30	197-198	)	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[2]	
1-31	199-202	may	_	
1-32	203-207	help	_	
1-33	208-215	improve	_	
1-34	216-224	efficacy	_	
1-35	225-227	of	_	
1-36	228-239	established	_	
1-37	240-250	treatments	_	
1-38	250-251	,	_	
1-39	252-256	like	_	
1-40	257-268	varenicline	_	
1-41	268-269	.	_	

#Text=Brain reactivity to drug-stimuli predicts relapse risk in nicotine and other substance use disorders in some studies.
2-1	270-275	Brain	_	
2-2	276-286	reactivity	_	
2-3	287-289	to	_	
2-4	290-302	drug-stimuli	_	
2-5	303-311	predicts	_	
2-6	312-319	relapse	_	
2-7	320-324	risk	_	
2-8	325-327	in	_	
2-9	328-336	nicotine	_	
2-10	337-340	and	_	
2-11	341-346	other	_	
2-12	347-356	substance	_	
2-13	357-360	use	_	
2-14	361-370	disorders	_	
2-15	371-373	in	_	
2-16	374-378	some	_	
2-17	379-386	studies	_	
2-18	386-387	.	_	

#Text=Activity in the default mode network (DMN) is affected by drug cues and other palatable cues, but its clinical significance is unclear.
3-1	388-396	Activity	_	
3-2	397-399	in	_	
3-3	400-403	the	_	
3-4	404-411	default	_	
3-5	412-416	mode	_	
3-6	417-424	network	_	
3-7	425-426	(	_	
3-8	426-429	DMN	_	
3-9	429-430	)	_	
3-10	431-433	is	_	
3-11	434-442	affected	_	
3-12	443-445	by	_	
3-13	446-450	drug	_	
3-14	451-455	cues	_	
3-15	456-459	and	_	
3-16	460-465	other	_	
3-17	466-475	palatable	_	
3-18	476-480	cues	_	
3-19	480-481	,	_	
3-20	482-485	but	_	
3-21	486-489	its	_	
3-22	490-498	clinical	_	
3-23	499-511	significance	_	
3-24	512-514	is	_	
3-25	515-522	unclear	_	
3-26	522-523	.	_	

#Text=In this study, 143 individuals with nicotine use disorder (NUD) (male n=91, ages 18–55) received a functional MRI scan during a visual cue task during which they were presented with a series of smoking- or food-related video clips prior to randomization to treatment with varenicline (n=80) or placebo.
4-1	524-526	In	_	
4-2	527-531	this	_	
4-3	532-537	study	_	
4-4	537-538	,	_	
4-5	539-542	143	_	
4-6	543-554	individuals	_	
4-7	555-559	with	_	
4-8	560-568	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[3]	
4-9	569-572	use	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[3]	
4-10	573-581	disorder	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[3]	
4-11	582-583	(	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[3]	
4-12	583-586	NUD	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[3]	
4-13	586-587	)	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[3]	
4-14	588-589	(	_	
4-15	589-593	male	_	
4-16	594-595	n	_	
4-17	595-596	=	_	
4-18	596-598	91	_	
4-19	598-599	,	_	
4-20	600-604	ages	_	
4-21	605-607	18	_	
4-22	607-608	–	_	
4-23	608-610	55	_	
4-24	610-611	)	_	
4-25	612-620	received	_	
4-26	621-622	a	_	
4-27	623-633	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
4-28	634-637	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
4-29	638-642	scan	_	
4-30	643-649	during	_	
4-31	650-651	a	_	
4-32	652-658	visual	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
4-33	659-662	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
4-34	663-667	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[5]	
4-35	668-674	during	_	
4-36	675-680	which	_	
4-37	681-685	they	_	
4-38	686-690	were	_	
4-39	691-700	presented	_	
4-40	701-705	with	_	
4-41	706-707	a	_	
4-42	708-714	series	_	
4-43	715-717	of	_	
4-44	718-725	smoking	_	
4-45	725-726	-	_	
4-46	727-729	or	_	
4-47	730-742	food-related	_	
4-48	743-748	video	_	
4-49	749-754	clips	_	
4-50	755-760	prior	_	
4-51	761-763	to	_	
4-52	764-777	randomization	_	
4-53	778-780	to	_	
4-54	781-790	treatment	_	
4-55	791-795	with	_	
4-56	796-807	varenicline	_	
4-57	808-809	(	_	
4-58	809-810	n	_	
4-59	810-811	=	_	
4-60	811-813	80	_	
4-61	813-814	)	_	
4-62	815-817	or	_	
4-63	818-825	placebo	_	
4-64	825-826	.	_	

#Text=Group independent components analysis was utilized to isolate the DMN, and temporal sorting was used to calculate the difference between the DMN BOLD signal during smoke versus food cues for each individual.
5-1	827-832	Group	_	
5-2	833-844	independent	_	
5-3	845-855	components	_	
5-4	856-864	analysis	_	
5-5	865-868	was	_	
5-6	869-877	utilized	_	
5-7	878-880	to	_	
5-8	881-888	isolate	_	
5-9	889-892	the	_	
5-10	893-896	DMN	_	
5-11	896-897	,	_	
5-12	898-901	and	_	
5-13	902-910	temporal	_	
5-14	911-918	sorting	_	
5-15	919-922	was	_	
5-16	923-927	used	_	
5-17	928-930	to	_	
5-18	931-940	calculate	_	
5-19	941-944	the	_	
5-20	945-955	difference	_	
5-21	956-963	between	_	
5-22	964-967	the	_	
5-23	968-971	DMN	_	
5-24	972-976	BOLD	_	
5-25	977-983	signal	_	
5-26	984-990	during	_	
5-27	991-996	smoke	_	
5-28	997-1003	versus	_	
5-29	1004-1008	food	_	
5-30	1009-1013	cues	_	
5-31	1014-1017	for	_	
5-32	1018-1022	each	_	
5-33	1023-1033	individual	_	
5-34	1033-1034	.	_	

#Text=Food cues were associated with greater deactivation compared to smoke cues in the DMN.
6-1	1035-1039	Food	_	
6-2	1040-1044	cues	_	
6-3	1045-1049	were	_	
6-4	1050-1060	associated	_	
6-5	1061-1065	with	_	
6-6	1066-1073	greater	_	
6-7	1074-1086	deactivation	_	
6-8	1087-1095	compared	_	
6-9	1096-1098	to	_	
6-10	1099-1104	smoke	_	
6-11	1105-1109	cues	_	
6-12	1110-1112	in	_	
6-13	1113-1116	the	_	
6-14	1117-1120	DMN	_	
6-15	1120-1121	.	_	

#Text=Correcting for baseline smoking and other clinical variables which have been shown to be related to treatment outcome in previous work, a less positive Smoke-Food difference score predicted greater smoking at 6 and 12 weeks when both treatment groups were combined (p=0.005, beta=−0.766).
7-1	1122-1132	Correcting	_	
7-2	1133-1136	for	_	
7-3	1137-1145	baseline	_	
7-4	1146-1153	smoking	_	
7-5	1154-1157	and	_	
7-6	1158-1163	other	_	
7-7	1164-1172	clinical	_	
7-8	1173-1182	variables	_	
7-9	1183-1188	which	_	
7-10	1189-1193	have	_	
7-11	1194-1198	been	_	
7-12	1199-1204	shown	_	
7-13	1205-1207	to	_	
7-14	1208-1210	be	_	
7-15	1211-1218	related	_	
7-16	1219-1221	to	_	
7-17	1222-1231	treatment	_	
7-18	1232-1239	outcome	_	
7-19	1240-1242	in	_	
7-20	1243-1251	previous	_	
7-21	1252-1256	work	_	
7-22	1256-1257	,	_	
7-23	1258-1259	a	_	
7-24	1260-1264	less	_	
7-25	1265-1273	positive	_	
7-26	1274-1284	Smoke-Food	_	
7-27	1285-1295	difference	_	
7-28	1296-1301	score	_	
7-29	1302-1311	predicted	_	
7-30	1312-1319	greater	_	
7-31	1320-1327	smoking	_	
7-32	1328-1330	at	_	
7-33	1331-1332	6	_	
7-34	1333-1336	and	_	
7-35	1337-1339	12	_	
7-36	1340-1345	weeks	_	
7-37	1346-1350	when	_	
7-38	1351-1355	both	_	
7-39	1356-1365	treatment	_	
7-40	1366-1372	groups	_	
7-41	1373-1377	were	_	
7-42	1378-1386	combined	_	
7-43	1387-1388	(	_	
7-44	1388-1389	p	_	
7-45	1389-1390	=	_	
7-46	1390-1395	0.005	_	
7-47	1395-1396	,	_	
7-48	1397-1401	beta	_	
7-49	1401-1402	=	_	
7-50	1402-1403	−	_	
7-51	1403-1408	0.766	_	
7-52	1408-1409	)	_	
7-53	1409-1410	.	_	

#Text=An exploratory analysis of executive control (ECN) and salience networks demonstrated that a more positive Smoke-Food difference score for ECN predicted a more robust response to varenicline relative to placebo.
8-1	1411-1413	An	_	
8-2	1414-1425	exploratory	_	
8-3	1426-1434	analysis	_	
8-4	1435-1437	of	_	
8-5	1438-1447	executive	_	
8-6	1448-1455	control	_	
8-7	1456-1457	(	_	
8-8	1457-1460	ECN	_	
8-9	1460-1461	)	_	
8-10	1462-1465	and	_	
8-11	1466-1474	salience	_	
8-12	1475-1483	networks	_	
8-13	1484-1496	demonstrated	_	
8-14	1497-1501	that	_	
8-15	1502-1503	a	_	
8-16	1504-1508	more	_	
8-17	1509-1517	positive	_	
8-18	1518-1528	Smoke-Food	_	
8-19	1529-1539	difference	_	
8-20	1540-1545	score	_	
8-21	1546-1549	for	_	
8-22	1550-1553	ECN	_	
8-23	1554-1563	predicted	_	
8-24	1564-1565	a	_	
8-25	1566-1570	more	_	
8-26	1571-1577	robust	_	
8-27	1578-1586	response	_	
8-28	1587-1589	to	_	
8-29	1590-1601	varenicline	_	
8-30	1602-1610	relative	_	
8-31	1611-1613	to	_	
8-32	1614-1621	placebo	_	
8-33	1621-1622	.	_	

#Text=These findings provide further support to theories that brain reactivity to palatable cues, and in particular in DMN, may have direct clinical relevance in NUD.
9-1	1623-1628	These	_	
9-2	1629-1637	findings	_	
9-3	1638-1645	provide	_	
9-4	1646-1653	further	_	
9-5	1654-1661	support	_	
9-6	1662-1664	to	_	
9-7	1665-1673	theories	_	
9-8	1674-1678	that	_	
9-9	1679-1684	brain	_	
9-10	1685-1695	reactivity	_	
9-11	1696-1698	to	_	
9-12	1699-1708	palatable	_	
9-13	1709-1713	cues	_	
9-14	1713-1714	,	_	
9-15	1715-1718	and	_	
9-16	1719-1721	in	_	
9-17	1722-1732	particular	_	
9-18	1733-1735	in	_	
9-19	1736-1739	DMN	_	
9-20	1739-1740	,	_	
9-21	1741-1744	may	_	
9-22	1745-1749	have	_	
9-23	1750-1756	direct	_	
9-24	1757-1765	clinical	_	
9-25	1766-1775	relevance	_	
9-26	1776-1778	in	_	
9-27	1779-1782	NUD	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse	
9-28	1782-1783	.	_	

#Text=Introduction
#Text=There are several efficacious pharmacotherapeutic agents for the treatment of nicotine use disorder (NUD), including buprioprion, varenicline, and nicotine replacement therapies (NRT).
10-1	1784-1796	Introduction	_	
10-2	1797-1802	There	_	
10-3	1803-1806	are	_	
10-4	1807-1814	several	_	
10-5	1815-1826	efficacious	_	
10-6	1827-1846	pharmacotherapeutic	_	
10-7	1847-1853	agents	_	
10-8	1854-1857	for	_	
10-9	1858-1861	the	_	
10-10	1862-1871	treatment	_	
10-11	1872-1874	of	_	
10-12	1875-1883	nicotine	_	
10-13	1884-1887	use	_	
10-14	1888-1896	disorder	_	
10-15	1897-1898	(	_	
10-16	1898-1901	NUD	_	
10-17	1901-1902	)	_	
10-18	1902-1903	,	_	
10-19	1904-1913	including	_	
10-20	1914-1925	buprioprion	_	
10-21	1925-1926	,	_	
10-22	1927-1938	varenicline	_	
10-23	1938-1939	,	_	
10-24	1940-1943	and	_	
10-25	1944-1952	nicotine	_	
10-26	1953-1964	replacement	_	
10-27	1965-1974	therapies	_	
10-28	1975-1976	(	_	
10-29	1976-1979	NRT	_	
10-30	1979-1980	)	_	
10-31	1980-1981	.	_	

#Text=In particular, varenicline, a partial agonist at the nicotinic acetylcholinergic receptor is associated with higher quit rates compared to NRT and buproprion, with no evidence of a significant increase in serious adverse events.
11-1	1982-1984	In	_	
11-2	1985-1995	particular	_	
11-3	1995-1996	,	_	
11-4	1997-2008	varenicline	_	
11-5	2008-2009	,	_	
11-6	2010-2011	a	_	
11-7	2012-2019	partial	_	
11-8	2020-2027	agonist	_	
11-9	2028-2030	at	_	
11-10	2031-2034	the	_	
11-11	2035-2044	nicotinic	_	
11-12	2045-2062	acetylcholinergic	_	
11-13	2063-2071	receptor	_	
11-14	2072-2074	is	_	
11-15	2075-2085	associated	_	
11-16	2086-2090	with	_	
11-17	2091-2097	higher	_	
11-18	2098-2102	quit	_	
11-19	2103-2108	rates	_	
11-20	2109-2117	compared	_	
11-21	2118-2120	to	_	
11-22	2121-2124	NRT	_	
11-23	2125-2128	and	_	
11-24	2129-2139	buproprion	_	
11-25	2139-2140	,	_	
11-26	2141-2145	with	_	
11-27	2146-2148	no	_	
11-28	2149-2157	evidence	_	
11-29	2158-2160	of	_	
11-30	2161-2162	a	_	
11-31	2163-2174	significant	_	
11-32	2175-2183	increase	_	
11-33	2184-2186	in	_	
11-34	2187-2194	serious	_	
11-35	2195-2202	adverse	_	
11-36	2203-2209	events	_	
11-37	2209-2210	.	_	

#Text=However, more than 80% of individuals entering treatment, even when treated with varenicline, end up relapsing by 6 months.
12-1	2211-2218	However	_	
12-2	2218-2219	,	_	
12-3	2220-2224	more	_	
12-4	2225-2229	than	_	
12-5	2230-2233	80%	_	
12-6	2234-2236	of	_	
12-7	2237-2248	individuals	_	
12-8	2249-2257	entering	_	
12-9	2258-2267	treatment	_	
12-10	2267-2268	,	_	
12-11	2269-2273	even	_	
12-12	2274-2278	when	_	
12-13	2279-2286	treated	_	
12-14	2287-2291	with	_	
12-15	2292-2303	varenicline	_	
12-16	2303-2304	,	_	
12-17	2305-2308	end	_	
12-18	2309-2311	up	_	
12-19	2312-2321	relapsing	_	
12-20	2322-2324	by	_	
12-21	2325-2326	6	_	
12-22	2327-2333	months	_	
12-23	2333-2334	.	_	

#Text=Searching for individual characteristics to predict outcomes to particular treatments for substance use disorders (SUD) has been a focus of research for over 3 decades with the idea that by matching treatments to particular subgroups more likely to benefit, treatment efficacy can be enhanced.
13-1	2335-2344	Searching	_	
13-2	2345-2348	for	_	
13-3	2349-2359	individual	_	
13-4	2360-2375	characteristics	_	
13-5	2376-2378	to	_	
13-6	2379-2386	predict	_	
13-7	2387-2395	outcomes	_	
13-8	2396-2398	to	_	
13-9	2399-2409	particular	_	
13-10	2410-2420	treatments	_	
13-11	2421-2424	for	_	
13-12	2425-2434	substance	_	
13-13	2435-2438	use	_	
13-14	2439-2448	disorders	_	
13-15	2449-2450	(	_	
13-16	2450-2453	SUD	_	
13-17	2453-2454	)	_	
13-18	2455-2458	has	_	
13-19	2459-2463	been	_	
13-20	2464-2465	a	_	
13-21	2466-2471	focus	_	
13-22	2472-2474	of	_	
13-23	2475-2483	research	_	
13-24	2484-2487	for	_	
13-25	2488-2492	over	_	
13-26	2493-2494	3	_	
13-27	2495-2502	decades	_	
13-28	2503-2507	with	_	
13-29	2508-2511	the	_	
13-30	2512-2516	idea	_	
13-31	2517-2521	that	_	
13-32	2522-2524	by	_	
13-33	2525-2533	matching	_	
13-34	2534-2544	treatments	_	
13-35	2545-2547	to	_	
13-36	2548-2558	particular	_	
13-37	2559-2568	subgroups	_	
13-38	2569-2573	more	_	
13-39	2574-2580	likely	_	
13-40	2581-2583	to	_	
13-41	2584-2591	benefit	_	
13-42	2591-2592	,	_	
13-43	2593-2602	treatment	_	
13-44	2603-2611	efficacy	_	
13-45	2612-2615	can	_	
13-46	2616-2618	be	_	
13-47	2619-2627	enhanced	_	
13-48	2627-2628	.	_	

#Text=In alcohol use disorders (AUD), some progress has been made for some of the pharmacotherapeutic agents.
14-1	2629-2631	In	_	
14-2	2632-2639	alcohol	_	
14-3	2640-2643	use	_	
14-4	2644-2653	disorders	_	
14-5	2654-2655	(	_	
14-6	2655-2658	AUD	_	
14-7	2658-2659	)	_	
14-8	2659-2660	,	_	
14-9	2661-2665	some	_	
14-10	2666-2674	progress	_	
14-11	2675-2678	has	_	
14-12	2679-2683	been	_	
14-13	2684-2688	made	_	
14-14	2689-2692	for	_	
14-15	2693-2697	some	_	
14-16	2698-2700	of	_	
14-17	2701-2704	the	_	
14-18	2705-2724	pharmacotherapeutic	_	
14-19	2725-2731	agents	_	
14-20	2731-2732	.	_	

#Text=In NUD, the majority of the studies that have tried have not been able to identify subgroups more likely to respond to buproprion, NRT or varenicline.
15-1	2733-2735	In	_	
15-2	2736-2739	NUD	_	
15-3	2739-2740	,	_	
15-4	2741-2744	the	_	
15-5	2745-2753	majority	_	
15-6	2754-2756	of	_	
15-7	2757-2760	the	_	
15-8	2761-2768	studies	_	
15-9	2769-2773	that	_	
15-10	2774-2778	have	_	
15-11	2779-2784	tried	_	
15-12	2785-2789	have	_	
15-13	2790-2793	not	_	
15-14	2794-2798	been	_	
15-15	2799-2803	able	_	
15-16	2804-2806	to	_	
15-17	2807-2815	identify	_	
15-18	2816-2825	subgroups	_	
15-19	2826-2830	more	_	
15-20	2831-2837	likely	_	
15-21	2838-2840	to	_	
15-22	2841-2848	respond	_	
15-23	2849-2851	to	_	
15-24	2852-2862	buproprion	_	
15-25	2862-2863	,	_	
15-26	2864-2867	NRT	_	
15-27	2868-2870	or	_	
15-28	2871-2882	varenicline	_	
15-29	2882-2883	.	_	

#Text=For varenicline, a few exceptions to this exist.
16-1	2884-2887	For	_	
16-2	2888-2899	varenicline	_	
16-3	2899-2900	,	_	
16-4	2901-2902	a	_	
16-5	2903-2906	few	_	
16-6	2907-2917	exceptions	_	
16-7	2918-2920	to	_	
16-8	2921-2925	this	_	
16-9	2926-2931	exist	_	
16-10	2931-2932	.	_	

#Text=Studies have identified associations between activation in brain areas related to attentiveness and memory while resisting an urge to smoke, the presence of certain nAChR subunit genes, and nicotine metabolism rates and treatment outcome to varenicline.
17-1	2933-2940	Studies	_	
17-2	2941-2945	have	_	
17-3	2946-2956	identified	_	
17-4	2957-2969	associations	_	
17-5	2970-2977	between	_	
17-6	2978-2988	activation	_	
17-7	2989-2991	in	_	
17-8	2992-2997	brain	_	
17-9	2998-3003	areas	_	
17-10	3004-3011	related	_	
17-11	3012-3014	to	_	
17-12	3015-3028	attentiveness	_	
17-13	3029-3032	and	_	
17-14	3033-3039	memory	_	
17-15	3040-3045	while	_	
17-16	3046-3055	resisting	_	
17-17	3056-3058	an	_	
17-18	3059-3063	urge	_	
17-19	3064-3066	to	_	
17-20	3067-3072	smoke	_	
17-21	3072-3073	,	_	
17-22	3074-3077	the	_	
17-23	3078-3086	presence	_	
17-24	3087-3089	of	_	
17-25	3090-3097	certain	_	
17-26	3098-3103	nAChR	_	
17-27	3104-3111	subunit	_	
17-28	3112-3117	genes	_	
17-29	3117-3118	,	_	
17-30	3119-3122	and	_	
17-31	3123-3131	nicotine	_	
17-32	3132-3142	metabolism	_	
17-33	3143-3148	rates	_	
17-34	3149-3152	and	_	
17-35	3153-3162	treatment	_	
17-36	3163-3170	outcome	_	
17-37	3171-3173	to	_	
17-38	3174-3185	varenicline	_	
17-39	3185-3186	.	_	

#Text=To date, no studies have identified whether brain activation during smoking cues predict treatment outcome on varenicline, however.
18-1	3187-3189	To	_	
18-2	3190-3194	date	_	
18-3	3194-3195	,	_	
18-4	3196-3198	no	_	
18-5	3199-3206	studies	_	
18-6	3207-3211	have	_	
18-7	3212-3222	identified	_	
18-8	3223-3230	whether	_	
18-9	3231-3236	brain	_	
18-10	3237-3247	activation	_	
18-11	3248-3254	during	_	
18-12	3255-3262	smoking	_	
18-13	3263-3267	cues	_	
18-14	3268-3275	predict	_	
18-15	3276-3285	treatment	_	
18-16	3286-3293	outcome	_	
18-17	3294-3296	on	_	
18-18	3297-3308	varenicline	_	
18-19	3308-3309	,	_	
18-20	3310-3317	however	_	
18-21	3317-3318	.	_	

#Text=Predicting outcomes in general during treatment is also important; clinically it can help inform decisions about treatment intensity such as those regarding high versus low doses or combined treatments versus single treatments.
19-1	3319-3329	Predicting	_	
19-2	3330-3338	outcomes	_	
19-3	3339-3341	in	_	
19-4	3342-3349	general	_	
19-5	3350-3356	during	_	
19-6	3357-3366	treatment	_	
19-7	3367-3369	is	_	
19-8	3370-3374	also	_	
19-9	3375-3384	important	_	
19-10	3384-3385	;	_	
19-11	3386-3396	clinically	_	
19-12	3397-3399	it	_	
19-13	3400-3403	can	_	
19-14	3404-3408	help	_	
19-15	3409-3415	inform	_	
19-16	3416-3425	decisions	_	
19-17	3426-3431	about	_	
19-18	3432-3441	treatment	_	
19-19	3442-3451	intensity	_	
19-20	3452-3456	such	_	
19-21	3457-3459	as	_	
19-22	3460-3465	those	_	
19-23	3466-3475	regarding	_	
19-24	3476-3480	high	_	
19-25	3481-3487	versus	_	
19-26	3488-3491	low	_	
19-27	3492-3497	doses	_	
19-28	3498-3500	or	_	
19-29	3501-3509	combined	_	
19-30	3510-3520	treatments	_	
19-31	3521-3527	versus	_	
19-32	3528-3534	single	_	
19-33	3535-3545	treatments	_	
19-34	3545-3546	.	_	

#Text=For overall outcome prediction in NUD, results have been mixed but indicate that absence of neuropsychiatric disorder and lower psychiatric symptom severity, older age, longer duration of previous quit attempts, lower dependence severity, adherence to pharmacotherapy, absence of smoking-related disease, male gender, low level of current alcohol problems, living as a couple and lower impulsivity predict better treatment outcomes.
20-1	3547-3550	For	_	
20-2	3551-3558	overall	_	
20-3	3559-3566	outcome	_	
20-4	3567-3577	prediction	_	
20-5	3578-3580	in	_	
20-6	3581-3584	NUD	_	
20-7	3584-3585	,	_	
20-8	3586-3593	results	_	
20-9	3594-3598	have	_	
20-10	3599-3603	been	_	
20-11	3604-3609	mixed	_	
20-12	3610-3613	but	_	
20-13	3614-3622	indicate	_	
20-14	3623-3627	that	_	
20-15	3628-3635	absence	_	
20-16	3636-3638	of	_	
20-17	3639-3655	neuropsychiatric	_	
20-18	3656-3664	disorder	_	
20-19	3665-3668	and	_	
20-20	3669-3674	lower	_	
20-21	3675-3686	psychiatric	_	
20-22	3687-3694	symptom	_	
20-23	3695-3703	severity	_	
20-24	3703-3704	,	_	
20-25	3705-3710	older	_	
20-26	3711-3714	age	_	
20-27	3714-3715	,	_	
20-28	3716-3722	longer	_	
20-29	3723-3731	duration	_	
20-30	3732-3734	of	_	
20-31	3735-3743	previous	_	
20-32	3744-3748	quit	_	
20-33	3749-3757	attempts	_	
20-34	3757-3758	,	_	
20-35	3759-3764	lower	_	
20-36	3765-3775	dependence	_	
20-37	3776-3784	severity	_	
20-38	3784-3785	,	_	
20-39	3786-3795	adherence	_	
20-40	3796-3798	to	_	
20-41	3799-3814	pharmacotherapy	_	
20-42	3814-3815	,	_	
20-43	3816-3823	absence	_	
20-44	3824-3826	of	_	
20-45	3827-3842	smoking-related	_	
20-46	3843-3850	disease	_	
20-47	3850-3851	,	_	
20-48	3852-3856	male	_	
20-49	3857-3863	gender	_	
20-50	3863-3864	,	_	
20-51	3865-3868	low	_	
20-52	3869-3874	level	_	
20-53	3875-3877	of	_	
20-54	3878-3885	current	_	
20-55	3886-3893	alcohol	_	
20-56	3894-3902	problems	_	
20-57	3902-3903	,	_	
20-58	3904-3910	living	_	
20-59	3911-3913	as	_	
20-60	3914-3915	a	_	
20-61	3916-3922	couple	_	
20-62	3923-3926	and	_	
20-63	3927-3932	lower	_	
20-64	3933-3944	impulsivity	_	
20-65	3945-3952	predict	_	
20-66	3953-3959	better	_	
20-67	3960-3969	treatment	_	
20-68	3970-3978	outcomes	_	
20-69	3978-3979	.	_	

#Text=Functional brain imaging may have an advantage overself-report measures because of its sensitivity and because of the mechanistic insights it provides.
21-1	3980-3990	Functional	_	
21-2	3991-3996	brain	_	
21-3	3997-4004	imaging	_	
21-4	4005-4008	may	_	
21-5	4009-4013	have	_	
21-6	4014-4016	an	_	
21-7	4017-4026	advantage	_	
21-8	4027-4042	overself-report	_	
21-9	4043-4051	measures	_	
21-10	4052-4059	because	_	
21-11	4060-4062	of	_	
21-12	4063-4066	its	_	
21-13	4067-4078	sensitivity	_	
21-14	4079-4082	and	_	
21-15	4083-4090	because	_	
21-16	4091-4093	of	_	
21-17	4094-4097	the	_	
21-18	4098-4109	mechanistic	_	
21-19	4110-4118	insights	_	
21-20	4119-4121	it	_	
21-21	4122-4130	provides	_	
21-22	4130-4131	.	_	

#Text=Incentive salience, referring to the wanting or desire response that the brain has to a drug-stimulus (as measured primarily in humans during fMRI by brain cue reactivity), is one of the three primary dimensions for the proposed Addictions Neuroclinical Assessment framework, highlighting its importance as a core functional domain underlying SUD pathophysiology.
22-1	4132-4141	Incentive	_	
22-2	4142-4150	salience	_	
22-3	4150-4151	,	_	
22-4	4152-4161	referring	_	
22-5	4162-4164	to	_	
22-6	4165-4168	the	_	
22-7	4169-4176	wanting	_	
22-8	4177-4179	or	_	
22-9	4180-4186	desire	_	
22-10	4187-4195	response	_	
22-11	4196-4200	that	_	
22-12	4201-4204	the	_	
22-13	4205-4210	brain	_	
22-14	4211-4214	has	_	
22-15	4215-4217	to	_	
22-16	4218-4219	a	_	
22-17	4220-4233	drug-stimulus	_	
22-18	4234-4235	(	_	
22-19	4235-4237	as	_	
22-20	4238-4246	measured	_	
22-21	4247-4256	primarily	_	
22-22	4257-4259	in	_	
22-23	4260-4266	humans	_	
22-24	4267-4273	during	_	
22-25	4274-4278	fMRI	_	
22-26	4279-4281	by	_	
22-27	4282-4287	brain	_	
22-28	4288-4291	cue	_	
22-29	4292-4302	reactivity	_	
22-30	4302-4303	)	_	
22-31	4303-4304	,	_	
22-32	4305-4307	is	_	
22-33	4308-4311	one	_	
22-34	4312-4314	of	_	
22-35	4315-4318	the	_	
22-36	4319-4324	three	_	
22-37	4325-4332	primary	_	
22-38	4333-4343	dimensions	_	
22-39	4344-4347	for	_	
22-40	4348-4351	the	_	
22-41	4352-4360	proposed	_	
22-42	4361-4371	Addictions	_	
22-43	4372-4385	Neuroclinical	_	
22-44	4386-4396	Assessment	_	
22-45	4397-4406	framework	_	
22-46	4406-4407	,	_	
22-47	4408-4420	highlighting	_	
22-48	4421-4424	its	_	
22-49	4425-4435	importance	_	
22-50	4436-4438	as	_	
22-51	4439-4440	a	_	
22-52	4441-4445	core	_	
22-53	4446-4456	functional	_	
22-54	4457-4463	domain	_	
22-55	4464-4474	underlying	_	
22-56	4475-4478	SUD	_	
22-57	4479-4494	pathophysiology	_	
22-58	4494-4495	.	_	

#Text=In particular, there is a growing literature on the potential importance of drug cue reactivity in predicting treatment response in a variety of SUD and it also has been shown to predict response to particular treatments in AUD.
23-1	4496-4498	In	_	
23-2	4499-4509	particular	_	
23-3	4509-4510	,	_	
23-4	4511-4516	there	_	
23-5	4517-4519	is	_	
23-6	4520-4521	a	_	
23-7	4522-4529	growing	_	
23-8	4530-4540	literature	_	
23-9	4541-4543	on	_	
23-10	4544-4547	the	_	
23-11	4548-4557	potential	_	
23-12	4558-4568	importance	_	
23-13	4569-4571	of	_	
23-14	4572-4576	drug	_	
23-15	4577-4580	cue	_	
23-16	4581-4591	reactivity	_	
23-17	4592-4594	in	_	
23-18	4595-4605	predicting	_	
23-19	4606-4615	treatment	_	
23-20	4616-4624	response	_	
23-21	4625-4627	in	_	
23-22	4628-4629	a	_	
23-23	4630-4637	variety	_	
23-24	4638-4640	of	_	
23-25	4641-4644	SUD	_	
23-26	4645-4648	and	_	
23-27	4649-4651	it	_	
23-28	4652-4656	also	_	
23-29	4657-4660	has	_	
23-30	4661-4665	been	_	
23-31	4666-4671	shown	_	
23-32	4672-4674	to	_	
23-33	4675-4682	predict	_	
23-34	4683-4691	response	_	
23-35	4692-4694	to	_	
23-36	4695-4705	particular	_	
23-37	4706-4716	treatments	_	
23-38	4717-4719	in	_	
23-39	4720-4723	AUD	_	
23-40	4723-4724	.	_	

#Text=The default mode network (DMN) is a set of brain regions that tends to demonstrate decreased activation during attentionally demanding and cognitively challenging tasks, and is anti-correlated with executive control networks mediating goal-oriented behavior.
24-1	4725-4728	The	_	
24-2	4729-4736	default	_	
24-3	4737-4741	mode	_	
24-4	4742-4749	network	_	
24-5	4750-4751	(	_	
24-6	4751-4754	DMN	_	
24-7	4754-4755	)	_	
24-8	4756-4758	is	_	
24-9	4759-4760	a	_	
24-10	4761-4764	set	_	
24-11	4765-4767	of	_	
24-12	4768-4773	brain	_	
24-13	4774-4781	regions	_	
24-14	4782-4786	that	_	
24-15	4787-4792	tends	_	
24-16	4793-4795	to	_	
24-17	4796-4807	demonstrate	_	
24-18	4808-4817	decreased	_	
24-19	4818-4828	activation	_	
24-20	4829-4835	during	_	
24-21	4836-4849	attentionally	_	
24-22	4850-4859	demanding	_	
24-23	4860-4863	and	_	
24-24	4864-4875	cognitively	_	
24-25	4876-4887	challenging	_	
24-26	4888-4893	tasks	_	
24-27	4893-4894	,	_	
24-28	4895-4898	and	_	
24-29	4899-4901	is	_	
24-30	4902-4917	anti-correlated	_	
24-31	4918-4922	with	_	
24-32	4923-4932	executive	_	
24-33	4933-4940	control	_	
24-34	4941-4949	networks	_	
24-35	4950-4959	mediating	_	
24-36	4960-4973	goal-oriented	_	
24-37	4974-4982	behavior	_	
24-38	4982-4983	.	_	

#Text=DMN deactivation likely plays an important role in successful goal-oriented cognition and behavior, which could hold relevance for drug-seeking on the one hand, or maintaining on-line a decision to remain abstinent, on the other.
25-1	4984-4987	DMN	_	
25-2	4988-5000	deactivation	_	
25-3	5001-5007	likely	_	
25-4	5008-5013	plays	_	
25-5	5014-5016	an	_	
25-6	5017-5026	important	_	
25-7	5027-5031	role	_	
25-8	5032-5034	in	_	
25-9	5035-5045	successful	_	
25-10	5046-5059	goal-oriented	_	
25-11	5060-5069	cognition	_	
25-12	5070-5073	and	_	
25-13	5074-5082	behavior	_	
25-14	5082-5083	,	_	
25-15	5084-5089	which	_	
25-16	5090-5095	could	_	
25-17	5096-5100	hold	_	
25-18	5101-5110	relevance	_	
25-19	5111-5114	for	_	
25-20	5115-5127	drug-seeking	_	
25-21	5128-5130	on	_	
25-22	5131-5134	the	_	
25-23	5135-5138	one	_	
25-24	5139-5143	hand	_	
25-25	5143-5144	,	_	
25-26	5145-5147	or	_	
25-27	5148-5159	maintaining	_	
25-28	5160-5167	on-line	_	
25-29	5168-5169	a	_	
25-30	5170-5178	decision	_	
25-31	5179-5181	to	_	
25-32	5182-5188	remain	_	
25-33	5189-5198	abstinent	_	
25-34	5198-5199	,	_	
25-35	5200-5202	on	_	
25-36	5203-5206	the	_	
25-37	5207-5212	other	_	
25-38	5212-5213	.	_	

#Text=Deactivation in regions of the DMN [rostral anterior cingulate cortex (rACC), posterior cingulate cortex (PCC)] has been observed in response to nicotine, cocaine and food cues in some studies, but in others, activation has been observed in these areas.
26-1	5214-5226	Deactivation	_	
26-2	5227-5229	in	_	
26-3	5230-5237	regions	_	
26-4	5238-5240	of	_	
26-5	5241-5244	the	_	
26-6	5245-5248	DMN	_	
26-7	5249-5250	[	_	
26-8	5250-5257	rostral	_	
26-9	5258-5266	anterior	_	
26-10	5267-5276	cingulate	_	
26-11	5277-5283	cortex	_	
26-12	5284-5285	(	_	
26-13	5285-5289	rACC	_	
26-14	5289-5290	)	_	
26-15	5290-5291	,	_	
26-16	5292-5301	posterior	_	
26-17	5302-5311	cingulate	_	
26-18	5312-5318	cortex	_	
26-19	5319-5320	(	_	
26-20	5320-5323	PCC	_	
26-21	5323-5324	)	_	
26-22	5324-5325	]	_	
26-23	5326-5329	has	_	
26-24	5330-5334	been	_	
26-25	5335-5343	observed	_	
26-26	5344-5346	in	_	
26-27	5347-5355	response	_	
26-28	5356-5358	to	_	
26-29	5359-5367	nicotine	_	
26-30	5367-5368	,	_	
26-31	5369-5376	cocaine	_	
26-32	5377-5380	and	_	
26-33	5381-5385	food	_	
26-34	5386-5390	cues	_	
26-35	5391-5393	in	_	
26-36	5394-5398	some	_	
26-37	5399-5406	studies	_	
26-38	5406-5407	,	_	
26-39	5408-5411	but	_	
26-40	5412-5414	in	_	
26-41	5415-5421	others	_	
26-42	5421-5422	,	_	
26-43	5423-5433	activation	_	
26-44	5434-5437	has	_	
26-45	5438-5442	been	_	
26-46	5443-5451	observed	_	
26-47	5452-5454	in	_	
26-48	5455-5460	these	_	
26-49	5461-5466	areas	_	
26-50	5466-5467	.	_	

#Text=Therefore, the findings regarding the effects of drug cues on the DMN and regions encompassing the DMN are mixed.
27-1	5468-5477	Therefore	_	
27-2	5477-5478	,	_	
27-3	5479-5482	the	_	
27-4	5483-5491	findings	_	
27-5	5492-5501	regarding	_	
27-6	5502-5505	the	_	
27-7	5506-5513	effects	_	
27-8	5514-5516	of	_	
27-9	5517-5521	drug	_	
27-10	5522-5526	cues	_	
27-11	5527-5529	on	_	
27-12	5530-5533	the	_	
27-13	5534-5537	DMN	_	
27-14	5538-5541	and	_	
27-15	5542-5549	regions	_	
27-16	5550-5562	encompassing	_	
27-17	5563-5566	the	_	
27-18	5567-5570	DMN	_	
27-19	5571-5574	are	_	
27-20	5575-5580	mixed	_	
27-21	5580-5581	.	_	

#Text=The significance of the brain’s response to these cues in driving relapse during SUD treatment is still unknown.
28-1	5582-5585	The	_	
28-2	5586-5598	significance	_	
28-3	5599-5601	of	_	
28-4	5602-5605	the	_	
28-5	5606-5611	brain	_	
28-6	5611-5612	’	_	
28-7	5612-5613	s	_	
28-8	5614-5622	response	_	
28-9	5623-5625	to	_	
28-10	5626-5631	these	_	
28-11	5632-5636	cues	_	
28-12	5637-5639	in	_	
28-13	5640-5647	driving	_	
28-14	5648-5655	relapse	_	
28-15	5656-5662	during	_	
28-16	5663-5666	SUD	_	
28-17	5667-5676	treatment	_	
28-18	5677-5679	is	_	
28-19	5680-5685	still	_	
28-20	5686-5693	unknown	_	
28-21	5693-5694	.	_	

#Text=Our primary aim in this study was to investigate the degree to which DMN deactivation to smoking cues relative to food cues would predict treatment response to varenicline in particular and overall treatment response in treatment-seeking individuals with NUD enrolled in a clinical trial of varenicline versus placebo.
29-1	5695-5698	Our	_	
29-2	5699-5706	primary	_	
29-3	5707-5710	aim	_	
29-4	5711-5713	in	_	
29-5	5714-5718	this	_	
29-6	5719-5724	study	_	
29-7	5725-5728	was	_	
29-8	5729-5731	to	_	
29-9	5732-5743	investigate	_	
29-10	5744-5747	the	_	
29-11	5748-5754	degree	_	
29-12	5755-5757	to	_	
29-13	5758-5763	which	_	
29-14	5764-5767	DMN	_	
29-15	5768-5780	deactivation	_	
29-16	5781-5783	to	_	
29-17	5784-5791	smoking	_	
29-18	5792-5796	cues	_	
29-19	5797-5805	relative	_	
29-20	5806-5808	to	_	
29-21	5809-5813	food	_	
29-22	5814-5818	cues	_	
29-23	5819-5824	would	_	
29-24	5825-5832	predict	_	
29-25	5833-5842	treatment	_	
29-26	5843-5851	response	_	
29-27	5852-5854	to	_	
29-28	5855-5866	varenicline	_	
29-29	5867-5869	in	_	
29-30	5870-5880	particular	_	
29-31	5881-5884	and	_	
29-32	5885-5892	overall	_	
29-33	5893-5902	treatment	_	
29-34	5903-5911	response	_	
29-35	5912-5914	in	_	
29-36	5915-5932	treatment-seeking	_	
29-37	5933-5944	individuals	_	
29-38	5945-5949	with	_	
29-39	5950-5953	NUD	_	
29-40	5954-5962	enrolled	_	
29-41	5963-5965	in	_	
29-42	5966-5967	a	_	
29-43	5968-5976	clinical	_	
29-44	5977-5982	trial	_	
29-45	5983-5985	of	_	
29-46	5986-5997	varenicline	_	
29-47	5998-6004	versus	_	
29-48	6005-6012	placebo	_	
29-49	6012-6013	.	_	

#Text=Since greater DMN deactivation to food cues compared to smoke cues was measured in a non-treatment seeking sample using the same task, we hypothesized that our sample would demonstrate a similar effect.
30-1	6014-6019	Since	_	
30-2	6020-6027	greater	_	
30-3	6028-6031	DMN	_	
30-4	6032-6044	deactivation	_	
30-5	6045-6047	to	_	
30-6	6048-6052	food	_	
30-7	6053-6057	cues	_	
30-8	6058-6066	compared	_	
30-9	6067-6069	to	_	
30-10	6070-6075	smoke	_	
30-11	6076-6080	cues	_	
30-12	6081-6084	was	_	
30-13	6085-6093	measured	_	
30-14	6094-6096	in	_	
30-15	6097-6098	a	_	
30-16	6099-6112	non-treatment	_	
30-17	6113-6120	seeking	_	
30-18	6121-6127	sample	_	
30-19	6128-6133	using	_	
30-20	6134-6137	the	_	
30-21	6138-6142	same	_	
30-22	6143-6147	task	_	
30-23	6147-6148	,	_	
30-24	6149-6151	we	_	
30-25	6152-6164	hypothesized	_	
30-26	6165-6169	that	_	
30-27	6170-6173	our	_	
30-28	6174-6180	sample	_	
30-29	6181-6186	would	_	
30-30	6187-6198	demonstrate	_	
30-31	6199-6200	a	_	
30-32	6201-6208	similar	_	
30-33	6209-6215	effect	_	
30-34	6215-6216	.	_	

#Text=Furthermore, we explored the degree to which deactivation to smoke cue, food cue, and the difference between them would predict better clinical outcomes, controlling for the predictive effects of self-report clinical measures which have shown to predict outcome in previous work.
31-1	6217-6228	Furthermore	_	
31-2	6228-6229	,	_	
31-3	6230-6232	we	_	
31-4	6233-6241	explored	_	
31-5	6242-6245	the	_	
31-6	6246-6252	degree	_	
31-7	6253-6255	to	_	
31-8	6256-6261	which	_	
31-9	6262-6274	deactivation	_	
31-10	6275-6277	to	_	
31-11	6278-6283	smoke	_	
31-12	6284-6287	cue	_	
31-13	6287-6288	,	_	
31-14	6289-6293	food	_	
31-15	6294-6297	cue	_	
31-16	6297-6298	,	_	
31-17	6299-6302	and	_	
31-18	6303-6306	the	_	
31-19	6307-6317	difference	_	
31-20	6318-6325	between	_	
31-21	6326-6330	them	_	
31-22	6331-6336	would	_	
31-23	6337-6344	predict	_	
31-24	6345-6351	better	_	
31-25	6352-6360	clinical	_	
31-26	6361-6369	outcomes	_	
31-27	6369-6370	,	_	
31-28	6371-6382	controlling	_	
31-29	6383-6386	for	_	
31-30	6387-6390	the	_	
31-31	6391-6401	predictive	_	
31-32	6402-6409	effects	_	
31-33	6410-6412	of	_	
31-34	6413-6424	self-report	_	
31-35	6425-6433	clinical	_	
31-36	6434-6442	measures	_	
31-37	6443-6448	which	_	
31-38	6449-6453	have	_	
31-39	6454-6459	shown	_	
31-40	6460-6462	to	_	
31-41	6463-6470	predict	_	
31-42	6471-6478	outcome	_	
31-43	6479-6481	in	_	
31-44	6482-6490	previous	_	
31-45	6491-6495	work	_	
31-46	6495-6496	.	_	

#Text=Finally, we explored activation in executive control and salience networks (ECN; SN) and their associations with outcomes, given the fact that these networks are often engaged by drug cues and anti-correlated with DMN.
32-1	6497-6504	Finally	_	
32-2	6504-6505	,	_	
32-3	6506-6508	we	_	
32-4	6509-6517	explored	_	
32-5	6518-6528	activation	_	
32-6	6529-6531	in	_	
32-7	6532-6541	executive	_	
32-8	6542-6549	control	_	
32-9	6550-6553	and	_	
32-10	6554-6562	salience	_	
32-11	6563-6571	networks	_	
32-12	6572-6573	(	_	
32-13	6573-6576	ECN	_	
32-14	6576-6577	;	_	
32-15	6578-6580	SN	_	
32-16	6580-6581	)	_	
32-17	6582-6585	and	_	
32-18	6586-6591	their	_	
32-19	6592-6604	associations	_	
32-20	6605-6609	with	_	
32-21	6610-6618	outcomes	_	
32-22	6618-6619	,	_	
32-23	6620-6625	given	_	
32-24	6626-6629	the	_	
32-25	6630-6634	fact	_	
32-26	6635-6639	that	_	
32-27	6640-6645	these	_	
32-28	6646-6654	networks	_	
32-29	6655-6658	are	_	
32-30	6659-6664	often	_	
32-31	6665-6672	engaged	_	
32-32	6673-6675	by	_	
32-33	6676-6680	drug	_	
32-34	6681-6685	cues	_	
32-35	6686-6689	and	_	
32-36	6690-6705	anti-correlated	_	
32-37	6706-6710	with	_	
32-38	6711-6714	DMN	_	
32-39	6714-6715	.	_	

#Text=Patients and Methods
#Text=Subjects
#Text=Subjects were treatment-seeking cigarette smokers between the ages of 18 and 55recruited and enrolled in a randomized, double-blind, placebo-controlled trial of varenicline which was designed to identify biomarkers of effectiveness [manuscript summarizing clinical results, under review ].
33-1	6716-6724	Patients	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
33-2	6725-6728	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
33-3	6729-6736	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
33-4	6737-6745	Subjects	_	
33-5	6746-6754	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-6	6755-6759	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-7	6760-6777	treatment-seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-8	6778-6787	cigarette	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-9	6788-6795	smokers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-10	6796-6803	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-11	6804-6807	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-12	6808-6812	ages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-13	6813-6815	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-14	6816-6818	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-15	6819-6822	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-16	6823-6834	55recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-17	6835-6838	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-18	6839-6847	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-19	6848-6850	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-20	6851-6852	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-21	6853-6863	randomized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-22	6863-6864	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-23	6865-6877	double-blind	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-24	6877-6878	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-25	6879-6897	placebo-controlled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-26	6898-6903	trial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-27	6904-6906	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-28	6907-6918	varenicline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-29	6919-6924	which	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-30	6925-6928	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-31	6929-6937	designed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-32	6938-6940	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-33	6941-6949	identify	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-34	6950-6960	biomarkers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-35	6961-6963	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-36	6964-6977	effectiveness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-37	6978-6979	[	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-38	6979-6989	manuscript	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-39	6990-7001	summarizing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-40	7002-7010	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-41	7011-7018	results	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-42	7018-7019	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-43	7020-7025	under	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-44	7026-7032	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-45	7033-7034	]	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-46	7034-7035	.	_	

#Text=Individuals were required to smoke at least 10 cigarettes per day and to have not previously taken varenicline.
34-1	7036-7047	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-2	7048-7052	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-3	7053-7061	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-4	7062-7064	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-5	7065-7070	smoke	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-6	7071-7073	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-7	7074-7079	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-8	7080-7082	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-9	7083-7093	cigarettes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-10	7094-7097	per	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-11	7098-7101	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-12	7102-7105	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-13	7106-7108	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-14	7109-7113	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-15	7114-7117	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-16	7118-7128	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-17	7129-7134	taken	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-18	7135-7146	varenicline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
34-19	7146-7147	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=Participants were excluded for current pregnancy/nursing, use of illicit drugs (excluding marijuana) in the past 60 days (confirmed by urine toxicology screen), serious health concerns (cardiovascular disease, uncontrolled hypertension, hepatic or renal disease, diabetes), or for meeting DSM-IV criteria for psychotic, bipolar, or major depressive disorder in the past year. 205 individuals were randomized using an urn randomization technique, and treated for 12 weeks.
35-1	7148-7160	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-2	7161-7165	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-3	7166-7174	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-4	7175-7178	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-5	7179-7186	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-6	7187-7196	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-7	7196-7197	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-8	7197-7204	nursing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-9	7204-7205	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-10	7206-7209	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-11	7210-7212	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-12	7213-7220	illicit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-13	7221-7226	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-14	7227-7228	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-15	7228-7237	excluding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-16	7238-7247	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-17	7247-7248	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-18	7249-7251	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-19	7252-7255	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-20	7256-7260	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-21	7261-7263	60	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-22	7264-7268	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-23	7269-7270	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-24	7270-7279	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-25	7280-7282	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-26	7283-7288	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-27	7289-7299	toxicology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-28	7300-7306	screen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-29	7306-7307	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-30	7307-7308	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-31	7309-7316	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-32	7317-7323	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-33	7324-7332	concerns	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-34	7333-7334	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-35	7334-7348	cardiovascular	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-36	7349-7356	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-37	7356-7357	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-38	7358-7370	uncontrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-39	7371-7383	hypertension	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-40	7383-7384	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-41	7385-7392	hepatic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-42	7393-7395	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-43	7396-7401	renal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-44	7402-7409	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-45	7409-7410	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-46	7411-7419	diabetes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-47	7419-7420	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-48	7420-7421	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-49	7422-7424	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-50	7425-7428	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-51	7429-7436	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-52	7437-7443	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-53	7444-7452	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-54	7453-7456	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-55	7457-7466	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-56	7466-7467	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-57	7468-7475	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-58	7475-7476	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-59	7477-7479	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-60	7480-7485	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-61	7486-7496	depressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-62	7497-7505	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-63	7506-7508	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-64	7509-7512	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-65	7513-7517	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-66	7518-7522	year	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-67	7522-7523	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-68	7524-7527	205	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-69	7528-7539	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-70	7540-7544	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-71	7545-7555	randomized	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-72	7556-7561	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-73	7562-7564	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-74	7565-7568	urn	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-75	7569-7582	randomization	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-76	7583-7592	technique	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-77	7592-7593	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-78	7594-7597	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-79	7598-7605	treated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-80	7606-7609	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-81	7610-7612	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-82	7613-7618	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
35-83	7618-7619	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Of these, 143 underwent a cue-exposure task during fMRI prior to medication initiation (male n=91; varenicline n=80; mean age 34.05 yrs, SD 10.16), and their data were used for the analyses that follow; individuals who chose not to have an MRI or had exclusions for MRI were still enrolled in the clinical trial.
36-1	7620-7622	Of	_	
36-2	7623-7628	these	_	
36-3	7628-7629	,	_	
36-4	7630-7633	143	_	
36-5	7634-7643	underwent	_	
36-6	7644-7645	a	_	
36-7	7646-7658	cue-exposure	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[10]	
36-8	7659-7663	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[10]	
36-9	7664-7670	during	_	
36-10	7671-7675	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
36-11	7676-7681	prior	_	
36-12	7682-7684	to	_	
36-13	7685-7695	medication	_	
36-14	7696-7706	initiation	_	
36-15	7707-7708	(	_	
36-16	7708-7712	male	_	
36-17	7713-7714	n	_	
36-18	7714-7715	=	_	
36-19	7715-7717	91	_	
36-20	7717-7718	;	_	
36-21	7719-7730	varenicline	_	
36-22	7731-7732	n	_	
36-23	7732-7733	=	_	
36-24	7733-7735	80	_	
36-25	7735-7736	;	_	
36-26	7737-7741	mean	_	
36-27	7742-7745	age	_	
36-28	7746-7751	34.05	_	
36-29	7752-7755	yrs	_	
36-30	7755-7756	,	_	
36-31	7757-7759	SD	_	
36-32	7760-7765	10.16	_	
36-33	7765-7766	)	_	
36-34	7766-7767	,	_	
36-35	7768-7771	and	_	
36-36	7772-7777	their	_	
36-37	7778-7782	data	_	
36-38	7783-7787	were	_	
36-39	7788-7792	used	_	
36-40	7793-7796	for	_	
36-41	7797-7800	the	_	
36-42	7801-7809	analyses	_	
36-43	7810-7814	that	_	
36-44	7815-7821	follow	_	
36-45	7821-7822	;	_	
36-46	7823-7834	individuals	_	
36-47	7835-7838	who	_	
36-48	7839-7844	chose	_	
36-49	7845-7848	not	_	
36-50	7849-7851	to	_	
36-51	7852-7856	have	_	
36-52	7857-7859	an	_	
36-53	7860-7863	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
36-54	7864-7866	or	_	
36-55	7867-7870	had	_	
36-56	7871-7881	exclusions	_	
36-57	7882-7885	for	_	
36-58	7886-7889	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
36-59	7890-7894	were	_	
36-60	7895-7900	still	_	
36-61	7901-7909	enrolled	_	
36-62	7910-7912	in	_	
36-63	7913-7916	the	_	
36-64	7917-7925	clinical	_	
36-65	7926-7931	trial	_	
36-66	7931-7932	.	_	

#Text=Clinical Trial Design
#Text=Consistent with previous trials patients were titrated to 1mg twice daily as follows: days 1–3, 0.5 mg per day; days 4–7, 0.5 mg twice per day, and after day 7, 1 mg twice per day.
37-1	7933-7941	Clinical	_	
37-2	7942-7947	Trial	_	
37-3	7948-7954	Design	_	
37-4	7955-7965	Consistent	_	
37-5	7966-7970	with	_	
37-6	7971-7979	previous	_	
37-7	7980-7986	trials	_	
37-8	7987-7995	patients	_	
37-9	7996-8000	were	_	
37-10	8001-8009	titrated	_	
37-11	8010-8012	to	_	
37-12	8013-8016	1mg	_	
37-13	8017-8022	twice	_	
37-14	8023-8028	daily	_	
37-15	8029-8031	as	_	
37-16	8032-8039	follows	_	
37-17	8039-8040	:	_	
37-18	8041-8045	days	_	
37-19	8046-8047	1	_	
37-20	8047-8048	–	_	
37-21	8048-8049	3	_	
37-22	8049-8050	,	_	
37-23	8051-8054	0.5	_	
37-24	8055-8057	mg	_	
37-25	8058-8061	per	_	
37-26	8062-8065	day	_	
37-27	8065-8066	;	_	
37-28	8067-8071	days	_	
37-29	8072-8073	4	_	
37-30	8073-8074	–	_	
37-31	8074-8075	7	_	
37-32	8075-8076	,	_	
37-33	8077-8080	0.5	_	
37-34	8081-8083	mg	_	
37-35	8084-8089	twice	_	
37-36	8090-8093	per	_	
37-37	8094-8097	day	_	
37-38	8097-8098	,	_	
37-39	8099-8102	and	_	
37-40	8103-8108	after	_	
37-41	8109-8112	day	_	
37-42	8113-8114	7	_	
37-43	8114-8115	,	_	
37-44	8116-8117	1	_	
37-45	8118-8120	mg	_	
37-46	8121-8126	twice	_	
37-47	8127-8130	per	_	
37-48	8131-8134	day	_	
37-49	8134-8135	.	_	

#Text=All participants received a 30 minute baseline motivational enhancement session during which a target quit date was set for day 8, and brief (10 minute) counseling visits with their assigned therapist at each assessment (2, 6, 12 weeks).
38-1	8136-8139	All	_	
38-2	8140-8152	participants	_	
38-3	8153-8161	received	_	
38-4	8162-8163	a	_	
38-5	8164-8166	30	_	
38-6	8167-8173	minute	_	
38-7	8174-8182	baseline	_	
38-8	8183-8195	motivational	_	
38-9	8196-8207	enhancement	_	
38-10	8208-8215	session	_	
38-11	8216-8222	during	_	
38-12	8223-8228	which	_	
38-13	8229-8230	a	_	
38-14	8231-8237	target	_	
38-15	8238-8242	quit	_	
38-16	8243-8247	date	_	
38-17	8248-8251	was	_	
38-18	8252-8255	set	_	
38-19	8256-8259	for	_	
38-20	8260-8263	day	_	
38-21	8264-8265	8	_	
38-22	8265-8266	,	_	
38-23	8267-8270	and	_	
38-24	8271-8276	brief	_	
38-25	8277-8278	(	_	
38-26	8278-8280	10	_	
38-27	8281-8287	minute	_	
38-28	8287-8288	)	_	
38-29	8289-8299	counseling	_	
38-30	8300-8306	visits	_	
38-31	8307-8311	with	_	
38-32	8312-8317	their	_	
38-33	8318-8326	assigned	_	
38-34	8327-8336	therapist	_	
38-35	8337-8339	at	_	
38-36	8340-8344	each	_	
38-37	8345-8355	assessment	_	
38-38	8356-8357	(	_	
38-39	8357-8358	2	_	
38-40	8358-8359	,	_	
38-41	8360-8361	6	_	
38-42	8361-8362	,	_	
38-43	8363-8365	12	_	
38-44	8366-8371	weeks	_	
38-45	8371-8372	)	_	
38-46	8372-8373	.	_	

#Text=Clinical Assessments
#Text=A battery of assessments were obtained at screen, baseline, 2, 6 and 12 weeks.
39-1	8374-8382	Clinical	_	
39-2	8383-8394	Assessments	_	
39-3	8395-8396	A	_	
39-4	8397-8404	battery	_	
39-5	8405-8407	of	_	
39-6	8408-8419	assessments	_	
39-7	8420-8424	were	_	
39-8	8425-8433	obtained	_	
39-9	8434-8436	at	_	
39-10	8437-8443	screen	_	
39-11	8443-8444	,	_	
39-12	8445-8453	baseline	_	
39-13	8453-8454	,	_	
39-14	8455-8456	2	_	
39-15	8456-8457	,	_	
39-16	8458-8459	6	_	
39-17	8460-8463	and	_	
39-18	8464-8466	12	_	
39-19	8467-8472	weeks	_	
39-20	8472-8473	.	_	

#Text=Only measures relevant to this study are summarized below; a full description of the clinical assessment measures is provided in the clinical outcomes paper.
40-1	8474-8478	Only	_	
40-2	8479-8487	measures	_	
40-3	8488-8496	relevant	_	
40-4	8497-8499	to	_	
40-5	8500-8504	this	_	
40-6	8505-8510	study	_	
40-7	8511-8514	are	_	
40-8	8515-8525	summarized	_	
40-9	8526-8531	below	_	
40-10	8531-8532	;	_	
40-11	8533-8534	a	_	
40-12	8535-8539	full	_	
40-13	8540-8551	description	_	
40-14	8552-8554	of	_	
40-15	8555-8558	the	_	
40-16	8559-8567	clinical	_	
40-17	8568-8578	assessment	_	
40-18	8579-8587	measures	_	
40-19	8588-8590	is	_	
40-20	8591-8599	provided	_	
40-21	8600-8602	in	_	
40-22	8603-8606	the	_	
40-23	8607-8615	clinical	_	
40-24	8616-8624	outcomes	_	
40-25	8625-8630	paper	_	
40-26	8630-8631	.	_	

#Text=Nicotine dependence was characterized using the Fagerstrom Test for Nicotine Dependence (FTND).
41-1	8632-8640	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[11]	
41-2	8641-8651	dependence	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[11]	
41-3	8652-8655	was	_	
41-4	8656-8669	characterized	_	
41-5	8670-8675	using	_	
41-6	8676-8679	the	_	
41-7	8680-8690	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
41-8	8691-8695	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
41-9	8696-8699	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
41-10	8700-8708	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
41-11	8709-8719	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
41-12	8720-8721	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
41-13	8721-8725	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
41-14	8725-8726	)	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence[12]	
41-15	8726-8727	.	_	

#Text=Nicotine withdrawal was assessed using the Wisconsin Smoking Withdrawal Scale (WSWS) and craving with the Questionnaire of Smoking Urges and were obtained 15–30 minutes before each MRI scan.
42-1	8728-8736	Nicotine	_	
42-2	8737-8747	withdrawal	_	
42-3	8748-8751	was	_	
42-4	8752-8760	assessed	_	
42-5	8761-8766	using	_	
42-6	8767-8770	the	_	
42-7	8771-8780	Wisconsin	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[13]	
42-8	8781-8788	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[13]	
42-9	8789-8799	Withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[13]	
42-10	8800-8805	Scale	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[13]	
42-11	8806-8807	(	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[13]	
42-12	8807-8811	WSWS	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[13]	
42-13	8811-8812	)	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[13]	
42-14	8813-8816	and	_	
42-15	8817-8824	craving	_	
42-16	8825-8829	with	_	
42-17	8830-8833	the	_	
42-18	8834-8847	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges[14]	
42-19	8848-8850	of	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges[14]	
42-20	8851-8858	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges[14]	
42-21	8859-8864	Urges	http://maven.renci.org/NeuroBridge/neurobridge#QuestionnaireonSmokingUrges[14]	
42-22	8865-8868	and	_	
42-23	8869-8873	were	_	
42-24	8874-8882	obtained	_	
42-25	8883-8885	15	_	
42-26	8885-8886	–	_	
42-27	8886-8888	30	_	
42-28	8889-8896	minutes	_	
42-29	8897-8903	before	_	
42-30	8904-8908	each	_	
42-31	8909-8912	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
42-32	8913-8917	scan	_	
42-33	8917-8918	.	_	

#Text=A separate subscale of the WSWS [WSWS(food)] which included only the questions that were related to desire for food was calculated (see Supporting Information for details).
43-1	8919-8920	A	_	
43-2	8921-8929	separate	_	
43-3	8930-8938	subscale	_	
43-4	8939-8941	of	_	
43-5	8942-8945	the	_	
43-6	8946-8950	WSWS	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[15]	
43-7	8951-8952	[	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[15]	
43-8	8952-8956	WSWS	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[15]	
43-9	8956-8957	(	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[15]	
43-10	8957-8961	food	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[15]	
43-11	8961-8962	)	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[15]	
43-12	8962-8963	]	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale[15]	
43-13	8964-8969	which	_	
43-14	8970-8978	included	_	
43-15	8979-8983	only	_	
43-16	8984-8987	the	_	
43-17	8988-8997	questions	_	
43-18	8998-9002	that	_	
43-19	9003-9007	were	_	
43-20	9008-9015	related	_	
43-21	9016-9018	to	_	
43-22	9019-9025	desire	_	
43-23	9026-9029	for	_	
43-24	9030-9034	food	_	
43-25	9035-9038	was	_	
43-26	9039-9049	calculated	_	
43-27	9050-9051	(	_	
43-28	9051-9054	see	_	
43-29	9055-9065	Supporting	_	
43-30	9066-9077	Information	_	
43-31	9078-9081	for	_	
43-32	9082-9089	details	_	
43-33	9089-9090	)	_	
43-34	9090-9091	.	_	

#Text=Number of hours since the last cigarette smoked was also obtained from the participant at the time of each MRI scan; participants were asked to be abstinent for 2 hours prior to the scan visit and there were only 8 participants who did not report being abstinent 2 hours prior to the scan.
44-1	9092-9098	Number	_	
44-2	9099-9101	of	_	
44-3	9102-9107	hours	_	
44-4	9108-9113	since	_	
44-5	9114-9117	the	_	
44-6	9118-9122	last	_	
44-7	9123-9132	cigarette	_	
44-8	9133-9139	smoked	_	
44-9	9140-9143	was	_	
44-10	9144-9148	also	_	
44-11	9149-9157	obtained	_	
44-12	9158-9162	from	_	
44-13	9163-9166	the	_	
44-14	9167-9178	participant	_	
44-15	9179-9181	at	_	
44-16	9182-9185	the	_	
44-17	9186-9190	time	_	
44-18	9191-9193	of	_	
44-19	9194-9198	each	_	
44-20	9199-9202	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
44-21	9203-9207	scan	_	
44-22	9207-9208	;	_	
44-23	9209-9221	participants	_	
44-24	9222-9226	were	_	
44-25	9227-9232	asked	_	
44-26	9233-9235	to	_	
44-27	9236-9238	be	_	
44-28	9239-9248	abstinent	_	
44-29	9249-9252	for	_	
44-30	9253-9254	2	_	
44-31	9255-9260	hours	_	
44-32	9261-9266	prior	_	
44-33	9267-9269	to	_	
44-34	9270-9273	the	_	
44-35	9274-9278	scan	_	
44-36	9279-9284	visit	_	
44-37	9285-9288	and	_	
44-38	9289-9294	there	_	
44-39	9295-9299	were	_	
44-40	9300-9304	only	_	
44-41	9305-9306	8	_	
44-42	9307-9319	participants	_	
44-43	9320-9323	who	_	
44-44	9324-9327	did	_	
44-45	9328-9331	not	_	
44-46	9332-9338	report	_	
44-47	9339-9344	being	_	
44-48	9345-9354	abstinent	_	
44-49	9355-9356	2	_	
44-50	9357-9362	hours	_	
44-51	9363-9368	prior	_	
44-52	9369-9371	to	_	
44-53	9372-9375	the	_	
44-54	9376-9380	scan	_	
44-55	9380-9381	.	_	

#Text=Additional measures included the Beck Anxiety Inventory (BAI), the Beck Depression Inventory (BDI), the Barratt Impulsiveness Questionnaire (BIQ), and the Alcohol Use Disorders Identification Test (AUDIT) (references for self-report measures listed in Supporting Information).
45-1	9382-9392	Additional	_	
45-2	9393-9401	measures	_	
45-3	9402-9410	included	_	
45-4	9411-9414	the	_	
45-5	9415-9419	Beck	_	
45-6	9420-9427	Anxiety	_	
45-7	9428-9437	Inventory	_	
45-8	9438-9439	(	_	
45-9	9439-9442	BAI	_	
45-10	9442-9443	)	_	
45-11	9443-9444	,	_	
45-12	9445-9448	the	_	
45-13	9449-9453	Beck	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
45-14	9454-9464	Depression	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
45-15	9465-9474	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
45-16	9475-9476	(	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
45-17	9476-9479	BDI	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
45-18	9479-9480	)	http://maven.renci.org/NeuroBridge/neurobridge#BeckDepressionInventory[16]	
45-19	9480-9481	,	_	
45-20	9482-9485	the	_	
45-21	9486-9493	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[17]	
45-22	9494-9507	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[17]	
45-23	9508-9521	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[17]	
45-24	9522-9523	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[17]	
45-25	9523-9526	BIQ	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[17]	
45-26	9526-9527	)	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[17]	
45-27	9527-9528	,	_	
45-28	9529-9532	and	_	
45-29	9533-9536	the	_	
45-30	9537-9544	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[18]	
45-31	9545-9548	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[18]	
45-32	9549-9558	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[18]	
45-33	9559-9573	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[18]	
45-34	9574-9578	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[18]	
45-35	9579-9580	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[18]	
45-36	9580-9585	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[18]	
45-37	9585-9586	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest[18]	
45-38	9587-9588	(	_	
45-39	9588-9598	references	_	
45-40	9599-9602	for	_	
45-41	9603-9614	self-report	_	
45-42	9615-9623	measures	_	
45-43	9624-9630	listed	_	
45-44	9631-9633	in	_	
45-45	9634-9644	Supporting	_	
45-46	9645-9656	Information	_	
45-47	9656-9657	)	_	
45-48	9657-9658	.	_	

#Text=All participants were also asked at the screen visit about the number of prior serious quit attempts they had made in their lives during which they remained abstinent from cigarettes for 12 hours or more.
46-1	9659-9662	All	_	
46-2	9663-9675	participants	_	
46-3	9676-9680	were	_	
46-4	9681-9685	also	_	
46-5	9686-9691	asked	_	
46-6	9692-9694	at	_	
46-7	9695-9698	the	_	
46-8	9699-9705	screen	_	
46-9	9706-9711	visit	_	
46-10	9712-9717	about	_	
46-11	9718-9721	the	_	
46-12	9722-9728	number	_	
46-13	9729-9731	of	_	
46-14	9732-9737	prior	_	
46-15	9738-9745	serious	_	
46-16	9746-9750	quit	_	
46-17	9751-9759	attempts	_	
46-18	9760-9764	they	_	
46-19	9765-9768	had	_	
46-20	9769-9773	made	_	
46-21	9774-9776	in	_	
46-22	9777-9782	their	_	
46-23	9783-9788	lives	_	
46-24	9789-9795	during	_	
46-25	9796-9801	which	_	
46-26	9802-9806	they	_	
46-27	9807-9815	remained	_	
46-28	9816-9825	abstinent	_	
46-29	9826-9830	from	_	
46-30	9831-9841	cigarettes	_	
46-31	9842-9845	for	_	
46-32	9846-9848	12	_	
46-33	9849-9854	hours	_	
46-34	9855-9857	or	_	
46-35	9858-9862	more	_	
46-36	9862-9863	.	_	

#Text=Carbon monoxide (CO) levels were obtained at all visits which were used to validate secondary abstinence-based outcome variables (Tables 6,7,S1–3).
47-1	9864-9870	Carbon	_	
47-2	9871-9879	monoxide	_	
47-3	9880-9881	(	_	
47-4	9881-9883	CO	_	
47-5	9883-9884	)	_	
47-6	9885-9891	levels	_	
47-7	9892-9896	were	_	
47-8	9897-9905	obtained	_	
47-9	9906-9908	at	_	
47-10	9909-9912	all	_	
47-11	9913-9919	visits	_	
47-12	9920-9925	which	_	
47-13	9926-9930	were	_	
47-14	9931-9935	used	_	
47-15	9936-9938	to	_	
47-16	9939-9947	validate	_	
47-17	9948-9957	secondary	_	
47-18	9958-9974	abstinence-based	_	
47-19	9975-9982	outcome	_	
47-20	9983-9992	variables	_	
47-21	9993-9994	(	_	
47-22	9994-10000	Tables	_	
47-23	10001-10004	6,7	_	
47-24	10004-10005	,	_	
47-25	10005-10007	S1	_	
47-26	10007-10008	–	_	
47-27	10008-10009	3	_	
47-28	10009-10010	)	_	
47-29	10010-10011	.	_	

#Text=The time-line follow-back procedure (TLFB) (reference in Supporting Information) was used to record tobacco product, alcohol, and drug use in the 60 days prior to the screen and during the interim period between each follow-up assessment.
48-1	10012-10015	The	_	
48-2	10016-10025	time-line	_	
48-3	10026-10037	follow-back	_	
48-4	10038-10047	procedure	_	
48-5	10048-10049	(	_	
48-6	10049-10053	TLFB	_	
48-7	10053-10054	)	_	
48-8	10055-10056	(	_	
48-9	10056-10065	reference	_	
48-10	10066-10068	in	_	
48-11	10069-10079	Supporting	_	
48-12	10080-10091	Information	_	
48-13	10091-10092	)	_	
48-14	10093-10096	was	_	
48-15	10097-10101	used	_	
48-16	10102-10104	to	_	
48-17	10105-10111	record	_	
48-18	10112-10119	tobacco	_	
48-19	10120-10127	product	_	
48-20	10127-10128	,	_	
48-21	10129-10136	alcohol	_	
48-22	10136-10137	,	_	
48-23	10138-10141	and	_	
48-24	10142-10146	drug	_	
48-25	10147-10150	use	_	
48-26	10151-10153	in	_	
48-27	10154-10157	the	_	
48-28	10158-10160	60	_	
48-29	10161-10165	days	_	
48-30	10166-10171	prior	_	
48-31	10172-10174	to	_	
48-32	10175-10178	the	_	
48-33	10179-10185	screen	_	
48-34	10186-10189	and	_	
48-35	10190-10196	during	_	
48-36	10197-10200	the	_	
48-37	10201-10208	interim	_	
48-38	10209-10215	period	_	
48-39	10216-10223	between	_	
48-40	10224-10228	each	_	
48-41	10229-10238	follow-up	_	
48-42	10239-10249	assessment	_	
48-43	10249-10250	.	_	

#Text=The baseline smoking rate was calculated as the total number of cigarettes smoked (NumCig) during the 60 days before the screen visit.
49-1	10251-10254	The	_	
49-2	10255-10263	baseline	_	
49-3	10264-10271	smoking	_	
49-4	10272-10276	rate	_	
49-5	10277-10280	was	_	
49-6	10281-10291	calculated	_	
49-7	10292-10294	as	_	
49-8	10295-10298	the	_	
49-9	10299-10304	total	_	
49-10	10305-10311	number	_	
49-11	10312-10314	of	_	
49-12	10315-10325	cigarettes	_	
49-13	10326-10332	smoked	_	
49-14	10333-10334	(	_	
49-15	10334-10340	NumCig	_	
49-16	10340-10341	)	_	
49-17	10342-10348	during	_	
49-18	10349-10352	the	_	
49-19	10353-10355	60	_	
49-20	10356-10360	days	_	
49-21	10361-10367	before	_	
49-22	10368-10371	the	_	
49-23	10372-10378	screen	_	
49-24	10379-10384	visit	_	
49-25	10384-10385	.	_	

#Text=Low rates of complete abstinence in the placebo group (n=4 at 6 weeks for 7 day point prevalence) rendered logistic regression problematic as a method of analysis to examine the interaction term [component beta × treatment group (RxGrp)], given small sample bias.
50-1	10386-10389	Low	_	
50-2	10390-10395	rates	_	
50-3	10396-10398	of	_	
50-4	10399-10407	complete	_	
50-5	10408-10418	abstinence	_	
50-6	10419-10421	in	_	
50-7	10422-10425	the	_	
50-8	10426-10433	placebo	_	
50-9	10434-10439	group	_	
50-10	10440-10441	(	_	
50-11	10441-10442	n	_	
50-12	10442-10443	=	_	
50-13	10443-10444	4	_	
50-14	10445-10447	at	_	
50-15	10448-10449	6	_	
50-16	10450-10455	weeks	_	
50-17	10456-10459	for	_	
50-18	10460-10461	7	_	
50-19	10462-10465	day	_	
50-20	10466-10471	point	_	
50-21	10472-10482	prevalence	_	
50-22	10482-10483	)	_	
50-23	10484-10492	rendered	_	
50-24	10493-10501	logistic	_	
50-25	10502-10512	regression	_	
50-26	10513-10524	problematic	_	
50-27	10525-10527	as	_	
50-28	10528-10529	a	_	
50-29	10530-10536	method	_	
50-30	10537-10539	of	_	
50-31	10540-10548	analysis	_	
50-32	10549-10551	to	_	
50-33	10552-10559	examine	_	
50-34	10560-10563	the	_	
50-35	10564-10575	interaction	_	
50-36	10576-10580	term	_	
50-37	10581-10582	[	_	
50-38	10582-10591	component	_	
50-39	10592-10596	beta	_	
50-40	10597-10598	×	_	
50-41	10599-10608	treatment	_	
50-42	10609-10614	group	_	
50-43	10615-10616	(	_	
50-44	10616-10621	RxGrp	_	
50-45	10621-10622	)	_	
50-46	10622-10623	]	_	
50-47	10623-10624	,	_	
50-48	10625-10630	given	_	
50-49	10631-10636	small	_	
50-50	10637-10643	sample	_	
50-51	10644-10648	bias	_	
50-52	10648-10649	.	_	

#Text=We therefore utilized continuous outcome variables as our primary outcome: NumCig during the previous 28 days for the 6 week smoking outcome and NumCig during the previous 30 days for the 12 week smoking outcome.
51-1	10650-10652	We	_	
51-2	10653-10662	therefore	_	
51-3	10663-10671	utilized	_	
51-4	10672-10682	continuous	_	
51-5	10683-10690	outcome	_	
51-6	10691-10700	variables	_	
51-7	10701-10703	as	_	
51-8	10704-10707	our	_	
51-9	10708-10715	primary	_	
51-10	10716-10723	outcome	_	
51-11	10723-10724	:	_	
51-12	10725-10731	NumCig	_	
51-13	10732-10738	during	_	
51-14	10739-10742	the	_	
51-15	10743-10751	previous	_	
51-16	10752-10754	28	_	
51-17	10755-10759	days	_	
51-18	10760-10763	for	_	
51-19	10764-10767	the	_	
51-20	10768-10769	6	_	
51-21	10770-10774	week	_	
51-22	10775-10782	smoking	_	
51-23	10783-10790	outcome	_	
51-24	10791-10794	and	_	
51-25	10795-10801	NumCig	_	
51-26	10802-10808	during	_	
51-27	10809-10812	the	_	
51-28	10813-10821	previous	_	
51-29	10822-10824	30	_	
51-30	10825-10829	days	_	
51-31	10830-10833	for	_	
51-32	10834-10837	the	_	
51-33	10838-10840	12	_	
51-34	10841-10845	week	_	
51-35	10846-10853	smoking	_	
51-36	10854-10861	outcome	_	
51-37	10861-10862	.	_	

#Text=Although abstinence is more commonly used as a measure of success in smoking cessation trials, smoking reduction is still a meaningful outcome that predicts later cessation.
52-1	10863-10871	Although	_	
52-2	10872-10882	abstinence	_	
52-3	10883-10885	is	_	
52-4	10886-10890	more	_	
52-5	10891-10899	commonly	_	
52-6	10900-10904	used	_	
52-7	10905-10907	as	_	
52-8	10908-10909	a	_	
52-9	10910-10917	measure	_	
52-10	10918-10920	of	_	
52-11	10921-10928	success	_	
52-12	10929-10931	in	_	
52-13	10932-10939	smoking	_	
52-14	10940-10949	cessation	_	
52-15	10950-10956	trials	_	
52-16	10956-10957	,	_	
52-17	10958-10965	smoking	_	
52-18	10966-10975	reduction	_	
52-19	10976-10978	is	_	
52-20	10979-10984	still	_	
52-21	10985-10986	a	_	
52-22	10987-10997	meaningful	_	
52-23	10998-11005	outcome	_	
52-24	11006-11010	that	_	
52-25	11011-11019	predicts	_	
52-26	11020-11025	later	_	
52-27	11026-11035	cessation	_	
52-28	11035-11036	.	_	

#Text=For dropouts, missing outcomes data were imputed to an adjusted screen visit value [eg.
53-1	11037-11040	For	_	
53-2	11041-11049	dropouts	_	
53-3	11049-11050	,	_	
53-4	11051-11058	missing	_	
53-5	11059-11067	outcomes	_	
53-6	11068-11072	data	_	
53-7	11073-11077	were	_	
53-8	11078-11085	imputed	_	
53-9	11086-11088	to	_	
53-10	11089-11091	an	_	
53-11	11092-11100	adjusted	_	
53-12	11101-11107	screen	_	
53-13	11108-11113	visit	_	
53-14	11114-11119	value	_	
53-15	11120-11121	[	_	
53-16	11121-11123	eg	_	
53-17	11123-11124	.	_	

#Text=(NumCig at screen visit)*28/60 = NumCig at 6 weeks] (n=27/143 for week 6 and n=44/143 for week 12) for our primary analysis.
54-1	11125-11126	(	_	
54-2	11126-11132	NumCig	_	
54-3	11133-11135	at	_	
54-4	11136-11142	screen	_	
54-5	11143-11148	visit	_	
54-6	11148-11149	)	_	
54-7	11149-11150	*	_	
54-8	11150-11152	28	_	
54-9	11152-11153	/	_	
54-10	11153-11155	60	_	
54-11	11156-11157	=	_	
54-12	11158-11164	NumCig	_	
54-13	11165-11167	at	_	
54-14	11168-11169	6	_	
54-15	11170-11175	weeks	_	
54-16	11175-11176	]	_	
54-17	11177-11178	(	_	
54-18	11178-11179	n	_	
54-19	11179-11180	=	_	
54-20	11180-11182	27	_	
54-21	11182-11183	/	_	
54-22	11183-11186	143	_	
54-23	11187-11190	for	_	
54-24	11191-11195	week	_	
54-25	11196-11197	6	_	
54-26	11198-11201	and	_	
54-27	11202-11203	n	_	
54-28	11203-11204	=	_	
54-29	11204-11206	44	_	
54-30	11206-11207	/	_	
54-31	11207-11210	143	_	
54-32	11211-11214	for	_	
54-33	11215-11219	week	_	
54-34	11220-11222	12	_	
54-35	11222-11223	)	_	
54-36	11224-11227	for	_	
54-37	11228-11231	our	_	
54-38	11232-11239	primary	_	
54-39	11240-11248	analysis	_	
54-40	11248-11249	.	_	

#Text=Imputing to baseline (assuming missing subjects revert to baseline smoking levels) is a common approach for smoking cessation clinical trials even when rates of dropout approach ours.
55-1	11250-11258	Imputing	_	
55-2	11259-11261	to	_	
55-3	11262-11270	baseline	_	
55-4	11271-11272	(	_	
55-5	11272-11280	assuming	_	
55-6	11281-11288	missing	_	
55-7	11289-11297	subjects	_	
55-8	11298-11304	revert	_	
55-9	11305-11307	to	_	
55-10	11308-11316	baseline	_	
55-11	11317-11324	smoking	_	
55-12	11325-11331	levels	_	
55-13	11331-11332	)	_	
55-14	11333-11335	is	_	
55-15	11336-11337	a	_	
55-16	11338-11344	common	_	
55-17	11345-11353	approach	_	
55-18	11354-11357	for	_	
55-19	11358-11365	smoking	_	
55-20	11366-11375	cessation	_	
55-21	11376-11384	clinical	_	
55-22	11385-11391	trials	_	
55-23	11392-11396	even	_	
55-24	11397-11401	when	_	
55-25	11402-11407	rates	_	
55-26	11408-11410	of	_	
55-27	11411-11418	dropout	_	
55-28	11419-11427	approach	_	
55-29	11428-11432	ours	_	
55-30	11432-11433	.	_	

#Text=We also present results for an analysis performed on individuals with complete data.
56-1	11434-11436	We	_	
56-2	11437-11441	also	_	
56-3	11442-11449	present	_	
56-4	11450-11457	results	_	
56-5	11458-11461	for	_	
56-6	11462-11464	an	_	
56-7	11465-11473	analysis	_	
56-8	11474-11483	performed	_	
56-9	11484-11486	on	_	
56-10	11487-11498	individuals	_	
56-11	11499-11503	with	_	
56-12	11504-11512	complete	_	
56-13	11513-11517	data	_	
56-14	11517-11518	.	_	

#Text=Cue-Exposure Task
#Text=The cue-exposure task is identical to the task for which results in a different sample of non treatment-seeking smokers is published (details in Supporting Information).
57-1	11519-11531	Cue-Exposure	_	
57-2	11532-11536	Task	_	
57-3	11537-11540	The	_	
57-4	11541-11553	cue-exposure	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
57-5	11554-11558	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]	
57-6	11559-11561	is	_	
57-7	11562-11571	identical	_	
57-8	11572-11574	to	_	
57-9	11575-11578	the	_	
57-10	11579-11583	task	_	
57-11	11584-11587	for	_	
57-12	11588-11593	which	_	
57-13	11594-11601	results	_	
57-14	11602-11604	in	_	
57-15	11605-11606	a	_	
57-16	11607-11616	different	_	
57-17	11617-11623	sample	_	
57-18	11624-11626	of	_	
57-19	11627-11630	non	_	
57-20	11631-11648	treatment-seeking	_	
57-21	11649-11656	smokers	_	
57-22	11657-11659	is	_	
57-23	11660-11669	published	_	
57-24	11670-11671	(	_	
57-25	11671-11678	details	_	
57-26	11679-11681	in	_	
57-27	11682-11692	Supporting	_	
57-28	11693-11704	Information	_	
57-29	11704-11705	)	_	
57-30	11705-11706	.	_	

#Text=In brief, the task consisted of two 6-min runs with pseudorandom presentations of seven different smoking- related videos and seven different food-related videos per run, ranging in length from 7 to 14 seconds, and depicting images of preparation of the stimulus for ingestion and the act of ingestion itself.
58-1	11707-11709	In	_	
58-2	11710-11715	brief	_	
58-3	11715-11716	,	_	
58-4	11717-11720	the	_	
58-5	11721-11725	task	_	
58-6	11726-11735	consisted	_	
58-7	11736-11738	of	_	
58-8	11739-11742	two	_	
58-9	11743-11744	6	_	
58-10	11744-11745	-	_	
58-11	11745-11748	min	_	
58-12	11749-11753	runs	_	
58-13	11754-11758	with	_	
58-14	11759-11771	pseudorandom	_	
58-15	11772-11785	presentations	_	
58-16	11786-11788	of	_	
58-17	11789-11794	seven	_	
58-18	11795-11804	different	_	
58-19	11805-11812	smoking	_	
58-20	11812-11813	-	_	
58-21	11814-11821	related	_	
58-22	11822-11828	videos	_	
58-23	11829-11832	and	_	
58-24	11833-11838	seven	_	
58-25	11839-11848	different	_	
58-26	11849-11861	food-related	_	
58-27	11862-11868	videos	_	
58-28	11869-11872	per	_	
58-29	11873-11876	run	_	
58-30	11876-11877	,	_	
58-31	11878-11885	ranging	_	
58-32	11886-11888	in	_	
58-33	11889-11895	length	_	
58-34	11896-11900	from	_	
58-35	11901-11902	7	_	
58-36	11903-11905	to	_	
58-37	11906-11908	14	_	
58-38	11909-11916	seconds	_	
58-39	11916-11917	,	_	
58-40	11918-11921	and	_	
58-41	11922-11931	depicting	_	
58-42	11932-11938	images	_	
58-43	11939-11941	of	_	
58-44	11942-11953	preparation	_	
58-45	11954-11956	of	_	
58-46	11957-11960	the	_	
58-47	11961-11969	stimulus	_	
58-48	11970-11973	for	_	
58-49	11974-11983	ingestion	_	
58-50	11984-11987	and	_	
58-51	11988-11991	the	_	
58-52	11992-11995	act	_	
58-53	11996-11998	of	_	
58-54	11999-12008	ingestion	_	
58-55	12009-12015	itself	_	
58-56	12015-12016	.	_	

#Text=MRI Acquisition and Preprocessing
#Text=All scans were acquired on a Siemens 3T Trio scanner located at the Mind Research Network in Albuquerque NM using procedures previously described.
59-1	12017-12020	MRI	_	
59-2	12021-12032	Acquisition	_	
59-3	12033-12036	and	_	
59-4	12037-12050	Preprocessing	_	
59-5	12051-12054	All	_	
59-6	12055-12060	scans	_	
59-7	12061-12065	were	_	
59-8	12066-12074	acquired	_	
59-9	12075-12077	on	_	
59-10	12078-12079	a	_	
59-11	12080-12087	Siemens	_	
59-12	12088-12090	3T	_	
59-13	12091-12095	Trio	_	
59-14	12096-12103	scanner	_	
59-15	12104-12111	located	_	
59-16	12112-12114	at	_	
59-17	12115-12118	the	_	
59-18	12119-12123	Mind	_	
59-19	12124-12132	Research	_	
59-20	12133-12140	Network	_	
59-21	12141-12143	in	_	
59-22	12144-12155	Albuquerque	_	
59-23	12156-12158	NM	_	
59-24	12159-12164	using	_	
59-25	12165-12175	procedures	_	
59-26	12176-12186	previously	_	
59-27	12187-12196	described	_	
59-28	12196-12197	.	_	

#Text=Data were preprocessed using SPM5 software (http://fil.ion.ucl.ac.uk/spm/software/spm5) using standard methods (details in Supporting Information).
60-1	12198-12202	Data	_	
60-2	12203-12207	were	_	
60-3	12208-12220	preprocessed	_	
60-4	12221-12226	using	_	
60-5	12227-12231	SPM5	_	
60-6	12232-12240	software	_	
60-7	12241-12242	(	_	
60-8	12242-12246	http	_	
60-9	12246-12247	:	_	
60-10	12247-12248	/	_	
60-11	12248-12249	/	_	
60-12	12249-12266	fil.ion.ucl.ac.uk	_	
60-13	12266-12267	/	_	
60-14	12267-12270	spm	_	
60-15	12270-12271	/	_	
60-16	12271-12279	software	_	
60-17	12279-12280	/	_	
60-18	12280-12284	spm5	_	
60-19	12284-12285	)	_	
60-20	12286-12291	using	_	
60-21	12292-12300	standard	_	
60-22	12301-12308	methods	_	
60-23	12309-12310	(	_	
60-24	12310-12317	details	_	
60-25	12318-12320	in	_	
60-26	12321-12331	Supporting	_	
60-27	12332-12343	Information	_	
60-28	12343-12344	)	_	
60-29	12344-12345	.	_	

#Text=ICA Methods
#Text=Infomax group spatial ICA was conducted to decompose the data into components using GIFT software (http://mialab.mrn.org/software/gift). 35 components for the previous data reduction step, and 30 components for the final data reduction step were chosen (typical for low order models).
61-1	12346-12349	ICA	_	
61-2	12350-12357	Methods	_	
61-3	12358-12365	Infomax	_	
61-4	12366-12371	group	_	
61-5	12372-12379	spatial	_	
61-6	12380-12383	ICA	_	
61-7	12384-12387	was	_	
61-8	12388-12397	conducted	_	
61-9	12398-12400	to	_	
61-10	12401-12410	decompose	_	
61-11	12411-12414	the	_	
61-12	12415-12419	data	_	
61-13	12420-12424	into	_	
61-14	12425-12435	components	_	
61-15	12436-12441	using	_	
61-16	12442-12446	GIFT	_	
61-17	12447-12455	software	_	
61-18	12456-12457	(	_	
61-19	12457-12461	http	_	
61-20	12461-12462	:	_	
61-21	12462-12463	/	_	
61-22	12463-12464	/	_	
61-23	12464-12478	mialab.mrn.org	_	
61-24	12478-12479	/	_	
61-25	12479-12487	software	_	
61-26	12487-12488	/	_	
61-27	12488-12492	gift	_	
61-28	12492-12493	)	_	
61-29	12493-12494	.	_	
61-30	12495-12497	35	_	
61-31	12498-12508	components	_	
61-32	12509-12512	for	_	
61-33	12513-12516	the	_	
61-34	12517-12525	previous	_	
61-35	12526-12530	data	_	
61-36	12531-12540	reduction	_	
61-37	12541-12545	step	_	
61-38	12545-12546	,	_	
61-39	12547-12550	and	_	
61-40	12551-12553	30	_	
61-41	12554-12564	components	_	
61-42	12565-12568	for	_	
61-43	12569-12572	the	_	
61-44	12573-12578	final	_	
61-45	12579-12583	data	_	
61-46	12584-12593	reduction	_	
61-47	12594-12598	step	_	
61-48	12599-12603	were	_	
61-49	12604-12610	chosen	_	
61-50	12611-12612	(	_	
61-51	12612-12619	typical	_	
61-52	12620-12623	for	_	
61-53	12624-12627	low	_	
61-54	12628-12633	order	_	
61-55	12634-12640	models	_	
61-56	12640-12641	)	_	
61-57	12641-12642	.	_	

#Text=To estimate subject-specific spatial maps and time-courses, the GICA back-reconstruction method was used.
62-1	12643-12645	To	_	
62-2	12646-12654	estimate	_	
62-3	12655-12671	subject-specific	_	
62-4	12672-12679	spatial	_	
62-5	12680-12684	maps	_	
62-6	12685-12688	and	_	
62-7	12689-12701	time-courses	_	
62-8	12701-12702	,	_	
62-9	12703-12706	the	_	
62-10	12707-12711	GICA	_	
62-11	12712-12731	back-reconstruction	_	
62-12	12732-12738	method	_	
62-13	12739-12742	was	_	
62-14	12743-12747	used	_	
62-15	12747-12748	.	_	

#Text=ICA was repeated 10 times using ICASSO (http://research.ics.aalto.fi/ica/icasso/) and the “best run” was selected to mitigate variation due to the stochastic estimation process.
63-1	12749-12752	ICA	_	
63-2	12753-12756	was	_	
63-3	12757-12765	repeated	_	
63-4	12766-12768	10	_	
63-5	12769-12774	times	_	
63-6	12775-12780	using	_	
63-7	12781-12787	ICASSO	_	
63-8	12788-12789	(	_	
63-9	12789-12793	http	_	
63-10	12793-12794	:	_	
63-11	12794-12795	/	_	
63-12	12795-12796	/	_	
63-13	12796-12817	research.ics.aalto.fi	_	
63-14	12817-12818	/	_	
63-15	12818-12821	ica	_	
63-16	12821-12822	/	_	
63-17	12822-12828	icasso	_	
63-18	12828-12829	/	_	
63-19	12829-12830	)	_	
63-20	12831-12834	and	_	
63-21	12835-12838	the	_	
63-22	12839-12840	“	_	
63-23	12840-12844	best	_	
63-24	12845-12848	run	_	
63-25	12848-12849	”	_	
63-26	12850-12853	was	_	
63-27	12854-12862	selected	_	
63-28	12863-12865	to	_	
63-29	12866-12874	mitigate	_	
63-30	12875-12884	variation	_	
63-31	12885-12888	due	_	
63-32	12889-12891	to	_	
63-33	12892-12895	the	_	
63-34	12896-12906	stochastic	_	
63-35	12907-12917	estimation	_	
63-36	12918-12925	process	_	
63-37	12925-12926	.	_	

#Text=The resulting component runs were also clustered to estimate the reliability of the decomposition.
64-1	12927-12930	The	_	
64-2	12931-12940	resulting	_	
64-3	12941-12950	component	_	
64-4	12951-12955	runs	_	
64-5	12956-12960	were	_	
64-6	12961-12965	also	_	
64-7	12966-12975	clustered	_	
64-8	12976-12978	to	_	
64-9	12979-12987	estimate	_	
64-10	12988-12991	the	_	
64-11	12992-13003	reliability	_	
64-12	13004-13006	of	_	
64-13	13007-13010	the	_	
64-14	13011-13024	decomposition	_	
64-15	13024-13025	.	_	

#Text=Robustness and reliability of components were well-validated by the ICASSO results showing compact and independent/non-overlapping clusters.
65-1	13026-13036	Robustness	_	
65-2	13037-13040	and	_	
65-3	13041-13052	reliability	_	
65-4	13053-13055	of	_	
65-5	13056-13066	components	_	
65-6	13067-13071	were	_	
65-7	13072-13086	well-validated	_	
65-8	13087-13089	by	_	
65-9	13090-13093	the	_	
65-10	13094-13100	ICASSO	_	
65-11	13101-13108	results	_	
65-12	13109-13116	showing	_	
65-13	13117-13124	compact	_	
65-14	13125-13128	and	_	
65-15	13129-13140	independent	_	
65-16	13140-13141	/	_	
65-17	13141-13156	non-overlapping	_	
65-18	13157-13165	clusters	_	
65-19	13165-13166	.	_	

#Text=Following ICA, time series were filtered using a low-pass filter of > 0.15 Hz, and detrending to remove low frequency noise (high-pass filter).
66-1	13167-13176	Following	_	
66-2	13177-13180	ICA	_	
66-3	13180-13181	,	_	
66-4	13182-13186	time	_	
66-5	13187-13193	series	_	
66-6	13194-13198	were	_	
66-7	13199-13207	filtered	_	
66-8	13208-13213	using	_	
66-9	13214-13215	a	_	
66-10	13216-13224	low-pass	_	
66-11	13225-13231	filter	_	
66-12	13232-13234	of	_	
66-13	13235-13236	>	_	
66-14	13237-13241	0.15	_	
66-15	13242-13244	Hz	_	
66-16	13244-13245	,	_	
66-17	13246-13249	and	_	
66-18	13250-13260	detrending	_	
66-19	13261-13263	to	_	
66-20	13264-13270	remove	_	
66-21	13271-13274	low	_	
66-22	13275-13284	frequency	_	
66-23	13285-13290	noise	_	
66-24	13291-13292	(	_	
66-25	13292-13301	high-pass	_	
66-26	13302-13308	filter	_	
66-27	13308-13309	)	_	
66-28	13309-13310	.	_	

#Text=To correct for head motion, time series were then despiked, and motion was regressed out on a per-subject basis using the six motion parameters.
67-1	13311-13313	To	_	
67-2	13314-13321	correct	_	
67-3	13322-13325	for	_	
67-4	13326-13330	head	_	
67-5	13331-13337	motion	_	
67-6	13337-13338	,	_	
67-7	13339-13343	time	_	
67-8	13344-13350	series	_	
67-9	13351-13355	were	_	
67-10	13356-13360	then	_	
67-11	13361-13369	despiked	_	
67-12	13369-13370	,	_	
67-13	13371-13374	and	_	
67-14	13375-13381	motion	_	
67-15	13382-13385	was	_	
67-16	13386-13395	regressed	_	
67-17	13396-13399	out	_	
67-18	13400-13402	on	_	
67-19	13403-13404	a	_	
67-20	13405-13416	per-subject	_	
67-21	13417-13422	basis	_	
67-22	13423-13428	using	_	
67-23	13429-13432	the	_	
67-24	13433-13436	six	_	
67-25	13437-13443	motion	_	
67-26	13444-13454	parameters	_	
67-27	13454-13455	.	_	

#Text=In addition, mean root mean squared translational (rmsTrans) and rotational (rmsRot) framewise displacement (FD) were calculated for each subject.
68-1	13456-13458	In	_	
68-2	13459-13467	addition	_	
68-3	13467-13468	,	_	
68-4	13469-13473	mean	_	
68-5	13474-13478	root	_	
68-6	13479-13483	mean	_	
68-7	13484-13491	squared	_	
68-8	13492-13505	translational	_	
68-9	13506-13507	(	_	
68-10	13507-13515	rmsTrans	_	
68-11	13515-13516	)	_	
68-12	13517-13520	and	_	
68-13	13521-13531	rotational	_	
68-14	13532-13533	(	_	
68-15	13533-13539	rmsRot	_	
68-16	13539-13540	)	_	
68-17	13541-13550	framewise	_	
68-18	13551-13563	displacement	_	
68-19	13564-13565	(	_	
68-20	13565-13567	FD	_	
68-21	13567-13568	)	_	
68-22	13569-13573	were	_	
68-23	13574-13584	calculated	_	
68-24	13585-13588	for	_	
68-25	13589-13593	each	_	
68-26	13594-13601	subject	_	
68-27	13601-13602	.	_	

#Text=Component Selection
#Text=Spatial maps were reconstructed and converted to Z values for each of the subjects.
69-1	13603-13612	Component	_	
69-2	13613-13622	Selection	_	
69-3	13623-13630	Spatial	_	
69-4	13631-13635	maps	_	
69-5	13636-13640	were	_	
69-6	13641-13654	reconstructed	_	
69-7	13655-13658	and	_	
69-8	13659-13668	converted	_	
69-9	13669-13671	to	_	
69-10	13672-13673	Z	_	
69-11	13674-13680	values	_	
69-12	13681-13684	for	_	
69-13	13685-13689	each	_	
69-14	13690-13692	of	_	
69-15	13693-13696	the	_	
69-16	13697-13705	subjects	_	
69-17	13705-13706	.	_	

#Text=A standardized DMN mask [rDMN_ICA_REST*.nii; http://mialab.mrn.org/data ] was used to select the DMN component from the 30 estimated components using the spatial sort function in GIFT; we selected the component which was most strongly associated with our apriori template R2 = 0.42) (Figure 1a).
70-1	13707-13708	A	_	
70-2	13709-13721	standardized	_	
70-3	13722-13725	DMN	_	
70-4	13726-13730	mask	_	
70-5	13731-13732	[	_	
70-6	13732-13745	rDMN_ICA_REST	_	
70-7	13745-13746	*	_	
70-8	13746-13747	.	_	
70-9	13747-13750	nii	_	
70-10	13750-13751	;	_	
70-11	13752-13756	http	_	
70-12	13756-13757	:	_	
70-13	13757-13758	/	_	
70-14	13758-13759	/	_	
70-15	13759-13773	mialab.mrn.org	_	
70-16	13773-13774	/	_	
70-17	13774-13778	data	_	
70-18	13779-13780	]	_	
70-19	13781-13784	was	_	
70-20	13785-13789	used	_	
70-21	13790-13792	to	_	
70-22	13793-13799	select	_	
70-23	13800-13803	the	_	
70-24	13804-13807	DMN	_	
70-25	13808-13817	component	_	
70-26	13818-13822	from	_	
70-27	13823-13826	the	_	
70-28	13827-13829	30	_	
70-29	13830-13839	estimated	_	
70-30	13840-13850	components	_	
70-31	13851-13856	using	_	
70-32	13857-13860	the	_	
70-33	13861-13868	spatial	_	
70-34	13869-13873	sort	_	
70-35	13874-13882	function	_	
70-36	13883-13885	in	_	
70-37	13886-13890	GIFT	_	
70-38	13890-13891	;	_	
70-39	13892-13894	we	_	
70-40	13895-13903	selected	_	
70-41	13904-13907	the	_	
70-42	13908-13917	component	_	
70-43	13918-13923	which	_	
70-44	13924-13927	was	_	
70-45	13928-13932	most	_	
70-46	13933-13941	strongly	_	
70-47	13942-13952	associated	_	
70-48	13953-13957	with	_	
70-49	13958-13961	our	_	
70-50	13962-13969	apriori	_	
70-51	13970-13978	template	_	
70-52	13979-13981	R2	_	
70-53	13982-13983	=	_	
70-54	13984-13988	0.42	_	
70-55	13988-13989	)	_	
70-56	13990-13991	(	_	
70-57	13991-13997	Figure	_	
70-58	13998-14000	1a	_	
70-59	14000-14001	)	_	
70-60	14001-14002	.	_	

#Text=This method was chosen so that our analyses could be systematically replicated in other samples.
71-1	14003-14007	This	_	
71-2	14008-14014	method	_	
71-3	14015-14018	was	_	
71-4	14019-14025	chosen	_	
71-5	14026-14028	so	_	
71-6	14029-14033	that	_	
71-7	14034-14037	our	_	
71-8	14038-14046	analyses	_	
71-9	14047-14052	could	_	
71-10	14053-14055	be	_	
71-11	14056-14070	systematically	_	
71-12	14071-14081	replicated	_	
71-13	14082-14084	in	_	
71-14	14085-14090	other	_	
71-15	14091-14098	samples	_	
71-16	14098-14099	.	_	

#Text=Compared to rest, previous works have shown that tasks may also modulate some of the spatial maps, but the change is not large, so the use of a rest DMN template is reasonable.
72-1	14100-14108	Compared	_	
72-2	14109-14111	to	_	
72-3	14112-14116	rest	_	
72-4	14116-14117	,	_	
72-5	14118-14126	previous	_	
72-6	14127-14132	works	_	
72-7	14133-14137	have	_	
72-8	14138-14143	shown	_	
72-9	14144-14148	that	_	
72-10	14149-14154	tasks	_	
72-11	14155-14158	may	_	
72-12	14159-14163	also	_	
72-13	14164-14172	modulate	_	
72-14	14173-14177	some	_	
72-15	14178-14180	of	_	
72-16	14181-14184	the	_	
72-17	14185-14192	spatial	_	
72-18	14193-14197	maps	_	
72-19	14197-14198	,	_	
72-20	14199-14202	but	_	
72-21	14203-14206	the	_	
72-22	14207-14213	change	_	
72-23	14214-14216	is	_	
72-24	14217-14220	not	_	
72-25	14221-14226	large	_	
72-26	14226-14227	,	_	
72-27	14228-14230	so	_	
72-28	14231-14234	the	_	
72-29	14235-14238	use	_	
72-30	14239-14241	of	_	
72-31	14242-14243	a	_	
72-32	14244-14248	rest	_	
72-33	14249-14252	DMN	_	
72-34	14253-14261	template	_	
72-35	14262-14264	is	_	
72-36	14265-14275	reasonable	_	
72-37	14275-14276	.	_	

#Text=The ECN [right(R) and left(L)] and SN were identified visually by anatomical overlap with previous studies of these networks in smokers.
73-1	14277-14280	The	_	
73-2	14281-14284	ECN	_	
73-3	14285-14286	[	_	
73-4	14286-14291	right	_	
73-5	14291-14292	(	_	
73-6	14292-14293	R	_	
73-7	14293-14294	)	_	
73-8	14295-14298	and	_	
73-9	14299-14303	left	_	
73-10	14303-14304	(	_	
73-11	14304-14305	L	_	
73-12	14305-14306	)	_	
73-13	14306-14307	]	_	
73-14	14308-14311	and	_	
73-15	14312-14314	SN	_	
73-16	14315-14319	were	_	
73-17	14320-14330	identified	_	
73-18	14331-14339	visually	_	
73-19	14340-14342	by	_	
73-20	14343-14353	anatomical	_	
73-21	14354-14361	overlap	_	
73-22	14362-14366	with	_	
73-23	14367-14375	previous	_	
73-24	14376-14383	studies	_	
73-25	14384-14386	of	_	
73-26	14387-14392	these	_	
73-27	14393-14401	networks	_	
73-28	14402-14404	in	_	
73-29	14405-14412	smokers	_	
73-30	14412-14413	.	_	

#Text=Temporal Sort and Development of the Component Predictor Variables
#Text=For each component, we determined its task-relatedness using temporal sorting in GIFT, which utilizes the time-course of the component as the dependent variable, and variables from the design matrix of the task as independent variables.
74-1	14414-14422	Temporal	_	
74-2	14423-14427	Sort	_	
74-3	14428-14431	and	_	
74-4	14432-14443	Development	_	
74-5	14444-14446	of	_	
74-6	14447-14450	the	_	
74-7	14451-14460	Component	_	
74-8	14461-14470	Predictor	_	
74-9	14471-14480	Variables	_	
74-10	14481-14484	For	_	
74-11	14485-14489	each	_	
74-12	14490-14499	component	_	
74-13	14499-14500	,	_	
74-14	14501-14503	we	_	
74-15	14504-14514	determined	_	
74-16	14515-14518	its	_	
74-17	14519-14535	task-relatedness	_	
74-18	14536-14541	using	_	
74-19	14542-14550	temporal	_	
74-20	14551-14558	sorting	_	
74-21	14559-14561	in	_	
74-22	14562-14566	GIFT	_	
74-23	14566-14567	,	_	
74-24	14568-14573	which	_	
74-25	14574-14582	utilizes	_	
74-26	14583-14586	the	_	
74-27	14587-14598	time-course	_	
74-28	14599-14601	of	_	
74-29	14602-14605	the	_	
74-30	14606-14615	component	_	
74-31	14616-14618	as	_	
74-32	14619-14622	the	_	
74-33	14623-14632	dependent	_	
74-34	14633-14641	variable	_	
74-35	14641-14642	,	_	
74-36	14643-14646	and	_	
74-37	14647-14656	variables	_	
74-38	14657-14661	from	_	
74-39	14662-14665	the	_	
74-40	14666-14672	design	_	
74-41	14673-14679	matrix	_	
74-42	14680-14682	of	_	
74-43	14683-14686	the	_	
74-44	14687-14691	task	_	
74-45	14692-14694	as	_	
74-46	14695-14706	independent	_	
74-47	14707-14716	variables	_	
74-48	14716-14717	.	_	

#Text=Food cues, smoking cues, and a constant were modeled which produced betas associated with each of the regressors.
75-1	14718-14722	Food	_	
75-2	14723-14727	cues	_	
75-3	14727-14728	,	_	
75-4	14729-14736	smoking	_	
75-5	14737-14741	cues	_	
75-6	14741-14742	,	_	
75-7	14743-14746	and	_	
75-8	14747-14748	a	_	
75-9	14749-14757	constant	_	
75-10	14758-14762	were	_	
75-11	14763-14770	modeled	_	
75-12	14771-14776	which	_	
75-13	14777-14785	produced	_	
75-14	14786-14791	betas	_	
75-15	14792-14802	associated	_	
75-16	14803-14807	with	_	
75-17	14808-14812	each	_	
75-18	14813-14815	of	_	
75-19	14816-14819	the	_	
75-20	14820-14830	regressors	_	
75-21	14830-14831	.	_	

#Text=These betas are similar to those one would see from a typical voxelwise GLM analysis such as those performed in previous work with the same task, except that the betas represent the degree to which the condition of interest is associated with increases/decreases in network activity rather than individual voxel activity.
76-1	14832-14837	These	_	
76-2	14838-14843	betas	_	
76-3	14844-14847	are	_	
76-4	14848-14855	similar	_	
76-5	14856-14858	to	_	
76-6	14859-14864	those	_	
76-7	14865-14868	one	_	
76-8	14869-14874	would	_	
76-9	14875-14878	see	_	
76-10	14879-14883	from	_	
76-11	14884-14885	a	_	
76-12	14886-14893	typical	_	
76-13	14894-14903	voxelwise	_	
76-14	14904-14907	GLM	_	
76-15	14908-14916	analysis	_	
76-16	14917-14921	such	_	
76-17	14922-14924	as	_	
76-18	14925-14930	those	_	
76-19	14931-14940	performed	_	
76-20	14941-14943	in	_	
76-21	14944-14952	previous	_	
76-22	14953-14957	work	_	
76-23	14958-14962	with	_	
76-24	14963-14966	the	_	
76-25	14967-14971	same	_	
76-26	14972-14976	task	_	
76-27	14976-14977	,	_	
76-28	14978-14984	except	_	
76-29	14985-14989	that	_	
76-30	14990-14993	the	_	
76-31	14994-14999	betas	_	
76-32	15000-15009	represent	_	
76-33	15010-15013	the	_	
76-34	15014-15020	degree	_	
76-35	15021-15023	to	_	
76-36	15024-15029	which	_	
76-37	15030-15033	the	_	
76-38	15034-15043	condition	_	
76-39	15044-15046	of	_	
76-40	15047-15055	interest	_	
76-41	15056-15058	is	_	
76-42	15059-15069	associated	_	
76-43	15070-15074	with	_	
76-44	15075-15084	increases	_	
76-45	15084-15085	/	_	
76-46	15085-15094	decreases	_	
76-47	15095-15097	in	_	
76-48	15098-15105	network	_	
76-49	15106-15114	activity	_	
76-50	15115-15121	rather	_	
76-51	15122-15126	than	_	
76-52	15127-15137	individual	_	
76-53	15138-15143	voxel	_	
76-54	15144-15152	activity	_	
76-55	15152-15153	.	_	

#Text=Similar analyses were performed for the ECN, SN and bilateral cuneus (negative control).
77-1	15154-15161	Similar	_	
77-2	15162-15170	analyses	_	
77-3	15171-15175	were	_	
77-4	15176-15185	performed	_	
77-5	15186-15189	for	_	
77-6	15190-15193	the	_	
77-7	15194-15197	ECN	_	
77-8	15197-15198	,	_	
77-9	15199-15201	SN	_	
77-10	15202-15205	and	_	
77-11	15206-15215	bilateral	_	
77-12	15216-15222	cuneus	_	
77-13	15223-15224	(	_	
77-14	15224-15232	negative	_	
77-15	15233-15240	control	_	
77-16	15240-15241	)	_	
77-17	15241-15242	.	_	

#Text=Betas associated with smoke cues (Smoke) and food cues (Food) were extracted for each individual subject, and the difference between Smoke and Food was calculated (Smoke-Food).
78-1	15243-15248	Betas	_	
78-2	15249-15259	associated	_	
78-3	15260-15264	with	_	
78-4	15265-15270	smoke	_	
78-5	15271-15275	cues	_	
78-6	15276-15277	(	_	
78-7	15277-15282	Smoke	_	
78-8	15282-15283	)	_	
78-9	15284-15287	and	_	
78-10	15288-15292	food	_	
78-11	15293-15297	cues	_	
78-12	15298-15299	(	_	
78-13	15299-15303	Food	_	
78-14	15303-15304	)	_	
78-15	15305-15309	were	_	
78-16	15310-15319	extracted	_	
78-17	15320-15323	for	_	
78-18	15324-15328	each	_	
78-19	15329-15339	individual	_	
78-20	15340-15347	subject	_	
78-21	15347-15348	,	_	
78-22	15349-15352	and	_	
78-23	15353-15356	the	_	
78-24	15357-15367	difference	_	
78-25	15368-15375	between	_	
78-26	15376-15381	Smoke	_	
78-27	15382-15385	and	_	
78-28	15386-15390	Food	_	
78-29	15391-15394	was	_	
78-30	15395-15405	calculated	_	
78-31	15406-15407	(	_	
78-32	15407-15417	Smoke-Food	_	
78-33	15417-15418	)	_	
78-34	15418-15419	.	_	

#Text=T tests were computed on the beta values corresponding to Food and Smoke to establish whether or not there was a difference between the networks’ response to the two cue types.
79-1	15420-15421	T	_	
79-2	15422-15427	tests	_	
79-3	15428-15432	were	_	
79-4	15433-15441	computed	_	
79-5	15442-15444	on	_	
79-6	15445-15448	the	_	
79-7	15449-15453	beta	_	
79-8	15454-15460	values	_	
79-9	15461-15474	corresponding	_	
79-10	15475-15477	to	_	
79-11	15478-15482	Food	_	
79-12	15483-15486	and	_	
79-13	15487-15492	Smoke	_	
79-14	15493-15495	to	_	
79-15	15496-15505	establish	_	
79-16	15506-15513	whether	_	
79-17	15514-15516	or	_	
79-18	15517-15520	not	_	
79-19	15521-15526	there	_	
79-20	15527-15530	was	_	
79-21	15531-15532	a	_	
79-22	15533-15543	difference	_	
79-23	15544-15551	between	_	
79-24	15552-15555	the	_	
79-25	15556-15564	networks	_	
79-26	15564-15565	’	_	
79-27	15566-15574	response	_	
79-28	15575-15577	to	_	
79-29	15578-15581	the	_	
79-30	15582-15585	two	_	
79-31	15586-15589	cue	_	
79-32	15590-15595	types	_	
79-33	15595-15596	.	_	

#Text=Clinical Outcome Prediction
#Text=Our outcome variables (NumCig 6 and 12 weeks) were count variables which appeared to have a Poisson distribution, but did not meet the assumption required for a Poisson distribution (mean equaling variance) so we chose a negative binomial with log link model to predict clinical outcomes in SPSS.
80-1	15597-15605	Clinical	_	
80-2	15606-15613	Outcome	_	
80-3	15614-15624	Prediction	_	
80-4	15625-15628	Our	_	
80-5	15629-15636	outcome	_	
80-6	15637-15646	variables	_	
80-7	15647-15648	(	_	
80-8	15648-15654	NumCig	_	
80-9	15655-15656	6	_	
80-10	15657-15660	and	_	
80-11	15661-15663	12	_	
80-12	15664-15669	weeks	_	
80-13	15669-15670	)	_	
80-14	15671-15675	were	_	
80-15	15676-15681	count	_	
80-16	15682-15691	variables	_	
80-17	15692-15697	which	_	
80-18	15698-15706	appeared	_	
80-19	15707-15709	to	_	
80-20	15710-15714	have	_	
80-21	15715-15716	a	_	
80-22	15717-15724	Poisson	_	
80-23	15725-15737	distribution	_	
80-24	15737-15738	,	_	
80-25	15739-15742	but	_	
80-26	15743-15746	did	_	
80-27	15747-15750	not	_	
80-28	15751-15755	meet	_	
80-29	15756-15759	the	_	
80-30	15760-15770	assumption	_	
80-31	15771-15779	required	_	
80-32	15780-15783	for	_	
80-33	15784-15785	a	_	
80-34	15786-15793	Poisson	_	
80-35	15794-15806	distribution	_	
80-36	15807-15808	(	_	
80-37	15808-15812	mean	_	
80-38	15813-15821	equaling	_	
80-39	15822-15830	variance	_	
80-40	15830-15831	)	_	
80-41	15832-15834	so	_	
80-42	15835-15837	we	_	
80-43	15838-15843	chose	_	
80-44	15844-15845	a	_	
80-45	15846-15854	negative	_	
80-46	15855-15863	binomial	_	
80-47	15864-15868	with	_	
80-48	15869-15872	log	_	
80-49	15873-15877	link	_	
80-50	15878-15883	model	_	
80-51	15884-15886	to	_	
80-52	15887-15894	predict	_	
80-53	15895-15903	clinical	_	
80-54	15904-15912	outcomes	_	
80-55	15913-15915	in	_	
80-56	15916-15920	SPSS	_	
80-57	15920-15921	.	_	

#Text=This is the model of choice when a dependent variable has many zero values, and it assumes over-dispersion.
81-1	15922-15926	This	_	
81-2	15927-15929	is	_	
81-3	15930-15933	the	_	
81-4	15934-15939	model	_	
81-5	15940-15942	of	_	
81-6	15943-15949	choice	_	
81-7	15950-15954	when	_	
81-8	15955-15956	a	_	
81-9	15957-15966	dependent	_	
81-10	15967-15975	variable	_	
81-11	15976-15979	has	_	
81-12	15980-15984	many	_	
81-13	15985-15989	zero	_	
81-14	15990-15996	values	_	
81-15	15996-15997	,	_	
81-16	15998-16001	and	_	
81-17	16002-16004	it	_	
81-18	16005-16012	assumes	_	
81-19	16013-16028	over-dispersion	_	
81-20	16028-16029	.	_	

#Text=In order to test a repeated measures outcome comprised of correlated variables (smoking at 6 week and 12 weeks) we used generalized estimating equations (GEE) with a robust covariance estimation method and assigned time as a within-subjects variable, and smoking as our outcome variable, which outputs a single test for the relationship between predictor and smoking outcome incorporating both 6 week and 12 week smoking outcomes.
82-1	16030-16032	In	_	
82-2	16033-16038	order	_	
82-3	16039-16041	to	_	
82-4	16042-16046	test	_	
82-5	16047-16048	a	_	
82-6	16049-16057	repeated	_	
82-7	16058-16066	measures	_	
82-8	16067-16074	outcome	_	
82-9	16075-16084	comprised	_	
82-10	16085-16087	of	_	
82-11	16088-16098	correlated	_	
82-12	16099-16108	variables	_	
82-13	16109-16110	(	_	
82-14	16110-16117	smoking	_	
82-15	16118-16120	at	_	
82-16	16121-16122	6	_	
82-17	16123-16127	week	_	
82-18	16128-16131	and	_	
82-19	16132-16134	12	_	
82-20	16135-16140	weeks	_	
82-21	16140-16141	)	_	
82-22	16142-16144	we	_	
82-23	16145-16149	used	_	
82-24	16150-16161	generalized	_	
82-25	16162-16172	estimating	_	
82-26	16173-16182	equations	_	
82-27	16183-16184	(	_	
82-28	16184-16187	GEE	_	
82-29	16187-16188	)	_	
82-30	16189-16193	with	_	
82-31	16194-16195	a	_	
82-32	16196-16202	robust	_	
82-33	16203-16213	covariance	_	
82-34	16214-16224	estimation	_	
82-35	16225-16231	method	_	
82-36	16232-16235	and	_	
82-37	16236-16244	assigned	_	
82-38	16245-16249	time	_	
82-39	16250-16252	as	_	
82-40	16253-16254	a	_	
82-41	16255-16270	within-subjects	_	
82-42	16271-16279	variable	_	
82-43	16279-16280	,	_	
82-44	16281-16284	and	_	
82-45	16285-16292	smoking	_	
82-46	16293-16295	as	_	
82-47	16296-16299	our	_	
82-48	16300-16307	outcome	_	
82-49	16308-16316	variable	_	
82-50	16316-16317	,	_	
82-51	16318-16323	which	_	
82-52	16324-16331	outputs	_	
82-53	16332-16333	a	_	
82-54	16334-16340	single	_	
82-55	16341-16345	test	_	
82-56	16346-16349	for	_	
82-57	16350-16353	the	_	
82-58	16354-16366	relationship	_	
82-59	16367-16374	between	_	
82-60	16375-16384	predictor	_	
82-61	16385-16388	and	_	
82-62	16389-16396	smoking	_	
82-63	16397-16404	outcome	_	
82-64	16405-16418	incorporating	_	
82-65	16419-16423	both	_	
82-66	16424-16425	6	_	
82-67	16426-16430	week	_	
82-68	16431-16434	and	_	
82-69	16435-16437	12	_	
82-70	16438-16442	week	_	
82-71	16443-16450	smoking	_	
82-72	16451-16459	outcomes	_	
82-73	16459-16460	.	_	

#Text=Maximum likelihood estimation (MLE) was used to estimate the negative binomial dispersion parameters and correlation matrix representing within subjects dependencies was assigned as AR(1).
83-1	16461-16468	Maximum	_	
83-2	16469-16479	likelihood	_	
83-3	16480-16490	estimation	_	
83-4	16491-16492	(	_	
83-5	16492-16495	MLE	_	
83-6	16495-16496	)	_	
83-7	16497-16500	was	_	
83-8	16501-16505	used	_	
83-9	16506-16508	to	_	
83-10	16509-16517	estimate	_	
83-11	16518-16521	the	_	
83-12	16522-16530	negative	_	
83-13	16531-16539	binomial	_	
83-14	16540-16550	dispersion	_	
83-15	16551-16561	parameters	_	
83-16	16562-16565	and	_	
83-17	16566-16577	correlation	_	
83-18	16578-16584	matrix	_	
83-19	16585-16597	representing	_	
83-20	16598-16604	within	_	
83-21	16605-16613	subjects	_	
83-22	16614-16626	dependencies	_	
83-23	16627-16630	was	_	
83-24	16631-16639	assigned	_	
83-25	16640-16642	as	_	
83-26	16643-16645	AR	_	
83-27	16645-16646	(	_	
83-28	16646-16647	1	_	
83-29	16647-16648	)	_	
83-30	16648-16649	.	_	

#Text=P values associated with the Wald Chi Square were used to test significance of predictors.
84-1	16650-16651	P	_	
84-2	16652-16658	values	_	
84-3	16659-16669	associated	_	
84-4	16670-16674	with	_	
84-5	16675-16678	the	_	
84-6	16679-16683	Wald	_	
84-7	16684-16687	Chi	_	
84-8	16688-16694	Square	_	
84-9	16695-16699	were	_	
84-10	16700-16704	used	_	
84-11	16705-16707	to	_	
84-12	16708-16712	test	_	
84-13	16713-16725	significance	_	
84-14	16726-16728	of	_	
84-15	16729-16739	predictors	_	
84-16	16739-16740	.	_	

#Text=Given previous work highlighting the importance of comorbid psychiatric symptoms, age, dependence severity, longer duration of prior quit attempts, gender, presence or absence of current alcohol problems and impulsiveness in treatment success, we chose to include the following clinical predictors in our outcome prediction model: FTND, age, gender, BDI, BAI, BIQ, number of serious previous quit attempts, and AUDIT.
85-1	16741-16746	Given	_	
85-2	16747-16755	previous	_	
85-3	16756-16760	work	_	
85-4	16761-16773	highlighting	_	
85-5	16774-16777	the	_	
85-6	16778-16788	importance	_	
85-7	16789-16791	of	_	
85-8	16792-16800	comorbid	_	
85-9	16801-16812	psychiatric	_	
85-10	16813-16821	symptoms	_	
85-11	16821-16822	,	_	
85-12	16823-16826	age	_	
85-13	16826-16827	,	_	
85-14	16828-16838	dependence	_	
85-15	16839-16847	severity	_	
85-16	16847-16848	,	_	
85-17	16849-16855	longer	_	
85-18	16856-16864	duration	_	
85-19	16865-16867	of	_	
85-20	16868-16873	prior	_	
85-21	16874-16878	quit	_	
85-22	16879-16887	attempts	_	
85-23	16887-16888	,	_	
85-24	16889-16895	gender	_	
85-25	16895-16896	,	_	
85-26	16897-16905	presence	_	
85-27	16906-16908	or	_	
85-28	16909-16916	absence	_	
85-29	16917-16919	of	_	
85-30	16920-16927	current	_	
85-31	16928-16935	alcohol	_	
85-32	16936-16944	problems	_	
85-33	16945-16948	and	_	
85-34	16949-16962	impulsiveness	_	
85-35	16963-16965	in	_	
85-36	16966-16975	treatment	_	
85-37	16976-16983	success	_	
85-38	16983-16984	,	_	
85-39	16985-16987	we	_	
85-40	16988-16993	chose	_	
85-41	16994-16996	to	_	
85-42	16997-17004	include	_	
85-43	17005-17008	the	_	
85-44	17009-17018	following	_	
85-45	17019-17027	clinical	_	
85-46	17028-17038	predictors	_	
85-47	17039-17041	in	_	
85-48	17042-17045	our	_	
85-49	17046-17053	outcome	_	
85-50	17054-17064	prediction	_	
85-51	17065-17070	model	_	
85-52	17070-17071	:	_	
85-53	17072-17076	FTND	_	
85-54	17076-17077	,	_	
85-55	17078-17081	age	_	
85-56	17081-17082	,	_	
85-57	17083-17089	gender	_	
85-58	17089-17090	,	_	
85-59	17091-17094	BDI	_	
85-60	17094-17095	,	_	
85-61	17096-17099	BAI	_	
85-62	17099-17100	,	_	
85-63	17101-17104	BIQ	_	
85-64	17104-17105	,	_	
85-65	17106-17112	number	_	
85-66	17113-17115	of	_	
85-67	17116-17123	serious	_	
85-68	17124-17132	previous	_	
85-69	17133-17137	quit	_	
85-70	17138-17146	attempts	_	
85-71	17146-17147	,	_	
85-72	17148-17151	and	_	
85-73	17152-17157	AUDIT	_	
85-74	17157-17158	.	_	

#Text=NumCig at screen (over the previous 60 days), RxGrp, baseline demographic and clinical predictors associated with outcome in previous work, the neuroimaging predictor (Smoke-Food), and an interaction term (Smoke-Food/Smoke/Food × RxGrp) were also entered as predictors, and NumCig at 6 and 12 weeks (over the previous 28 and 30 days respectively) as the predicted outcomes.
86-1	17159-17165	NumCig	_	
86-2	17166-17168	at	_	
86-3	17169-17175	screen	_	
86-4	17176-17177	(	_	
86-5	17177-17181	over	_	
86-6	17182-17185	the	_	
86-7	17186-17194	previous	_	
86-8	17195-17197	60	_	
86-9	17198-17202	days	_	
86-10	17202-17203	)	_	
86-11	17203-17204	,	_	
86-12	17205-17210	RxGrp	_	
86-13	17210-17211	,	_	
86-14	17212-17220	baseline	_	
86-15	17221-17232	demographic	_	
86-16	17233-17236	and	_	
86-17	17237-17245	clinical	_	
86-18	17246-17256	predictors	_	
86-19	17257-17267	associated	_	
86-20	17268-17272	with	_	
86-21	17273-17280	outcome	_	
86-22	17281-17283	in	_	
86-23	17284-17292	previous	_	
86-24	17293-17297	work	_	
86-25	17297-17298	,	_	
86-26	17299-17302	the	_	
86-27	17303-17315	neuroimaging	_	
86-28	17316-17325	predictor	_	
86-29	17326-17327	(	_	
86-30	17327-17337	Smoke-Food	_	
86-31	17337-17338	)	_	
86-32	17338-17339	,	_	
86-33	17340-17343	and	_	
86-34	17344-17346	an	_	
86-35	17347-17358	interaction	_	
86-36	17359-17363	term	_	
86-37	17364-17365	(	_	
86-38	17365-17375	Smoke-Food	_	
86-39	17375-17376	/	_	
86-40	17376-17381	Smoke	_	
86-41	17381-17382	/	_	
86-42	17382-17386	Food	_	
86-43	17387-17388	×	_	
86-44	17389-17394	RxGrp	_	
86-45	17394-17395	)	_	
86-46	17396-17400	were	_	
86-47	17401-17405	also	_	
86-48	17406-17413	entered	_	
86-49	17414-17416	as	_	
86-50	17417-17427	predictors	_	
86-51	17427-17428	,	_	
86-52	17429-17432	and	_	
86-53	17433-17439	NumCig	_	
86-54	17440-17442	at	_	
86-55	17443-17444	6	_	
86-56	17445-17448	and	_	
86-57	17449-17451	12	_	
86-58	17452-17457	weeks	_	
86-59	17458-17459	(	_	
86-60	17459-17463	over	_	
86-61	17464-17467	the	_	
86-62	17468-17476	previous	_	
86-63	17477-17479	28	_	
86-64	17480-17483	and	_	
86-65	17484-17486	30	_	
86-66	17487-17491	days	_	
86-67	17492-17504	respectively	_	
86-68	17504-17505	)	_	
86-69	17506-17508	as	_	
86-70	17509-17512	the	_	
86-71	17513-17522	predicted	_	
86-72	17523-17531	outcomes	_	
86-73	17531-17532	.	_	

#Text=When the interaction term was not significant, we reran the model without it.
87-1	17533-17537	When	_	
87-2	17538-17541	the	_	
87-3	17542-17553	interaction	_	
87-4	17554-17558	term	_	
87-5	17559-17562	was	_	
87-6	17563-17566	not	_	
87-7	17567-17578	significant	_	
87-8	17578-17579	,	_	
87-9	17580-17582	we	_	
87-10	17583-17588	reran	_	
87-11	17589-17592	the	_	
87-12	17593-17598	model	_	
87-13	17599-17606	without	_	
87-14	17607-17609	it	_	
87-15	17609-17610	.	_	

#Text=In addition, we also ran the same model that we ran using Smoke-Food but using Smoke or Food alone as the neuroimaging predictor variable.
88-1	17611-17613	In	_	
88-2	17614-17622	addition	_	
88-3	17622-17623	,	_	
88-4	17624-17626	we	_	
88-5	17627-17631	also	_	
88-6	17632-17635	ran	_	
88-7	17636-17639	the	_	
88-8	17640-17644	same	_	
88-9	17645-17650	model	_	
88-10	17651-17655	that	_	
88-11	17656-17658	we	_	
88-12	17659-17662	ran	_	
88-13	17663-17668	using	_	
88-14	17669-17679	Smoke-Food	_	
88-15	17680-17683	but	_	
88-16	17684-17689	using	_	
88-17	17690-17695	Smoke	_	
88-18	17696-17698	or	_	
88-19	17699-17703	Food	_	
88-20	17704-17709	alone	_	
88-21	17710-17712	as	_	
88-22	17713-17716	the	_	
88-23	17717-17729	neuroimaging	_	
88-24	17730-17739	predictor	_	
88-25	17740-17748	variable	_	
88-26	17748-17749	.	_	

#Text=Additionally, we also ran the same models in the subset of individuals with complete data only.
89-1	17750-17762	Additionally	_	
89-2	17762-17763	,	_	
89-3	17764-17766	we	_	
89-4	17767-17771	also	_	
89-5	17772-17775	ran	_	
89-6	17776-17779	the	_	
89-7	17780-17784	same	_	
89-8	17785-17791	models	_	
89-9	17792-17794	in	_	
89-10	17795-17798	the	_	
89-11	17799-17805	subset	_	
89-12	17806-17808	of	_	
89-13	17809-17820	individuals	_	
89-14	17821-17825	with	_	
89-15	17826-17834	complete	_	
89-16	17835-17839	data	_	
89-17	17840-17844	only	_	
89-18	17844-17845	.	_	

#Text=Finally, we reran the models with fewer (only the essential) covariates.
90-1	17846-17853	Finally	_	
90-2	17853-17854	,	_	
90-3	17855-17857	we	_	
90-4	17858-17863	reran	_	
90-5	17864-17867	the	_	
90-6	17868-17874	models	_	
90-7	17875-17879	with	_	
90-8	17880-17885	fewer	_	
90-9	17886-17887	(	_	
90-10	17887-17891	only	_	
90-11	17892-17895	the	_	
90-12	17896-17905	essential	_	
90-13	17905-17906	)	_	
90-14	17907-17917	covariates	_	
90-15	17917-17918	.	_	

#Text=Finally, we used independent samples t-tests to compare the values for Smoke-Food, Smoke, and Food between abstinent and non-abstinent individuals at 6 and 12 weeks respectively, results for which are summarized in Table 6,7,S1–3.
91-1	17919-17926	Finally	_	
91-2	17926-17927	,	_	
91-3	17928-17930	we	_	
91-4	17931-17935	used	_	
91-5	17936-17947	independent	_	
91-6	17948-17955	samples	_	
91-7	17956-17963	t-tests	_	
91-8	17964-17966	to	_	
91-9	17967-17974	compare	_	
91-10	17975-17978	the	_	
91-11	17979-17985	values	_	
91-12	17986-17989	for	_	
91-13	17990-18000	Smoke-Food	_	
91-14	18000-18001	,	_	
91-15	18002-18007	Smoke	_	
91-16	18007-18008	,	_	
91-17	18009-18012	and	_	
91-18	18013-18017	Food	_	
91-19	18018-18025	between	_	
91-20	18026-18035	abstinent	_	
91-21	18036-18039	and	_	
91-22	18040-18053	non-abstinent	_	
91-23	18054-18065	individuals	_	
91-24	18066-18068	at	_	
91-25	18069-18070	6	_	
91-26	18071-18074	and	_	
91-27	18075-18077	12	_	
91-28	18078-18083	weeks	_	
91-29	18084-18096	respectively	_	
91-30	18096-18097	,	_	
91-31	18098-18105	results	_	
91-32	18106-18109	for	_	
91-33	18110-18115	which	_	
91-34	18116-18119	are	_	
91-35	18120-18130	summarized	_	
91-36	18131-18133	in	_	
91-37	18134-18139	Table	_	
91-38	18140-18143	6,7	_	
91-39	18143-18144	,	_	
91-40	18144-18146	S1	_	
91-41	18146-18147	–	_	
91-42	18147-18148	3	_	
91-43	18148-18149	.	_	

#Text=Results
#Text=Table 1 presents the baseline demographic characteristics of individuals included in these analyses by medication group, and shows no significant differences between groups at baseline.
92-1	18150-18157	Results	_	
92-2	18158-18163	Table	_	
92-3	18164-18165	1	_	
92-4	18166-18174	presents	_	
92-5	18175-18178	the	_	
92-6	18179-18187	baseline	_	
92-7	18188-18199	demographic	_	
92-8	18200-18215	characteristics	_	
92-9	18216-18218	of	_	
92-10	18219-18230	individuals	_	
92-11	18231-18239	included	_	
92-12	18240-18242	in	_	
92-13	18243-18248	these	_	
92-14	18249-18257	analyses	_	
92-15	18258-18260	by	_	
92-16	18261-18271	medication	_	
92-17	18272-18277	group	_	
92-18	18277-18278	,	_	
92-19	18279-18282	and	_	
92-20	18283-18288	shows	_	
92-21	18289-18291	no	_	
92-22	18292-18303	significant	_	
92-23	18304-18315	differences	_	
92-24	18316-18323	between	_	
92-25	18324-18330	groups	_	
92-26	18331-18333	at	_	
92-27	18334-18342	baseline	_	
92-28	18342-18343	.	_	

#Text=Correlations (Spearman’s rho) between demographic and clinical variables and between these potential predictors and outcome were calculated and presented in Table 2.
93-1	18344-18356	Correlations	_	
93-2	18357-18358	(	_	
93-3	18358-18366	Spearman	_	
93-4	18366-18367	’	_	
93-5	18367-18368	s	_	
93-6	18369-18372	rho	_	
93-7	18372-18373	)	_	
93-8	18374-18381	between	_	
93-9	18382-18393	demographic	_	
93-10	18394-18397	and	_	
93-11	18398-18406	clinical	_	
93-12	18407-18416	variables	_	
93-13	18417-18420	and	_	
93-14	18421-18428	between	_	
93-15	18429-18434	these	_	
93-16	18435-18444	potential	_	
93-17	18445-18455	predictors	_	
93-18	18456-18459	and	_	
93-19	18460-18467	outcome	_	
93-20	18468-18472	were	_	
93-21	18473-18483	calculated	_	
93-22	18484-18487	and	_	
93-23	18488-18497	presented	_	
93-24	18498-18500	in	_	
93-25	18501-18506	Table	_	
93-26	18507-18508	2	_	
93-27	18508-18509	.	_	

#Text=Although head motion (FD as measured by rmsRot and rmsTrans) was not correlated with Smoke, Food or Smoke-Food (ps > 0.1), it was negatively correlated with NumCig at 12 week (Table 2).
94-1	18510-18518	Although	_	
94-2	18519-18523	head	_	
94-3	18524-18530	motion	_	
94-4	18531-18532	(	_	
94-5	18532-18534	FD	_	
94-6	18535-18537	as	_	
94-7	18538-18546	measured	_	
94-8	18547-18549	by	_	
94-9	18550-18556	rmsRot	_	
94-10	18557-18560	and	_	
94-11	18561-18569	rmsTrans	_	
94-12	18569-18570	)	_	
94-13	18571-18574	was	_	
94-14	18575-18578	not	_	
94-15	18579-18589	correlated	_	
94-16	18590-18594	with	_	
94-17	18595-18600	Smoke	_	
94-18	18600-18601	,	_	
94-19	18602-18606	Food	_	
94-20	18607-18609	or	_	
94-21	18610-18620	Smoke-Food	_	
94-22	18621-18622	(	_	
94-23	18622-18624	ps	_	
94-24	18625-18626	>	_	
94-25	18627-18630	0.1	_	
94-26	18630-18631	)	_	
94-27	18631-18632	,	_	
94-28	18633-18635	it	_	
94-29	18636-18639	was	_	
94-30	18640-18650	negatively	_	
94-31	18651-18661	correlated	_	
94-32	18662-18666	with	_	
94-33	18667-18673	NumCig	_	
94-34	18674-18676	at	_	
94-35	18677-18679	12	_	
94-36	18680-18684	week	_	
94-37	18685-18686	(	_	
94-38	18686-18691	Table	_	
94-39	18692-18693	2	_	
94-40	18693-18694	)	_	
94-41	18694-18695	.	_	

#Text=Because rmsRot and rmsTrans were highly correlated with one another (rho=0.817, p<0.001), to avoid problems of multicollinearity we chose to include only rmsRot as a covariate in all outcomes analyses because it was more strongly correlated with 12 week NumCig (rho=−0.218, p=0.009) than rmsTrans.
95-1	18696-18703	Because	_	
95-2	18704-18710	rmsRot	_	
95-3	18711-18714	and	_	
95-4	18715-18723	rmsTrans	_	
95-5	18724-18728	were	_	
95-6	18729-18735	highly	_	
95-7	18736-18746	correlated	_	
95-8	18747-18751	with	_	
95-9	18752-18755	one	_	
95-10	18756-18763	another	_	
95-11	18764-18765	(	_	
95-12	18765-18768	rho	_	
95-13	18768-18769	=	_	
95-14	18769-18774	0.817	_	
95-15	18774-18775	,	_	
95-16	18776-18777	p	_	
95-17	18777-18778	<	_	
95-18	18778-18783	0.001	_	
95-19	18783-18784	)	_	
95-20	18784-18785	,	_	
95-21	18786-18788	to	_	
95-22	18789-18794	avoid	_	
95-23	18795-18803	problems	_	
95-24	18804-18806	of	_	
95-25	18807-18824	multicollinearity	_	
95-26	18825-18827	we	_	
95-27	18828-18833	chose	_	
95-28	18834-18836	to	_	
95-29	18837-18844	include	_	
95-30	18845-18849	only	_	
95-31	18850-18856	rmsRot	_	
95-32	18857-18859	as	_	
95-33	18860-18861	a	_	
95-34	18862-18871	covariate	_	
95-35	18872-18874	in	_	
95-36	18875-18878	all	_	
95-37	18879-18887	outcomes	_	
95-38	18888-18896	analyses	_	
95-39	18897-18904	because	_	
95-40	18905-18907	it	_	
95-41	18908-18911	was	_	
95-42	18912-18916	more	_	
95-43	18917-18925	strongly	_	
95-44	18926-18936	correlated	_	
95-45	18937-18941	with	_	
95-46	18942-18944	12	_	
95-47	18945-18949	week	_	
95-48	18950-18956	NumCig	_	
95-49	18957-18958	(	_	
95-50	18958-18961	rho	_	
95-51	18961-18962	=	_	
95-52	18962-18963	−	_	
95-53	18963-18968	0.218	_	
95-54	18968-18969	,	_	
95-55	18970-18971	p	_	
95-56	18971-18972	=	_	
95-57	18972-18977	0.009	_	
95-58	18977-18978	)	_	
95-59	18979-18983	than	_	
95-60	18984-18992	rmsTrans	_	
95-61	18992-18993	.	_	

#Text=Both WSWS and WSWS(food) were weakly correlated with the DMN Food (rho = 0.141, p = 0.094) and Smoke-Food (rho = −0.154, p=0.068) betas respectively, and so both were included as covariates in the analyses.
96-1	18994-18998	Both	_	
96-2	18999-19003	WSWS	_	
96-3	19004-19007	and	_	
96-4	19008-19012	WSWS	_	
96-5	19012-19013	(	_	
96-6	19013-19017	food	_	
96-7	19017-19018	)	_	
96-8	19019-19023	were	_	
96-9	19024-19030	weakly	_	
96-10	19031-19041	correlated	_	
96-11	19042-19046	with	_	
96-12	19047-19050	the	_	
96-13	19051-19054	DMN	_	
96-14	19055-19059	Food	_	
96-15	19060-19061	(	_	
96-16	19061-19064	rho	_	
96-17	19065-19066	=	_	
96-18	19067-19072	0.141	_	
96-19	19072-19073	,	_	
96-20	19074-19075	p	_	
96-21	19076-19077	=	_	
96-22	19078-19083	0.094	_	
96-23	19083-19084	)	_	
96-24	19085-19088	and	_	
96-25	19089-19099	Smoke-Food	_	
96-26	19100-19101	(	_	
96-27	19101-19104	rho	_	
96-28	19105-19106	=	_	
96-29	19107-19108	−	_	
96-30	19108-19113	0.154	_	
96-31	19113-19114	,	_	
96-32	19115-19116	p	_	
96-33	19116-19117	=	_	
96-34	19117-19122	0.068	_	
96-35	19122-19123	)	_	
96-36	19124-19129	betas	_	
96-37	19130-19142	respectively	_	
96-38	19142-19143	,	_	
96-39	19144-19147	and	_	
96-40	19148-19150	so	_	
96-41	19151-19155	both	_	
96-42	19156-19160	were	_	
96-43	19161-19169	included	_	
96-44	19170-19172	as	_	
96-45	19173-19183	covariates	_	
96-46	19184-19186	in	_	
96-47	19187-19190	the	_	
96-48	19191-19199	analyses	_	
96-49	19199-19200	.	_	

#Text=Although QSU was not correlated with DMN Smoke-Food or NumCig at 6 weeks, it was weakly correlated with Smoke (rho = 0.144 p = 0.087), Food (rho = 0.151, p=0.072), and NumCig at 12 weeks (rho = 0.168, p=0.045) and so was also used as a covariate in all analyses.
97-1	19201-19209	Although	_	
97-2	19210-19213	QSU	_	
97-3	19214-19217	was	_	
97-4	19218-19221	not	_	
97-5	19222-19232	correlated	_	
97-6	19233-19237	with	_	
97-7	19238-19241	DMN	_	
97-8	19242-19252	Smoke-Food	_	
97-9	19253-19255	or	_	
97-10	19256-19262	NumCig	_	
97-11	19263-19265	at	_	
97-12	19266-19267	6	_	
97-13	19268-19273	weeks	_	
97-14	19273-19274	,	_	
97-15	19275-19277	it	_	
97-16	19278-19281	was	_	
97-17	19282-19288	weakly	_	
97-18	19289-19299	correlated	_	
97-19	19300-19304	with	_	
97-20	19305-19310	Smoke	_	
97-21	19311-19312	(	_	
97-22	19312-19315	rho	_	
97-23	19316-19317	=	_	
97-24	19318-19323	0.144	_	
97-25	19324-19325	p	_	
97-26	19326-19327	=	_	
97-27	19328-19333	0.087	_	
97-28	19333-19334	)	_	
97-29	19334-19335	,	_	
97-30	19336-19340	Food	_	
97-31	19341-19342	(	_	
97-32	19342-19345	rho	_	
97-33	19346-19347	=	_	
97-34	19348-19353	0.151	_	
97-35	19353-19354	,	_	
97-36	19355-19356	p	_	
97-37	19356-19357	=	_	
97-38	19357-19362	0.072	_	
97-39	19362-19363	)	_	
97-40	19363-19364	,	_	
97-41	19365-19368	and	_	
97-42	19369-19375	NumCig	_	
97-43	19376-19378	at	_	
97-44	19379-19381	12	_	
97-45	19382-19387	weeks	_	
97-46	19388-19389	(	_	
97-47	19389-19392	rho	_	
97-48	19393-19394	=	_	
97-49	19395-19400	0.168	_	
97-50	19400-19401	,	_	
97-51	19402-19403	p	_	
97-52	19403-19404	=	_	
97-53	19404-19409	0.045	_	
97-54	19409-19410	)	_	
97-55	19411-19414	and	_	
97-56	19415-19417	so	_	
97-57	19418-19421	was	_	
97-58	19422-19426	also	_	
97-59	19427-19431	used	_	
97-60	19432-19434	as	_	
97-61	19435-19436	a	_	
97-62	19437-19446	covariate	_	
97-63	19447-19449	in	_	
97-64	19450-19453	all	_	
97-65	19454-19462	analyses	_	
97-66	19462-19463	.	_	

#Text=Hours since last smoked at the time of the scan was correlated neither with the neuroimaging predictor of interest (Smoke-Food) nor with NumCig at 6 or 12 weeks (Table 2) and was not used as a covariate.
98-1	19464-19469	Hours	_	
98-2	19470-19475	since	_	
98-3	19476-19480	last	_	
98-4	19481-19487	smoked	_	
98-5	19488-19490	at	_	
98-6	19491-19494	the	_	
98-7	19495-19499	time	_	
98-8	19500-19502	of	_	
98-9	19503-19506	the	_	
98-10	19507-19511	scan	_	
98-11	19512-19515	was	_	
98-12	19516-19526	correlated	_	
98-13	19527-19534	neither	_	
98-14	19535-19539	with	_	
98-15	19540-19543	the	_	
98-16	19544-19556	neuroimaging	_	
98-17	19557-19566	predictor	_	
98-18	19567-19569	of	_	
98-19	19570-19578	interest	_	
98-20	19579-19580	(	_	
98-21	19580-19590	Smoke-Food	_	
98-22	19590-19591	)	_	
98-23	19592-19595	nor	_	
98-24	19596-19600	with	_	
98-25	19601-19607	NumCig	_	
98-26	19608-19610	at	_	
98-27	19611-19612	6	_	
98-28	19613-19615	or	_	
98-29	19616-19618	12	_	
98-30	19619-19624	weeks	_	
98-31	19625-19626	(	_	
98-32	19626-19631	Table	_	
98-33	19632-19633	2	_	
98-34	19633-19634	)	_	
98-35	19635-19638	and	_	
98-36	19639-19642	was	_	
98-37	19643-19646	not	_	
98-38	19647-19651	used	_	
98-39	19652-19654	as	_	
98-40	19655-19656	a	_	
98-41	19657-19666	covariate	_	
98-42	19666-19667	.	_	

#Text=CO levels were obtained, and not used in the analyses, but were highly correlated with NumCig at 6 (p=0.000, rho = 0.732) and 12 (rho=0.606, p9003C;0.001) weeks.
99-1	19668-19670	CO	_	
99-2	19671-19677	levels	_	
99-3	19678-19682	were	_	
99-4	19683-19691	obtained	_	
99-5	19691-19692	,	_	
99-6	19693-19696	and	_	
99-7	19697-19700	not	_	
99-8	19701-19705	used	_	
99-9	19706-19708	in	_	
99-10	19709-19712	the	_	
99-11	19713-19721	analyses	_	
99-12	19721-19722	,	_	
99-13	19723-19726	but	_	
99-14	19727-19731	were	_	
99-15	19732-19738	highly	_	
99-16	19739-19749	correlated	_	
99-17	19750-19754	with	_	
99-18	19755-19761	NumCig	_	
99-19	19762-19764	at	_	
99-20	19765-19766	6	_	
99-21	19767-19768	(	_	
99-22	19768-19769	p	_	
99-23	19769-19770	=	_	
99-24	19770-19775	0.000	_	
99-25	19775-19776	,	_	
99-26	19777-19780	rho	_	
99-27	19781-19782	=	_	
99-28	19783-19788	0.732	_	
99-29	19788-19789	)	_	
99-30	19790-19793	and	_	
99-31	19794-19796	12	_	
99-32	19797-19798	(	_	
99-33	19798-19801	rho	_	
99-34	19801-19802	=	_	
99-35	19802-19807	0.606	_	
99-36	19807-19808	,	_	
99-37	19809-19815	p9003C	_	
99-38	19815-19816	;	_	
99-39	19816-19821	0.001	_	
99-40	19821-19822	)	_	
99-41	19823-19828	weeks	_	
99-42	19828-19829	.	_	

#Text=Of those with a CO > 10ppm, only 2 subjects reported no cigarettes smoked at 6 weeks and only 3 subjects at 12 weeks.
100-1	19830-19832	Of	_	
100-2	19833-19838	those	_	
100-3	19839-19843	with	_	
100-4	19844-19845	a	_	
100-5	19846-19848	CO	_	
100-6	19849-19850	>	_	
100-7	19851-19856	10ppm	_	
100-8	19856-19857	,	_	
100-9	19858-19862	only	_	
100-10	19863-19864	2	_	
100-11	19865-19873	subjects	_	
100-12	19874-19882	reported	_	
100-13	19883-19885	no	_	
100-14	19886-19896	cigarettes	_	
100-15	19897-19903	smoked	_	
100-16	19904-19906	at	_	
100-17	19907-19908	6	_	
100-18	19909-19914	weeks	_	
100-19	19915-19918	and	_	
100-20	19919-19923	only	_	
100-21	19924-19925	3	_	
100-22	19926-19934	subjects	_	
100-23	19935-19937	at	_	
100-24	19938-19940	12	_	
100-25	19941-19946	weeks	_	
100-26	19946-19947	.	_	

#Text=The only clinical variable that was significantly correlated with Smoke-Food was the BIQ (rho=−0.20, p<0.05).
101-1	19948-19951	The	_	
101-2	19952-19956	only	_	
101-3	19957-19965	clinical	_	
101-4	19966-19974	variable	_	
101-5	19975-19979	that	_	
101-6	19980-19983	was	_	
101-7	19984-19997	significantly	_	
101-8	19998-20008	correlated	_	
101-9	20009-20013	with	_	
101-10	20014-20024	Smoke-Food	_	
101-11	20025-20028	was	_	
101-12	20029-20032	the	_	
101-13	20033-20036	BIQ	_	
101-14	20037-20038	(	_	
101-15	20038-20041	rho	_	
101-16	20041-20042	=	_	
101-17	20042-20043	−	_	
101-18	20043-20047	0.20	_	
101-19	20047-20048	,	_	
101-20	20049-20050	p	_	
101-21	20050-20051	<	_	
101-22	20051-20055	0.05	_	
101-23	20055-20056	)	_	
101-24	20056-20057	.	_	

#Text=The DMN component was strongly negatively associated with onset of Food and weakly negatively associated with onset of Smoke (Table 3; Figure 1b).
102-1	20058-20061	The	_	
102-2	20062-20065	DMN	_	
102-3	20066-20075	component	_	
102-4	20076-20079	was	_	
102-5	20080-20088	strongly	_	
102-6	20089-20099	negatively	_	
102-7	20100-20110	associated	_	
102-8	20111-20115	with	_	
102-9	20116-20121	onset	_	
102-10	20122-20124	of	_	
102-11	20125-20129	Food	_	
102-12	20130-20133	and	_	
102-13	20134-20140	weakly	_	
102-14	20141-20151	negatively	_	
102-15	20152-20162	associated	_	
102-16	20163-20167	with	_	
102-17	20168-20173	onset	_	
102-18	20174-20176	of	_	
102-19	20177-20182	Smoke	_	
102-20	20183-20184	(	_	
102-21	20184-20189	Table	_	
102-22	20190-20191	3	_	
102-23	20191-20192	;	_	
102-24	20193-20199	Figure	_	
102-25	20200-20202	1b	_	
102-26	20202-20203	)	_	
102-27	20203-20204	.	_	

#Text=A paired T-test (n=143) demonstrated significant differences between betas associated with Smoke versus those associated with Food.
103-1	20205-20206	A	_	
103-2	20207-20213	paired	_	
103-3	20214-20220	T-test	_	
103-4	20221-20222	(	_	
103-5	20222-20223	n	_	
103-6	20223-20224	=	_	
103-7	20224-20227	143	_	
103-8	20227-20228	)	_	
103-9	20229-20241	demonstrated	_	
103-10	20242-20253	significant	_	
103-11	20254-20265	differences	_	
103-12	20266-20273	between	_	
103-13	20274-20279	betas	_	
103-14	20280-20290	associated	_	
103-15	20291-20295	with	_	
103-16	20296-20301	Smoke	_	
103-17	20302-20308	versus	_	
103-18	20309-20314	those	_	
103-19	20315-20325	associated	_	
103-20	20326-20330	with	_	
103-21	20331-20335	Food	_	
103-22	20335-20336	.	_	

#Text=For our exploratory components, paired T-tests demonstrated significant differences between the betas associated with Smoke versus Food for R ECN and L ECN but not for SN (Table 3).
104-1	20337-20340	For	_	
104-2	20341-20344	our	_	
104-3	20345-20356	exploratory	_	
104-4	20357-20367	components	_	
104-5	20367-20368	,	_	
104-6	20369-20375	paired	_	
104-7	20376-20383	T-tests	_	
104-8	20384-20396	demonstrated	_	
104-9	20397-20408	significant	_	
104-10	20409-20420	differences	_	
104-11	20421-20428	between	_	
104-12	20429-20432	the	_	
104-13	20433-20438	betas	_	
104-14	20439-20449	associated	_	
104-15	20450-20454	with	_	
104-16	20455-20460	Smoke	_	
104-17	20461-20467	versus	_	
104-18	20468-20472	Food	_	
104-19	20473-20476	for	_	
104-20	20477-20478	R	_	
104-21	20479-20482	ECN	_	
104-22	20483-20486	and	_	
104-23	20487-20488	L	_	
104-24	20489-20492	ECN	_	
104-25	20493-20496	but	_	
104-26	20497-20500	not	_	
104-27	20501-20504	for	_	
104-28	20505-20507	SN	_	
104-29	20508-20509	(	_	
104-30	20509-20514	Table	_	
104-31	20515-20516	3	_	
104-32	20516-20517	)	_	
104-33	20517-20518	.	_	

#Text=Correlations between the DMN and exploratory components (Table 4) demonstrated a negative correlation between DMN and SN (Smoke-Food, Smoke, Food), and a positive correlation between DMN and R ECN (Food), and between DMN and L ECN (Smoke-Food, Smoke).
105-1	20519-20531	Correlations	_	
105-2	20532-20539	between	_	
105-3	20540-20543	the	_	
105-4	20544-20547	DMN	_	
105-5	20548-20551	and	_	
105-6	20552-20563	exploratory	_	
105-7	20564-20574	components	_	
105-8	20575-20576	(	_	
105-9	20576-20581	Table	_	
105-10	20582-20583	4	_	
105-11	20583-20584	)	_	
105-12	20585-20597	demonstrated	_	
105-13	20598-20599	a	_	
105-14	20600-20608	negative	_	
105-15	20609-20620	correlation	_	
105-16	20621-20628	between	_	
105-17	20629-20632	DMN	_	
105-18	20633-20636	and	_	
105-19	20637-20639	SN	_	
105-20	20640-20641	(	_	
105-21	20641-20651	Smoke-Food	_	
105-22	20651-20652	,	_	
105-23	20653-20658	Smoke	_	
105-24	20658-20659	,	_	
105-25	20660-20664	Food	_	
105-26	20664-20665	)	_	
105-27	20665-20666	,	_	
105-28	20667-20670	and	_	
105-29	20671-20672	a	_	
105-30	20673-20681	positive	_	
105-31	20682-20693	correlation	_	
105-32	20694-20701	between	_	
105-33	20702-20705	DMN	_	
105-34	20706-20709	and	_	
105-35	20710-20711	R	_	
105-36	20712-20715	ECN	_	
105-37	20716-20717	(	_	
105-38	20717-20721	Food	_	
105-39	20721-20722	)	_	
105-40	20722-20723	,	_	
105-41	20724-20727	and	_	
105-42	20728-20735	between	_	
105-43	20736-20739	DMN	_	
105-44	20740-20743	and	_	
105-45	20744-20745	L	_	
105-46	20746-20749	ECN	_	
105-47	20750-20751	(	_	
105-48	20751-20761	Smoke-Food	_	
105-49	20761-20762	,	_	
105-50	20763-20768	Smoke	_	
105-51	20768-20769	)	_	
105-52	20769-20770	.	_	

#Text=For Smoke-Food for the DMN component, the interaction term (Smoke-Food × RxGrp) was not significant (p=0.673), and the model was rerun without it.
106-1	20771-20774	For	_	
106-2	20775-20785	Smoke-Food	_	
106-3	20786-20789	for	_	
106-4	20790-20793	the	_	
106-5	20794-20797	DMN	_	
106-6	20798-20807	component	_	
106-7	20807-20808	,	_	
106-8	20809-20812	the	_	
106-9	20813-20824	interaction	_	
106-10	20825-20829	term	_	
106-11	20830-20831	(	_	
106-12	20831-20841	Smoke-Food	_	
106-13	20842-20843	×	_	
106-14	20844-20849	RxGrp	_	
106-15	20849-20850	)	_	
106-16	20851-20854	was	_	
106-17	20855-20858	not	_	
106-18	20859-20870	significant	_	
106-19	20871-20872	(	_	
106-20	20872-20873	p	_	
106-21	20873-20874	=	_	
106-22	20874-20879	0.673	_	
106-23	20879-20880	)	_	
106-24	20880-20881	,	_	
106-25	20882-20885	and	_	
106-26	20886-20889	the	_	
106-27	20890-20895	model	_	
106-28	20896-20899	was	_	
106-29	20900-20905	rerun	_	
106-30	20906-20913	without	_	
106-31	20914-20916	it	_	
106-32	20916-20917	.	_	

#Text=There was a significant overall effect (p=0.005, beta = −0.767, exponential beta [Exp(B)]=0.46) of the DMN component for Smoke-Food on smoking outcome, such that a smaller beta weight difference predicted less reduction in smoking at the follow-up appointment (Table 5).
107-1	20918-20923	There	_	
107-2	20924-20927	was	_	
107-3	20928-20929	a	_	
107-4	20930-20941	significant	_	
107-5	20942-20949	overall	_	
107-6	20950-20956	effect	_	
107-7	20957-20958	(	_	
107-8	20958-20959	p	_	
107-9	20959-20960	=	_	
107-10	20960-20965	0.005	_	
107-11	20965-20966	,	_	
107-12	20967-20971	beta	_	
107-13	20972-20973	=	_	
107-14	20974-20975	−	_	
107-15	20975-20980	0.767	_	
107-16	20980-20981	,	_	
107-17	20982-20993	exponential	_	
107-18	20994-20998	beta	_	
107-19	20999-21000	[	_	
107-20	21000-21003	Exp	_	
107-21	21003-21004	(	_	
107-22	21004-21005	B	_	
107-23	21005-21006	)	_	
107-24	21006-21007	]	_	
107-25	21007-21008	=	_	
107-26	21008-21012	0.46	_	
107-27	21012-21013	)	_	
107-28	21014-21016	of	_	
107-29	21017-21020	the	_	
107-30	21021-21024	DMN	_	
107-31	21025-21034	component	_	
107-32	21035-21038	for	_	
107-33	21039-21049	Smoke-Food	_	
107-34	21050-21052	on	_	
107-35	21053-21060	smoking	_	
107-36	21061-21068	outcome	_	
107-37	21068-21069	,	_	
107-38	21070-21074	such	_	
107-39	21075-21079	that	_	
107-40	21080-21081	a	_	
107-41	21082-21089	smaller	_	
107-42	21090-21094	beta	_	
107-43	21095-21101	weight	_	
107-44	21102-21112	difference	_	
107-45	21113-21122	predicted	_	
107-46	21123-21127	less	_	
107-47	21128-21137	reduction	_	
107-48	21138-21140	in	_	
107-49	21141-21148	smoking	_	
107-50	21149-21151	at	_	
107-51	21152-21155	the	_	
107-52	21156-21165	follow-up	_	
107-53	21166-21177	appointment	_	
107-54	21178-21179	(	_	
107-55	21179-21184	Table	_	
107-56	21185-21186	5	_	
107-57	21186-21187	)	_	
107-58	21187-21188	.	_	

#Text=These findings indicated that the more the profile of the DMN component during the smoke cues approached that of the food cues, the worse the treatment outcome.
108-1	21189-21194	These	_	
108-2	21195-21203	findings	_	
108-3	21204-21213	indicated	_	
108-4	21214-21218	that	_	
108-5	21219-21222	the	_	
108-6	21223-21227	more	_	
108-7	21228-21231	the	_	
108-8	21232-21239	profile	_	
108-9	21240-21242	of	_	
108-10	21243-21246	the	_	
108-11	21247-21250	DMN	_	
108-12	21251-21260	component	_	
108-13	21261-21267	during	_	
108-14	21268-21271	the	_	
108-15	21272-21277	smoke	_	
108-16	21278-21282	cues	_	
108-17	21283-21293	approached	_	
108-18	21294-21298	that	_	
108-19	21299-21301	of	_	
108-20	21302-21305	the	_	
108-21	21306-21310	food	_	
108-22	21311-21315	cues	_	
108-23	21315-21316	,	_	
108-24	21317-21320	the	_	
108-25	21321-21326	worse	_	
108-26	21327-21330	the	_	
108-27	21331-21340	treatment	_	
108-28	21341-21348	outcome	_	
108-29	21348-21349	.	_	

#Text=Additionally, although there were no significant interaction terms when Food and Smoke models (Smoke×RxGrp p=0.796; Food×RxGrp p=0.809) were run separately, Food (p=0.006, beta=0.678, Exp(B)=1.97) but not Smoke (p=0.720, beta=−0.102, Exp(B)=0.72) predicted smoking outcome indicating that a smaller degree of DMN deactivation during food cues predicted a worse treatment outcome (Table 5).
109-1	21350-21362	Additionally	_	
109-2	21362-21363	,	_	
109-3	21364-21372	although	_	
109-4	21373-21378	there	_	
109-5	21379-21383	were	_	
109-6	21384-21386	no	_	
109-7	21387-21398	significant	_	
109-8	21399-21410	interaction	_	
109-9	21411-21416	terms	_	
109-10	21417-21421	when	_	
109-11	21422-21426	Food	_	
109-12	21427-21430	and	_	
109-13	21431-21436	Smoke	_	
109-14	21437-21443	models	_	
109-15	21444-21445	(	_	
109-16	21445-21450	Smoke	_	
109-17	21450-21451	×	_	
109-18	21451-21456	RxGrp	_	
109-19	21457-21458	p	_	
109-20	21458-21459	=	_	
109-21	21459-21464	0.796	_	
109-22	21464-21465	;	_	
109-23	21466-21470	Food	_	
109-24	21470-21471	×	_	
109-25	21471-21476	RxGrp	_	
109-26	21477-21478	p	_	
109-27	21478-21479	=	_	
109-28	21479-21484	0.809	_	
109-29	21484-21485	)	_	
109-30	21486-21490	were	_	
109-31	21491-21494	run	_	
109-32	21495-21505	separately	_	
109-33	21505-21506	,	_	
109-34	21507-21511	Food	_	
109-35	21512-21513	(	_	
109-36	21513-21514	p	_	
109-37	21514-21515	=	_	
109-38	21515-21520	0.006	_	
109-39	21520-21521	,	_	
109-40	21522-21526	beta	_	
109-41	21526-21527	=	_	
109-42	21527-21532	0.678	_	
109-43	21532-21533	,	_	
109-44	21534-21537	Exp	_	
109-45	21537-21538	(	_	
109-46	21538-21539	B	_	
109-47	21539-21540	)	_	
109-48	21540-21541	=	_	
109-49	21541-21545	1.97	_	
109-50	21545-21546	)	_	
109-51	21547-21550	but	_	
109-52	21551-21554	not	_	
109-53	21555-21560	Smoke	_	
109-54	21561-21562	(	_	
109-55	21562-21563	p	_	
109-56	21563-21564	=	_	
109-57	21564-21569	0.720	_	
109-58	21569-21570	,	_	
109-59	21571-21575	beta	_	
109-60	21575-21576	=	_	
109-61	21576-21577	−	_	
109-62	21577-21582	0.102	_	
109-63	21582-21583	,	_	
109-64	21584-21587	Exp	_	
109-65	21587-21588	(	_	
109-66	21588-21589	B	_	
109-67	21589-21590	)	_	
109-68	21590-21591	=	_	
109-69	21591-21595	0.72	_	
109-70	21595-21596	)	_	
109-71	21597-21606	predicted	_	
109-72	21607-21614	smoking	_	
109-73	21615-21622	outcome	_	
109-74	21623-21633	indicating	_	
109-75	21634-21638	that	_	
109-76	21639-21640	a	_	
109-77	21641-21648	smaller	_	
109-78	21649-21655	degree	_	
109-79	21656-21658	of	_	
109-80	21659-21662	DMN	_	
109-81	21663-21675	deactivation	_	
109-82	21676-21682	during	_	
109-83	21683-21687	food	_	
109-84	21688-21692	cues	_	
109-85	21693-21702	predicted	_	
109-86	21703-21704	a	_	
109-87	21705-21710	worse	_	
109-88	21711-21720	treatment	_	
109-89	21721-21728	outcome	_	
109-90	21729-21730	(	_	
109-91	21730-21735	Table	_	
109-92	21736-21737	5	_	
109-93	21737-21738	)	_	
109-94	21738-21739	.	_	

#Text=From the standpoint of clinical variables, the strongest outcome predictors in all three models were the number of cigarettes the participant reported in the 60 days prior to the screen visit, the medication group assignment, and the number of reported previous serious quit attempts.
110-1	21740-21744	From	_	
110-2	21745-21748	the	_	
110-3	21749-21759	standpoint	_	
110-4	21760-21762	of	_	
110-5	21763-21771	clinical	_	
110-6	21772-21781	variables	_	
110-7	21781-21782	,	_	
110-8	21783-21786	the	_	
110-9	21787-21796	strongest	_	
110-10	21797-21804	outcome	_	
110-11	21805-21815	predictors	_	
110-12	21816-21818	in	_	
110-13	21819-21822	all	_	
110-14	21823-21828	three	_	
110-15	21829-21835	models	_	
110-16	21836-21840	were	_	
110-17	21841-21844	the	_	
110-18	21845-21851	number	_	
110-19	21852-21854	of	_	
110-20	21855-21865	cigarettes	_	
110-21	21866-21869	the	_	
110-22	21870-21881	participant	_	
110-23	21882-21890	reported	_	
110-24	21891-21893	in	_	
110-25	21894-21897	the	_	
110-26	21898-21900	60	_	
110-27	21901-21905	days	_	
110-28	21906-21911	prior	_	
110-29	21912-21914	to	_	
110-30	21915-21918	the	_	
110-31	21919-21925	screen	_	
110-32	21926-21931	visit	_	
110-33	21931-21932	,	_	
110-34	21933-21936	the	_	
110-35	21937-21947	medication	_	
110-36	21948-21953	group	_	
110-37	21954-21964	assignment	_	
110-38	21964-21965	,	_	
110-39	21966-21969	and	_	
110-40	21970-21973	the	_	
110-41	21974-21980	number	_	
110-42	21981-21983	of	_	
110-43	21984-21992	reported	_	
110-44	21993-22001	previous	_	
110-45	22002-22009	serious	_	
110-46	22010-22014	quit	_	
110-47	22015-22023	attempts	_	
110-48	22023-22024	.	_	

#Text=Repeating the analyses with all of the same covariates on individuals with complete data only (not imputing to baseline smoking) showed no significant interaction terms (ps>0.01), a significant effect of Smoke-Food (p=0.049, beta=−0.715, Exp(B)=0.489) but no effects of Smoke (p=0.296, beta=−0.469, Exp(B)=0.626) or Food (p=0.427, beta=0.304, Exp(B)=1.355) on smoking outcome.
111-1	22025-22034	Repeating	_	
111-2	22035-22038	the	_	
111-3	22039-22047	analyses	_	
111-4	22048-22052	with	_	
111-5	22053-22056	all	_	
111-6	22057-22059	of	_	
111-7	22060-22063	the	_	
111-8	22064-22068	same	_	
111-9	22069-22079	covariates	_	
111-10	22080-22082	on	_	
111-11	22083-22094	individuals	_	
111-12	22095-22099	with	_	
111-13	22100-22108	complete	_	
111-14	22109-22113	data	_	
111-15	22114-22118	only	_	
111-16	22119-22120	(	_	
111-17	22120-22123	not	_	
111-18	22124-22132	imputing	_	
111-19	22133-22135	to	_	
111-20	22136-22144	baseline	_	
111-21	22145-22152	smoking	_	
111-22	22152-22153	)	_	
111-23	22154-22160	showed	_	
111-24	22161-22163	no	_	
111-25	22164-22175	significant	_	
111-26	22176-22187	interaction	_	
111-27	22188-22193	terms	_	
111-28	22194-22195	(	_	
111-29	22195-22197	ps	_	
111-30	22197-22198	>	_	
111-31	22198-22202	0.01	_	
111-32	22202-22203	)	_	
111-33	22203-22204	,	_	
111-34	22205-22206	a	_	
111-35	22207-22218	significant	_	
111-36	22219-22225	effect	_	
111-37	22226-22228	of	_	
111-38	22229-22239	Smoke-Food	_	
111-39	22240-22241	(	_	
111-40	22241-22242	p	_	
111-41	22242-22243	=	_	
111-42	22243-22248	0.049	_	
111-43	22248-22249	,	_	
111-44	22250-22254	beta	_	
111-45	22254-22255	=	_	
111-46	22255-22256	−	_	
111-47	22256-22261	0.715	_	
111-48	22261-22262	,	_	
111-49	22263-22266	Exp	_	
111-50	22266-22267	(	_	
111-51	22267-22268	B	_	
111-52	22268-22269	)	_	
111-53	22269-22270	=	_	
111-54	22270-22275	0.489	_	
111-55	22275-22276	)	_	
111-56	22277-22280	but	_	
111-57	22281-22283	no	_	
111-58	22284-22291	effects	_	
111-59	22292-22294	of	_	
111-60	22295-22300	Smoke	_	
111-61	22301-22302	(	_	
111-62	22302-22303	p	_	
111-63	22303-22304	=	_	
111-64	22304-22309	0.296	_	
111-65	22309-22310	,	_	
111-66	22311-22315	beta	_	
111-67	22315-22316	=	_	
111-68	22316-22317	−	_	
111-69	22317-22322	0.469	_	
111-70	22322-22323	,	_	
111-71	22324-22327	Exp	_	
111-72	22327-22328	(	_	
111-73	22328-22329	B	_	
111-74	22329-22330	)	_	
111-75	22330-22331	=	_	
111-76	22331-22336	0.626	_	
111-77	22336-22337	)	_	
111-78	22338-22340	or	_	
111-79	22341-22345	Food	_	
111-80	22346-22347	(	_	
111-81	22347-22348	p	_	
111-82	22348-22349	=	_	
111-83	22349-22354	0.427	_	
111-84	22354-22355	,	_	
111-85	22356-22360	beta	_	
111-86	22360-22361	=	_	
111-87	22361-22366	0.304	_	
111-88	22366-22367	,	_	
111-89	22368-22371	Exp	_	
111-90	22371-22372	(	_	
111-91	22372-22373	B	_	
111-92	22373-22374	)	_	
111-93	22374-22375	=	_	
111-94	22375-22380	1.355	_	
111-95	22380-22381	)	_	
111-96	22382-22384	on	_	
111-97	22385-22392	smoking	_	
111-98	22393-22400	outcome	_	
111-99	22400-22401	.	_	

#Text=These and results for abstinence based outcomes (Table 6,7,S1–3) support the particular importance of the Smoke-Food contrast over that of the individual cue types (Smoke alone, Food alone) for predicting treatment outcome.
112-1	22402-22407	These	_	
112-2	22408-22411	and	_	
112-3	22412-22419	results	_	
112-4	22420-22423	for	_	
112-5	22424-22434	abstinence	_	
112-6	22435-22440	based	_	
112-7	22441-22449	outcomes	_	
112-8	22450-22451	(	_	
112-9	22451-22456	Table	_	
112-10	22457-22460	6,7	_	
112-11	22460-22461	,	_	
112-12	22461-22463	S1	_	
112-13	22463-22464	–	_	
112-14	22464-22465	3	_	
112-15	22465-22466	)	_	
112-16	22467-22474	support	_	
112-17	22475-22478	the	_	
112-18	22479-22489	particular	_	
112-19	22490-22500	importance	_	
112-20	22501-22503	of	_	
112-21	22504-22507	the	_	
112-22	22508-22518	Smoke-Food	_	
112-23	22519-22527	contrast	_	
112-24	22528-22532	over	_	
112-25	22533-22537	that	_	
112-26	22538-22540	of	_	
112-27	22541-22544	the	_	
112-28	22545-22555	individual	_	
112-29	22556-22559	cue	_	
112-30	22560-22565	types	_	
112-31	22566-22567	(	_	
112-32	22567-22572	Smoke	_	
112-33	22573-22578	alone	_	
112-34	22578-22579	,	_	
112-35	22580-22584	Food	_	
112-36	22585-22590	alone	_	
112-37	22590-22591	)	_	
112-38	22592-22595	for	_	
112-39	22596-22606	predicting	_	
112-40	22607-22616	treatment	_	
112-41	22617-22624	outcome	_	
112-42	22624-22625	.	_	

#Text=Finally, to confirm that over fitting was not driving results, we reran the outcome prediction analyses dropping variables demonstrating no relationship with outcome which showed similar results (Table S4).
113-1	22626-22633	Finally	_	
113-2	22633-22634	,	_	
113-3	22635-22637	to	_	
113-4	22638-22645	confirm	_	
113-5	22646-22650	that	_	
113-6	22651-22655	over	_	
113-7	22656-22663	fitting	_	
113-8	22664-22667	was	_	
113-9	22668-22671	not	_	
113-10	22672-22679	driving	_	
113-11	22680-22687	results	_	
113-12	22687-22688	,	_	
113-13	22689-22691	we	_	
113-14	22692-22697	reran	_	
113-15	22698-22701	the	_	
113-16	22702-22709	outcome	_	
113-17	22710-22720	prediction	_	
113-18	22721-22729	analyses	_	
113-19	22730-22738	dropping	_	
113-20	22739-22748	variables	_	
113-21	22749-22762	demonstrating	_	
113-22	22763-22765	no	_	
113-23	22766-22778	relationship	_	
113-24	22779-22783	with	_	
113-25	22784-22791	outcome	_	
113-26	22792-22797	which	_	
113-27	22798-22804	showed	_	
113-28	22805-22812	similar	_	
113-29	22813-22820	results	_	
113-30	22821-22822	(	_	
113-31	22822-22827	Table	_	
113-32	22828-22830	S4	_	
113-33	22830-22831	)	_	
113-34	22831-22832	.	_	

#Text=For the exploratory components, we ran the same GEE models using a smaller subset of covariates to avoid over-fitting (see Supporting Information for details), and observed significant (or trending towards significant) interaction terms for R ECN for the full (imputed) sample for Smoke (p=0.048) and Smoke-Food (p=0.059), for L ECN for individuals with complete data only (non-imputed) sample for Smoke-Food (p=0.045), and for SN for Food for individuals with complete data only (p=0.009) and for SN for individuals with complete data only for Smoke-Food (p=0.067).
114-1	22833-22836	For	_	
114-2	22837-22840	the	_	
114-3	22841-22852	exploratory	_	
114-4	22853-22863	components	_	
114-5	22863-22864	,	_	
114-6	22865-22867	we	_	
114-7	22868-22871	ran	_	
114-8	22872-22875	the	_	
114-9	22876-22880	same	_	
114-10	22881-22884	GEE	_	
114-11	22885-22891	models	_	
114-12	22892-22897	using	_	
114-13	22898-22899	a	_	
114-14	22900-22907	smaller	_	
114-15	22908-22914	subset	_	
114-16	22915-22917	of	_	
114-17	22918-22928	covariates	_	
114-18	22929-22931	to	_	
114-19	22932-22937	avoid	_	
114-20	22938-22950	over-fitting	_	
114-21	22951-22952	(	_	
114-22	22952-22955	see	_	
114-23	22956-22966	Supporting	_	
114-24	22967-22978	Information	_	
114-25	22979-22982	for	_	
114-26	22983-22990	details	_	
114-27	22990-22991	)	_	
114-28	22991-22992	,	_	
114-29	22993-22996	and	_	
114-30	22997-23005	observed	_	
114-31	23006-23017	significant	_	
114-32	23018-23019	(	_	
114-33	23019-23021	or	_	
114-34	23022-23030	trending	_	
114-35	23031-23038	towards	_	
114-36	23039-23050	significant	_	
114-37	23050-23051	)	_	
114-38	23052-23063	interaction	_	
114-39	23064-23069	terms	_	
114-40	23070-23073	for	_	
114-41	23074-23075	R	_	
114-42	23076-23079	ECN	_	
114-43	23080-23083	for	_	
114-44	23084-23087	the	_	
114-45	23088-23092	full	_	
114-46	23093-23094	(	_	
114-47	23094-23101	imputed	_	
114-48	23101-23102	)	_	
114-49	23103-23109	sample	_	
114-50	23110-23113	for	_	
114-51	23114-23119	Smoke	_	
114-52	23120-23121	(	_	
114-53	23121-23122	p	_	
114-54	23122-23123	=	_	
114-55	23123-23128	0.048	_	
114-56	23128-23129	)	_	
114-57	23130-23133	and	_	
114-58	23134-23144	Smoke-Food	_	
114-59	23145-23146	(	_	
114-60	23146-23147	p	_	
114-61	23147-23148	=	_	
114-62	23148-23153	0.059	_	
114-63	23153-23154	)	_	
114-64	23154-23155	,	_	
114-65	23156-23159	for	_	
114-66	23160-23161	L	_	
114-67	23162-23165	ECN	_	
114-68	23166-23169	for	_	
114-69	23170-23181	individuals	_	
114-70	23182-23186	with	_	
114-71	23187-23195	complete	_	
114-72	23196-23200	data	_	
114-73	23201-23205	only	_	
114-74	23206-23207	(	_	
114-75	23207-23218	non-imputed	_	
114-76	23218-23219	)	_	
114-77	23220-23226	sample	_	
114-78	23227-23230	for	_	
114-79	23231-23241	Smoke-Food	_	
114-80	23242-23243	(	_	
114-81	23243-23244	p	_	
114-82	23244-23245	=	_	
114-83	23245-23250	0.045	_	
114-84	23250-23251	)	_	
114-85	23251-23252	,	_	
114-86	23253-23256	and	_	
114-87	23257-23260	for	_	
114-88	23261-23263	SN	_	
114-89	23264-23267	for	_	
114-90	23268-23272	Food	_	
114-91	23273-23276	for	_	
114-92	23277-23288	individuals	_	
114-93	23289-23293	with	_	
114-94	23294-23302	complete	_	
114-95	23303-23307	data	_	
114-96	23308-23312	only	_	
114-97	23313-23314	(	_	
114-98	23314-23315	p	_	
114-99	23315-23316	=	_	
114-100	23316-23321	0.009	_	
114-101	23321-23322	)	_	
114-102	23323-23326	and	_	
114-103	23327-23330	for	_	
114-104	23331-23333	SN	_	
114-105	23334-23337	for	_	
114-106	23338-23349	individuals	_	
114-107	23350-23354	with	_	
114-108	23355-23363	complete	_	
114-109	23364-23368	data	_	
114-110	23369-23373	only	_	
114-111	23374-23377	for	_	
114-112	23378-23388	Smoke-Food	_	
114-113	23389-23390	(	_	
114-114	23390-23391	p	_	
114-115	23391-23392	=	_	
114-116	23392-23397	0.067	_	
114-117	23397-23398	)	_	
114-118	23398-23399	.	_	

#Text=There were no additional significant interaction terms or, when models were rerun without the interaction terms, overall significant relationships between Food, Smoke, or Smoke-Food betas associated with ECN, SN, or cuneus (negative control) and outcome.
115-1	23400-23405	There	_	
115-2	23406-23410	were	_	
115-3	23411-23413	no	_	
115-4	23414-23424	additional	_	
115-5	23425-23436	significant	_	
115-6	23437-23448	interaction	_	
115-7	23449-23454	terms	_	
115-8	23455-23457	or	_	
115-9	23457-23458	,	_	
115-10	23459-23463	when	_	
115-11	23464-23470	models	_	
115-12	23471-23475	were	_	
115-13	23476-23481	rerun	_	
115-14	23482-23489	without	_	
115-15	23490-23493	the	_	
115-16	23494-23505	interaction	_	
115-17	23506-23511	terms	_	
115-18	23511-23512	,	_	
115-19	23513-23520	overall	_	
115-20	23521-23532	significant	_	
115-21	23533-23546	relationships	_	
115-22	23547-23554	between	_	
115-23	23555-23559	Food	_	
115-24	23559-23560	,	_	
115-25	23561-23566	Smoke	_	
115-26	23566-23567	,	_	
115-27	23568-23570	or	_	
115-28	23571-23581	Smoke-Food	_	
115-29	23582-23587	betas	_	
115-30	23588-23598	associated	_	
115-31	23599-23603	with	_	
115-32	23604-23607	ECN	_	
115-33	23607-23608	,	_	
115-34	23609-23611	SN	_	
115-35	23611-23612	,	_	
115-36	23613-23615	or	_	
115-37	23616-23622	cuneus	_	
115-38	23623-23624	(	_	
115-39	23624-23632	negative	_	
115-40	23633-23640	control	_	
115-41	23640-23641	)	_	
115-42	23642-23645	and	_	
115-43	23646-23653	outcome	_	
115-44	23653-23654	.	_	

#Text=The interactions were explored further (Table 8) in two ways: 1) we did a median split on the betas associated with the cue of interest, and then ran the analyses and looked for differences in the RxGrp effect 2) we split groups into varenicline and placebo groups and looked for differences in the ability of the betas to predict outcome.
116-1	23655-23658	The	_	
116-2	23659-23671	interactions	_	
116-3	23672-23676	were	_	
116-4	23677-23685	explored	_	
116-5	23686-23693	further	_	
116-6	23694-23695	(	_	
116-7	23695-23700	Table	_	
116-8	23701-23702	8	_	
116-9	23702-23703	)	_	
116-10	23704-23706	in	_	
116-11	23707-23710	two	_	
116-12	23711-23715	ways	_	
116-13	23715-23716	:	_	
116-14	23717-23718	1	_	
116-15	23718-23719	)	_	
116-16	23720-23722	we	_	
116-17	23723-23726	did	_	
116-18	23727-23728	a	_	
116-19	23729-23735	median	_	
116-20	23736-23741	split	_	
116-21	23742-23744	on	_	
116-22	23745-23748	the	_	
116-23	23749-23754	betas	_	
116-24	23755-23765	associated	_	
116-25	23766-23770	with	_	
116-26	23771-23774	the	_	
116-27	23775-23778	cue	_	
116-28	23779-23781	of	_	
116-29	23782-23790	interest	_	
116-30	23790-23791	,	_	
116-31	23792-23795	and	_	
116-32	23796-23800	then	_	
116-33	23801-23804	ran	_	
116-34	23805-23808	the	_	
116-35	23809-23817	analyses	_	
116-36	23818-23821	and	_	
116-37	23822-23828	looked	_	
116-38	23829-23832	for	_	
116-39	23833-23844	differences	_	
116-40	23845-23847	in	_	
116-41	23848-23851	the	_	
116-42	23852-23857	RxGrp	_	
116-43	23858-23864	effect	_	
116-44	23865-23866	2	_	
116-45	23866-23867	)	_	
116-46	23868-23870	we	_	
116-47	23871-23876	split	_	
116-48	23877-23883	groups	_	
116-49	23884-23888	into	_	
116-50	23889-23900	varenicline	_	
116-51	23901-23904	and	_	
116-52	23905-23912	placebo	_	
116-53	23913-23919	groups	_	
116-54	23920-23923	and	_	
116-55	23924-23930	looked	_	
116-56	23931-23934	for	_	
116-57	23935-23946	differences	_	
116-58	23947-23949	in	_	
116-59	23950-23953	the	_	
116-60	23954-23961	ability	_	
116-61	23962-23964	of	_	
116-62	23965-23968	the	_	
116-63	23969-23974	betas	_	
116-64	23975-23977	to	_	
116-65	23978-23985	predict	_	
116-66	23986-23993	outcome	_	
116-67	23993-23994	.	_	

#Text=These analyses indicated that varenicline worked best (relative to placebo) in individuals who had more positive values for Smoke and Smoke-Food in R ECN, who had more positive values for Smoke-Food in L ECN, and in in individuals who had greater activation of the SN to Food.
117-1	23995-24000	These	_	
117-2	24001-24009	analyses	_	
117-3	24010-24019	indicated	_	
117-4	24020-24024	that	_	
117-5	24025-24036	varenicline	_	
117-6	24037-24043	worked	_	
117-7	24044-24048	best	_	
117-8	24049-24050	(	_	
117-9	24050-24058	relative	_	
117-10	24059-24061	to	_	
117-11	24062-24069	placebo	_	
117-12	24069-24070	)	_	
117-13	24071-24073	in	_	
117-14	24074-24085	individuals	_	
117-15	24086-24089	who	_	
117-16	24090-24093	had	_	
117-17	24094-24098	more	_	
117-18	24099-24107	positive	_	
117-19	24108-24114	values	_	
117-20	24115-24118	for	_	
117-21	24119-24124	Smoke	_	
117-22	24125-24128	and	_	
117-23	24129-24139	Smoke-Food	_	
117-24	24140-24142	in	_	
117-25	24143-24144	R	_	
117-26	24145-24148	ECN	_	
117-27	24148-24149	,	_	
117-28	24150-24153	who	_	
117-29	24154-24157	had	_	
117-30	24158-24162	more	_	
117-31	24163-24171	positive	_	
117-32	24172-24178	values	_	
117-33	24179-24182	for	_	
117-34	24183-24193	Smoke-Food	_	
117-35	24194-24196	in	_	
117-36	24197-24198	L	_	
117-37	24199-24202	ECN	_	
117-38	24202-24203	,	_	
117-39	24204-24207	and	_	
117-40	24208-24210	in	_	
117-41	24211-24213	in	_	
117-42	24214-24225	individuals	_	
117-43	24226-24229	who	_	
117-44	24230-24233	had	_	
117-45	24234-24241	greater	_	
117-46	24242-24252	activation	_	
117-47	24253-24255	of	_	
117-48	24256-24259	the	_	
117-49	24260-24262	SN	_	
117-50	24263-24265	to	_	
117-51	24266-24270	Food	_	
117-52	24270-24271	.	_	

#Text=It also indicated that greater R ECN Smoke-Food predicted greater improvement in individuals on varenicline but not in those on placebo.
118-1	24272-24274	It	_	
118-2	24275-24279	also	_	
118-3	24280-24289	indicated	_	
118-4	24290-24294	that	_	
118-5	24295-24302	greater	_	
118-6	24303-24304	R	_	
118-7	24305-24308	ECN	_	
118-8	24309-24319	Smoke-Food	_	
118-9	24320-24329	predicted	_	
118-10	24330-24337	greater	_	
118-11	24338-24349	improvement	_	
118-12	24350-24352	in	_	
118-13	24353-24364	individuals	_	
118-14	24365-24367	on	_	
118-15	24368-24379	varenicline	_	
118-16	24380-24383	but	_	
118-17	24384-24387	not	_	
118-18	24388-24390	in	_	
118-19	24391-24396	those	_	
118-20	24397-24399	on	_	
118-21	24400-24407	placebo	_	
118-22	24407-24408	.	_	

#Text=Discussion
#Text=In summary, DMN response to smoke relative to food cues was associated with treatment outcome, controlling for several clinical variables associated with treatment outcome in previous work.
119-1	24409-24419	Discussion	_	
119-2	24420-24422	In	_	
119-3	24423-24430	summary	_	
119-4	24430-24431	,	_	
119-5	24432-24435	DMN	_	
119-6	24436-24444	response	_	
119-7	24445-24447	to	_	
119-8	24448-24453	smoke	_	
119-9	24454-24462	relative	_	
119-10	24463-24465	to	_	
119-11	24466-24470	food	_	
119-12	24471-24475	cues	_	
119-13	24476-24479	was	_	
119-14	24480-24490	associated	_	
119-15	24491-24495	with	_	
119-16	24496-24505	treatment	_	
119-17	24506-24513	outcome	_	
119-18	24513-24514	,	_	
119-19	24515-24526	controlling	_	
119-20	24527-24530	for	_	
119-21	24531-24538	several	_	
119-22	24539-24547	clinical	_	
119-23	24548-24557	variables	_	
119-24	24558-24568	associated	_	
119-25	24569-24573	with	_	
119-26	24574-24583	treatment	_	
119-27	24584-24591	outcome	_	
119-28	24592-24594	in	_	
119-29	24595-24603	previous	_	
119-30	24604-24608	work	_	
119-31	24608-24609	.	_	

#Text=Specifically, a lower value for Smoke–Food during the task predicted a greater likelihood of poor outcome during treatment, indicating that the more the deactivation of the DMN to the smoke cues approached that associated with the food cues, the worse outcome the individual was likely to have.
120-1	24610-24622	Specifically	_	
120-2	24622-24623	,	_	
120-3	24624-24625	a	_	
120-4	24626-24631	lower	_	
120-5	24632-24637	value	_	
120-6	24638-24641	for	_	
120-7	24642-24652	Smoke–Food	_	
120-8	24653-24659	during	_	
120-9	24660-24663	the	_	
120-10	24664-24668	task	_	
120-11	24669-24678	predicted	_	
120-12	24679-24680	a	_	
120-13	24681-24688	greater	_	
120-14	24689-24699	likelihood	_	
120-15	24700-24702	of	_	
120-16	24703-24707	poor	_	
120-17	24708-24715	outcome	_	
120-18	24716-24722	during	_	
120-19	24723-24732	treatment	_	
120-20	24732-24733	,	_	
120-21	24734-24744	indicating	_	
120-22	24745-24749	that	_	
120-23	24750-24753	the	_	
120-24	24754-24758	more	_	
120-25	24759-24762	the	_	
120-26	24763-24775	deactivation	_	
120-27	24776-24778	of	_	
120-28	24779-24782	the	_	
120-29	24783-24786	DMN	_	
120-30	24787-24789	to	_	
120-31	24790-24793	the	_	
120-32	24794-24799	smoke	_	
120-33	24800-24804	cues	_	
120-34	24805-24815	approached	_	
120-35	24816-24820	that	_	
120-36	24821-24831	associated	_	
120-37	24832-24836	with	_	
120-38	24837-24840	the	_	
120-39	24841-24845	food	_	
120-40	24846-24850	cues	_	
120-41	24850-24851	,	_	
120-42	24852-24855	the	_	
120-43	24856-24861	worse	_	
120-44	24862-24869	outcome	_	
120-45	24870-24873	the	_	
120-46	24874-24884	individual	_	
120-47	24885-24888	was	_	
120-48	24889-24895	likely	_	
120-49	24896-24898	to	_	
120-50	24899-24903	have	_	
120-51	24903-24904	.	_	

#Text=DMN is active in self-referential processing and rumination, and deactivated during tasks that are attention grabbing and require executive control.
121-1	24905-24908	DMN	_	
121-2	24909-24911	is	_	
121-3	24912-24918	active	_	
121-4	24919-24921	in	_	
121-5	24922-24938	self-referential	_	
121-6	24939-24949	processing	_	
121-7	24950-24953	and	_	
121-8	24954-24964	rumination	_	
121-9	24964-24965	,	_	
121-10	24966-24969	and	_	
121-11	24970-24981	deactivated	_	
121-12	24982-24988	during	_	
121-13	24989-24994	tasks	_	
121-14	24995-24999	that	_	
121-15	25000-25003	are	_	
121-16	25004-25013	attention	_	
121-17	25014-25022	grabbing	_	
121-18	25023-25026	and	_	
121-19	25027-25034	require	_	
121-20	25035-25044	executive	_	
121-21	25045-25052	control	_	
121-22	25052-25053	.	_	

#Text=We had expected that there would be greater deactivation in DMN to food cues compared to smoke cues, based on previous work.
122-1	25054-25056	We	_	
122-2	25057-25060	had	_	
122-3	25061-25069	expected	_	
122-4	25070-25074	that	_	
122-5	25075-25080	there	_	
122-6	25081-25086	would	_	
122-7	25087-25089	be	_	
122-8	25090-25097	greater	_	
122-9	25098-25110	deactivation	_	
122-10	25111-25113	in	_	
122-11	25114-25117	DMN	_	
122-12	25118-25120	to	_	
122-13	25121-25125	food	_	
122-14	25126-25130	cues	_	
122-15	25131-25139	compared	_	
122-16	25140-25142	to	_	
122-17	25143-25148	smoke	_	
122-18	25149-25153	cues	_	
122-19	25153-25154	,	_	
122-20	25155-25160	based	_	
122-21	25161-25163	on	_	
122-22	25164-25172	previous	_	
122-23	25173-25177	work	_	
122-24	25177-25178	.	_	

#Text=An explanation for this somewhat counter-intuitive but replicating finding is that, even in individuals with SUD, food cues are often still more palatable than drug cues (as demonstrated in previous work in AUD assessing palatability of alcohol versus food cues).
123-1	25179-25181	An	_	
123-2	25182-25193	explanation	_	
123-3	25194-25197	for	_	
123-4	25198-25202	this	_	
123-5	25203-25211	somewhat	_	
123-6	25212-25229	counter-intuitive	_	
123-7	25230-25233	but	_	
123-8	25234-25245	replicating	_	
123-9	25246-25253	finding	_	
123-10	25254-25256	is	_	
123-11	25257-25261	that	_	
123-12	25261-25262	,	_	
123-13	25263-25267	even	_	
123-14	25268-25270	in	_	
123-15	25271-25282	individuals	_	
123-16	25283-25287	with	_	
123-17	25288-25291	SUD	_	
123-18	25291-25292	,	_	
123-19	25293-25297	food	_	
123-20	25298-25302	cues	_	
123-21	25303-25306	are	_	
123-22	25307-25312	often	_	
123-23	25313-25318	still	_	
123-24	25319-25323	more	_	
123-25	25324-25333	palatable	_	
123-26	25334-25338	than	_	
123-27	25339-25343	drug	_	
123-28	25344-25348	cues	_	
123-29	25349-25350	(	_	
123-30	25350-25352	as	_	
123-31	25353-25365	demonstrated	_	
123-32	25366-25368	in	_	
123-33	25369-25377	previous	_	
123-34	25378-25382	work	_	
123-35	25383-25385	in	_	
123-36	25386-25389	AUD	_	
123-37	25390-25399	assessing	_	
123-38	25400-25412	palatability	_	
123-39	25413-25415	of	_	
123-40	25416-25423	alcohol	_	
123-41	25424-25430	versus	_	
123-42	25431-25435	food	_	
123-43	25436-25440	cues	_	
123-44	25440-25441	)	_	
123-45	25441-25442	.	_	

#Text=The degree of deactivation to food cues could be understood to represent the general capacity of the DMN to deactivate to a palatable cue and may serve as a baseline that represents the maximum degree to which the cue can capture an individual’s attention.
124-1	25443-25446	The	_	
124-2	25447-25453	degree	_	
124-3	25454-25456	of	_	
124-4	25457-25469	deactivation	_	
124-5	25470-25472	to	_	
124-6	25473-25477	food	_	
124-7	25478-25482	cues	_	
124-8	25483-25488	could	_	
124-9	25489-25491	be	_	
124-10	25492-25502	understood	_	
124-11	25503-25505	to	_	
124-12	25506-25515	represent	_	
124-13	25516-25519	the	_	
124-14	25520-25527	general	_	
124-15	25528-25536	capacity	_	
124-16	25537-25539	of	_	
124-17	25540-25543	the	_	
124-18	25544-25547	DMN	_	
124-19	25548-25550	to	_	
124-20	25551-25561	deactivate	_	
124-21	25562-25564	to	_	
124-22	25565-25566	a	_	
124-23	25567-25576	palatable	_	
124-24	25577-25580	cue	_	
124-25	25581-25584	and	_	
124-26	25585-25588	may	_	
124-27	25589-25594	serve	_	
124-28	25595-25597	as	_	
124-29	25598-25599	a	_	
124-30	25600-25608	baseline	_	
124-31	25609-25613	that	_	
124-32	25614-25624	represents	_	
124-33	25625-25628	the	_	
124-34	25629-25636	maximum	_	
124-35	25637-25643	degree	_	
124-36	25644-25646	to	_	
124-37	25647-25652	which	_	
124-38	25653-25656	the	_	
124-39	25657-25660	cue	_	
124-40	25661-25664	can	_	
124-41	25665-25672	capture	_	
124-42	25673-25675	an	_	
124-43	25676-25686	individual	_	
124-44	25686-25687	’	_	
124-45	25687-25688	s	_	
124-46	25689-25698	attention	_	
124-47	25698-25699	.	_	

#Text=Our outcome prediction findings could therefore indicate that individuals for whom the smoking cue has a greater ability to capture attention relative to the overall capacity of the DMN to deactivate (as represented by the response to food cue) are more vulnerable to relapse during treatment.
125-1	25700-25703	Our	_	
125-2	25704-25711	outcome	_	
125-3	25712-25722	prediction	_	
125-4	25723-25731	findings	_	
125-5	25732-25737	could	_	
125-6	25738-25747	therefore	_	
125-7	25748-25756	indicate	_	
125-8	25757-25761	that	_	
125-9	25762-25773	individuals	_	
125-10	25774-25777	for	_	
125-11	25778-25782	whom	_	
125-12	25783-25786	the	_	
125-13	25787-25794	smoking	_	
125-14	25795-25798	cue	_	
125-15	25799-25802	has	_	
125-16	25803-25804	a	_	
125-17	25805-25812	greater	_	
125-18	25813-25820	ability	_	
125-19	25821-25823	to	_	
125-20	25824-25831	capture	_	
125-21	25832-25841	attention	_	
125-22	25842-25850	relative	_	
125-23	25851-25853	to	_	
125-24	25854-25857	the	_	
125-25	25858-25865	overall	_	
125-26	25866-25874	capacity	_	
125-27	25875-25877	of	_	
125-28	25878-25881	the	_	
125-29	25882-25885	DMN	_	
125-30	25886-25888	to	_	
125-31	25889-25899	deactivate	_	
125-32	25900-25901	(	_	
125-33	25901-25903	as	_	
125-34	25904-25915	represented	_	
125-35	25916-25918	by	_	
125-36	25919-25922	the	_	
125-37	25923-25931	response	_	
125-38	25932-25934	to	_	
125-39	25935-25939	food	_	
125-40	25940-25943	cue	_	
125-41	25943-25944	)	_	
125-42	25945-25948	are	_	
125-43	25949-25953	more	_	
125-44	25954-25964	vulnerable	_	
125-45	25965-25967	to	_	
125-46	25968-25975	relapse	_	
125-47	25976-25982	during	_	
125-48	25983-25992	treatment	_	
125-49	25992-25993	.	_	

#Text=Another additional surprising finding was that the DMN’s response to food cue was independently able to predict treatment outcome, such that a lower degree of DMN deactivation during food cues predicted a worse treatment outcome.
126-1	25994-26001	Another	_	
126-2	26002-26012	additional	_	
126-3	26013-26023	surprising	_	
126-4	26024-26031	finding	_	
126-5	26032-26035	was	_	
126-6	26036-26040	that	_	
126-7	26041-26044	the	_	
126-8	26045-26048	DMN	_	
126-9	26048-26049	’	_	
126-10	26049-26050	s	_	
126-11	26051-26059	response	_	
126-12	26060-26062	to	_	
126-13	26063-26067	food	_	
126-14	26068-26071	cue	_	
126-15	26072-26075	was	_	
126-16	26076-26089	independently	_	
126-17	26090-26094	able	_	
126-18	26095-26097	to	_	
126-19	26098-26105	predict	_	
126-20	26106-26115	treatment	_	
126-21	26116-26123	outcome	_	
126-22	26123-26124	,	_	
126-23	26125-26129	such	_	
126-24	26130-26134	that	_	
126-25	26135-26136	a	_	
126-26	26137-26142	lower	_	
126-27	26143-26149	degree	_	
126-28	26150-26152	of	_	
126-29	26153-26156	DMN	_	
126-30	26157-26169	deactivation	_	
126-31	26170-26176	during	_	
126-32	26177-26181	food	_	
126-33	26182-26186	cues	_	
126-34	26187-26196	predicted	_	
126-35	26197-26198	a	_	
126-36	26199-26204	worse	_	
126-37	26205-26214	treatment	_	
126-38	26215-26222	outcome	_	
126-39	26222-26223	.	_	

#Text=Granted, this effect was not present in the supporting analyses which involved using only the available data, or the analyses comparing neuroimaging variable values between abstinent and non-abstinent individuals (Table 6,7,S1–3), and the effect of food cues in the primary analyses was smaller than that observed for the difference score.
127-1	26224-26231	Granted	_	
127-2	26231-26232	,	_	
127-3	26233-26237	this	_	
127-4	26238-26244	effect	_	
127-5	26245-26248	was	_	
127-6	26249-26252	not	_	
127-7	26253-26260	present	_	
127-8	26261-26263	in	_	
127-9	26264-26267	the	_	
127-10	26268-26278	supporting	_	
127-11	26279-26287	analyses	_	
127-12	26288-26293	which	_	
127-13	26294-26302	involved	_	
127-14	26303-26308	using	_	
127-15	26309-26313	only	_	
127-16	26314-26317	the	_	
127-17	26318-26327	available	_	
127-18	26328-26332	data	_	
127-19	26332-26333	,	_	
127-20	26334-26336	or	_	
127-21	26337-26340	the	_	
127-22	26341-26349	analyses	_	
127-23	26350-26359	comparing	_	
127-24	26360-26372	neuroimaging	_	
127-25	26373-26381	variable	_	
127-26	26382-26388	values	_	
127-27	26389-26396	between	_	
127-28	26397-26406	abstinent	_	
127-29	26407-26410	and	_	
127-30	26411-26424	non-abstinent	_	
127-31	26425-26436	individuals	_	
127-32	26437-26438	(	_	
127-33	26438-26443	Table	_	
127-34	26444-26447	6,7	_	
127-35	26447-26448	,	_	
127-36	26448-26450	S1	_	
127-37	26450-26451	–	_	
127-38	26451-26452	3	_	
127-39	26452-26453	)	_	
127-40	26453-26454	,	_	
127-41	26455-26458	and	_	
127-42	26459-26462	the	_	
127-43	26463-26469	effect	_	
127-44	26470-26472	of	_	
127-45	26473-26477	food	_	
127-46	26478-26482	cues	_	
127-47	26483-26485	in	_	
127-48	26486-26489	the	_	
127-49	26490-26497	primary	_	
127-50	26498-26506	analyses	_	
127-51	26507-26510	was	_	
127-52	26511-26518	smaller	_	
127-53	26519-26523	than	_	
127-54	26524-26528	that	_	
127-55	26529-26537	observed	_	
127-56	26538-26541	for	_	
127-57	26542-26545	the	_	
127-58	26546-26556	difference	_	
127-59	26557-26562	score	_	
127-60	26562-26563	.	_	

#Text=However, these findings could indicate that general DMN pathology is driving some of the Smoke-Food results, and that lower deactivation to food cue may be a biomarker of muted response to natural rewards.
128-1	26564-26571	However	_	
128-2	26571-26572	,	_	
128-3	26573-26578	these	_	
128-4	26579-26587	findings	_	
128-5	26588-26593	could	_	
128-6	26594-26602	indicate	_	
128-7	26603-26607	that	_	
128-8	26608-26615	general	_	
128-9	26616-26619	DMN	_	
128-10	26620-26629	pathology	_	
128-11	26630-26632	is	_	
128-12	26633-26640	driving	_	
128-13	26641-26645	some	_	
128-14	26646-26648	of	_	
128-15	26649-26652	the	_	
128-16	26653-26663	Smoke-Food	_	
128-17	26664-26671	results	_	
128-18	26671-26672	,	_	
128-19	26673-26676	and	_	
128-20	26677-26681	that	_	
128-21	26682-26687	lower	_	
128-22	26688-26700	deactivation	_	
128-23	26701-26703	to	_	
128-24	26704-26708	food	_	
128-25	26709-26712	cue	_	
128-26	26713-26716	may	_	
128-27	26717-26719	be	_	
128-28	26720-26721	a	_	
128-29	26722-26731	biomarker	_	
128-30	26732-26734	of	_	
128-31	26735-26740	muted	_	
128-32	26741-26749	response	_	
128-33	26750-26752	to	_	
128-34	26753-26760	natural	_	
128-35	26761-26768	rewards	_	
128-36	26768-26769	.	_	

#Text=Relatedly, individuals with more severe levels of dependence may have muted responses to food cues due to effects of chronic smoking on neuropeptide levels regulating appetite.
129-1	26770-26779	Relatedly	_	
129-2	26779-26780	,	_	
129-3	26781-26792	individuals	_	
129-4	26793-26797	with	_	
129-5	26798-26802	more	_	
129-6	26803-26809	severe	_	
129-7	26810-26816	levels	_	
129-8	26817-26819	of	_	
129-9	26820-26830	dependence	_	
129-10	26831-26834	may	_	
129-11	26835-26839	have	_	
129-12	26840-26845	muted	_	
129-13	26846-26855	responses	_	
129-14	26856-26858	to	_	
129-15	26859-26863	food	_	
129-16	26864-26868	cues	_	
129-17	26869-26872	due	_	
129-18	26873-26875	to	_	
129-19	26876-26883	effects	_	
129-20	26884-26886	of	_	
129-21	26887-26894	chronic	_	
129-22	26895-26902	smoking	_	
129-23	26903-26905	on	_	
129-24	26906-26918	neuropeptide	_	
129-25	26919-26925	levels	_	
129-26	26926-26936	regulating	_	
129-27	26937-26945	appetite	_	
129-28	26945-26946	.	_	

#Text=The predictive effects of DMN on smoking outcome were observed after correcting for the effects of other clinical covariates which have been previously observed to predict outcomes during smoking cessation treatment.
130-1	26947-26950	The	_	
130-2	26951-26961	predictive	_	
130-3	26962-26969	effects	_	
130-4	26970-26972	of	_	
130-5	26973-26976	DMN	_	
130-6	26977-26979	on	_	
130-7	26980-26987	smoking	_	
130-8	26988-26995	outcome	_	
130-9	26996-27000	were	_	
130-10	27001-27009	observed	_	
130-11	27010-27015	after	_	
130-12	27016-27026	correcting	_	
130-13	27027-27030	for	_	
130-14	27031-27034	the	_	
130-15	27035-27042	effects	_	
130-16	27043-27045	of	_	
130-17	27046-27051	other	_	
130-18	27052-27060	clinical	_	
130-19	27061-27071	covariates	_	
130-20	27072-27077	which	_	
130-21	27078-27082	have	_	
130-22	27083-27087	been	_	
130-23	27088-27098	previously	_	
130-24	27099-27107	observed	_	
130-25	27108-27110	to	_	
130-26	27111-27118	predict	_	
130-27	27119-27127	outcomes	_	
130-28	27128-27134	during	_	
130-29	27135-27142	smoking	_	
130-30	27143-27152	cessation	_	
130-31	27153-27162	treatment	_	
130-32	27162-27163	.	_	

#Text=In this study, baseline number of cigarettes smoked, number of previous quit attempts, and, more weakly, self-reported dependence severity were predictors of outcome (in addition to medication group assignment, as expected), but the other clinical variables were not.
131-1	27164-27166	In	_	
131-2	27167-27171	this	_	
131-3	27172-27177	study	_	
131-4	27177-27178	,	_	
131-5	27179-27187	baseline	_	
131-6	27188-27194	number	_	
131-7	27195-27197	of	_	
131-8	27198-27208	cigarettes	_	
131-9	27209-27215	smoked	_	
131-10	27215-27216	,	_	
131-11	27217-27223	number	_	
131-12	27224-27226	of	_	
131-13	27227-27235	previous	_	
131-14	27236-27240	quit	_	
131-15	27241-27249	attempts	_	
131-16	27249-27250	,	_	
131-17	27251-27254	and	_	
131-18	27254-27255	,	_	
131-19	27256-27260	more	_	
131-20	27261-27267	weakly	_	
131-21	27267-27268	,	_	
131-22	27269-27282	self-reported	_	
131-23	27283-27293	dependence	_	
131-24	27294-27302	severity	_	
131-25	27303-27307	were	_	
131-26	27308-27318	predictors	_	
131-27	27319-27321	of	_	
131-28	27322-27329	outcome	_	
131-29	27330-27331	(	_	
131-30	27331-27333	in	_	
131-31	27334-27342	addition	_	
131-32	27343-27345	to	_	
131-33	27346-27356	medication	_	
131-34	27357-27362	group	_	
131-35	27363-27373	assignment	_	
131-36	27373-27374	,	_	
131-37	27375-27377	as	_	
131-38	27378-27386	expected	_	
131-39	27386-27387	)	_	
131-40	27387-27388	,	_	
131-41	27389-27392	but	_	
131-42	27393-27396	the	_	
131-43	27397-27402	other	_	
131-44	27403-27411	clinical	_	
131-45	27412-27421	variables	_	
131-46	27422-27426	were	_	
131-47	27427-27430	not	_	
131-48	27430-27431	.	_	

#Text=These findings highlight the potential importance of using brain activation during drug cues to predict treatment outcomes as it may turn out to be a more sensitive or reliable marker of future clinical behavior.
132-1	27432-27437	These	_	
132-2	27438-27446	findings	_	
132-3	27447-27456	highlight	_	
132-4	27457-27460	the	_	
132-5	27461-27470	potential	_	
132-6	27471-27481	importance	_	
132-7	27482-27484	of	_	
132-8	27485-27490	using	_	
132-9	27491-27496	brain	_	
132-10	27497-27507	activation	_	
132-11	27508-27514	during	_	
132-12	27515-27519	drug	_	
132-13	27520-27524	cues	_	
132-14	27525-27527	to	_	
132-15	27528-27535	predict	_	
132-16	27536-27545	treatment	_	
132-17	27546-27554	outcomes	_	
132-18	27555-27557	as	_	
132-19	27558-27560	it	_	
132-20	27561-27564	may	_	
132-21	27565-27569	turn	_	
132-22	27570-27573	out	_	
132-23	27574-27576	to	_	
132-24	27577-27579	be	_	
132-25	27580-27581	a	_	
132-26	27582-27586	more	_	
132-27	27587-27596	sensitive	_	
132-28	27597-27599	or	_	
132-29	27600-27608	reliable	_	
132-30	27609-27615	marker	_	
132-31	27616-27618	of	_	
132-32	27619-27625	future	_	
132-33	27626-27634	clinical	_	
132-34	27635-27643	behavior	_	
132-35	27643-27644	.	_	

#Text=Indeed, in other work in NUD, greater insula activation to smoking cues was significantly predictive of worse outcome, observed with only 21 subjects (partial eta squared .27; large effect), and smokers who showed lower pre-quit levels of brain reactivity to pleasant stimuli than to cigarette-related cues were less likely to be abstinent 6 months after their quit attempt, observed with only 55 subjects (odds ratio of 6.34 at 24 weeks; medium to large effect).
133-1	27645-27651	Indeed	_	
133-2	27651-27652	,	_	
133-3	27653-27655	in	_	
133-4	27656-27661	other	_	
133-5	27662-27666	work	_	
133-6	27667-27669	in	_	
133-7	27670-27673	NUD	_	
133-8	27673-27674	,	_	
133-9	27675-27682	greater	_	
133-10	27683-27689	insula	_	
133-11	27690-27700	activation	_	
133-12	27701-27703	to	_	
133-13	27704-27711	smoking	_	
133-14	27712-27716	cues	_	
133-15	27717-27720	was	_	
133-16	27721-27734	significantly	_	
133-17	27735-27745	predictive	_	
133-18	27746-27748	of	_	
133-19	27749-27754	worse	_	
133-20	27755-27762	outcome	_	
133-21	27762-27763	,	_	
133-22	27764-27772	observed	_	
133-23	27773-27777	with	_	
133-24	27778-27782	only	_	
133-25	27783-27785	21	_	
133-26	27786-27794	subjects	_	
133-27	27795-27796	(	_	
133-28	27796-27803	partial	_	
133-29	27804-27807	eta	_	
133-30	27808-27815	squared	_	
133-31	27816-27819	.27	_	
133-32	27819-27820	;	_	
133-33	27821-27826	large	_	
133-34	27827-27833	effect	_	
133-35	27833-27834	)	_	
133-36	27834-27835	,	_	
133-37	27836-27839	and	_	
133-38	27840-27847	smokers	_	
133-39	27848-27851	who	_	
133-40	27852-27858	showed	_	
133-41	27859-27864	lower	_	
133-42	27865-27873	pre-quit	_	
133-43	27874-27880	levels	_	
133-44	27881-27883	of	_	
133-45	27884-27889	brain	_	
133-46	27890-27900	reactivity	_	
133-47	27901-27903	to	_	
133-48	27904-27912	pleasant	_	
133-49	27913-27920	stimuli	_	
133-50	27921-27925	than	_	
133-51	27926-27928	to	_	
133-52	27929-27946	cigarette-related	_	
133-53	27947-27951	cues	_	
133-54	27952-27956	were	_	
133-55	27957-27961	less	_	
133-56	27962-27968	likely	_	
133-57	27969-27971	to	_	
133-58	27972-27974	be	_	
133-59	27975-27984	abstinent	_	
133-60	27985-27986	6	_	
133-61	27987-27993	months	_	
133-62	27994-27999	after	_	
133-63	28000-28005	their	_	
133-64	28006-28010	quit	_	
133-65	28011-28018	attempt	_	
133-66	28018-28019	,	_	
133-67	28020-28028	observed	_	
133-68	28029-28033	with	_	
133-69	28034-28038	only	_	
133-70	28039-28041	55	_	
133-71	28042-28050	subjects	_	
133-72	28051-28052	(	_	
133-73	28052-28056	odds	_	
133-74	28057-28062	ratio	_	
133-75	28063-28065	of	_	
133-76	28066-28070	6.34	_	
133-77	28071-28073	at	_	
133-78	28074-28076	24	_	
133-79	28077-28082	weeks	_	
133-80	28082-28083	;	_	
133-81	28084-28090	medium	_	
133-82	28091-28093	to	_	
133-83	28094-28099	large	_	
133-84	28100-28106	effect	_	
133-85	28106-28107	)	_	
133-86	28107-28108	.	_	

#Text=The results from the exploratory analyses of ECN and SN were notable.
134-1	28109-28112	The	_	
134-2	28113-28120	results	_	
134-3	28121-28125	from	_	
134-4	28126-28129	the	_	
134-5	28130-28141	exploratory	_	
134-6	28142-28150	analyses	_	
134-7	28151-28153	of	_	
134-8	28154-28157	ECN	_	
134-9	28158-28161	and	_	
134-10	28162-28164	SN	_	
134-11	28165-28169	were	_	
134-12	28170-28177	notable	_	
134-13	28177-28178	.	_	

#Text=For one, in line with our working model that food cues were more engaging than smoke cues, food cues were associated with greater (positive) engagement of both ECN (significant) and SN (non-significant) compared to smoke cues.
135-1	28179-28182	For	_	
135-2	28183-28186	one	_	
135-3	28186-28187	,	_	
135-4	28188-28190	in	_	
135-5	28191-28195	line	_	
135-6	28196-28200	with	_	
135-7	28201-28204	our	_	
135-8	28205-28212	working	_	
135-9	28213-28218	model	_	
135-10	28219-28223	that	_	
135-11	28224-28228	food	_	
135-12	28229-28233	cues	_	
135-13	28234-28238	were	_	
135-14	28239-28243	more	_	
135-15	28244-28252	engaging	_	
135-16	28253-28257	than	_	
135-17	28258-28263	smoke	_	
135-18	28264-28268	cues	_	
135-19	28268-28269	,	_	
135-20	28270-28274	food	_	
135-21	28275-28279	cues	_	
135-22	28280-28284	were	_	
135-23	28285-28295	associated	_	
135-24	28296-28300	with	_	
135-25	28301-28308	greater	_	
135-26	28309-28310	(	_	
135-27	28310-28318	positive	_	
135-28	28318-28319	)	_	
135-29	28320-28330	engagement	_	
135-30	28331-28333	of	_	
135-31	28334-28338	both	_	
135-32	28339-28342	ECN	_	
135-33	28343-28344	(	_	
135-34	28344-28355	significant	_	
135-35	28355-28356	)	_	
135-36	28357-28360	and	_	
135-37	28361-28363	SN	_	
135-38	28364-28365	(	_	
135-39	28365-28380	non-significant	_	
135-40	28380-28381	)	_	
135-41	28382-28390	compared	_	
135-42	28391-28393	to	_	
135-43	28394-28399	smoke	_	
135-44	28400-28404	cues	_	
135-45	28404-28405	.	_	

#Text=Second, DMN was negatively correlated with SN, in line with previous work but, surprisingly, it was not negatively correlated with ECN.
136-1	28406-28412	Second	_	
136-2	28412-28413	,	_	
136-3	28414-28417	DMN	_	
136-4	28418-28421	was	_	
136-5	28422-28432	negatively	_	
136-6	28433-28443	correlated	_	
136-7	28444-28448	with	_	
136-8	28449-28451	SN	_	
136-9	28451-28452	,	_	
136-10	28453-28455	in	_	
136-11	28456-28460	line	_	
136-12	28461-28465	with	_	
136-13	28466-28474	previous	_	
136-14	28475-28479	work	_	
136-15	28480-28483	but	_	
136-16	28483-28484	,	_	
136-17	28485-28497	surprisingly	_	
136-18	28497-28498	,	_	
136-19	28499-28501	it	_	
136-20	28502-28505	was	_	
136-21	28506-28509	not	_	
136-22	28510-28520	negatively	_	
136-23	28521-28531	correlated	_	
136-24	28532-28536	with	_	
136-25	28537-28540	ECN	_	
136-26	28540-28541	.	_	

#Text=In the presence of appetitive cues, the relationships between ECN and DMN may be different than they are during cognitive tasks or at rest.
137-1	28542-28544	In	_	
137-2	28545-28548	the	_	
137-3	28549-28557	presence	_	
137-4	28558-28560	of	_	
137-5	28561-28571	appetitive	_	
137-6	28572-28576	cues	_	
137-7	28576-28577	,	_	
137-8	28578-28581	the	_	
137-9	28582-28595	relationships	_	
137-10	28596-28603	between	_	
137-11	28604-28607	ECN	_	
137-12	28608-28611	and	_	
137-13	28612-28615	DMN	_	
137-14	28616-28619	may	_	
137-15	28620-28622	be	_	
137-16	28623-28632	different	_	
137-17	28633-28637	than	_	
137-18	28638-28642	they	_	
137-19	28643-28646	are	_	
137-20	28647-28653	during	_	
137-21	28654-28663	cognitive	_	
137-22	28664-28669	tasks	_	
137-23	28670-28672	or	_	
137-24	28673-28675	at	_	
137-25	28676-28680	rest	_	
137-26	28680-28681	.	_	

#Text=Most importantly perhaps, there were significant interaction terms (Smoke-Food/Smoke/Food×RxGrp) when these networks were used as predictors.
138-1	28682-28686	Most	_	
138-2	28687-28698	importantly	_	
138-3	28699-28706	perhaps	_	
138-4	28706-28707	,	_	
138-5	28708-28713	there	_	
138-6	28714-28718	were	_	
138-7	28719-28730	significant	_	
138-8	28731-28742	interaction	_	
138-9	28743-28748	terms	_	
138-10	28749-28750	(	_	
138-11	28750-28760	Smoke-Food	_	
138-12	28760-28761	/	_	
138-13	28761-28766	Smoke	_	
138-14	28766-28767	/	_	
138-15	28767-28771	Food	_	
138-16	28771-28772	×	_	
138-17	28772-28777	RxGrp	_	
138-18	28777-28778	)	_	
138-19	28779-28783	when	_	
138-20	28784-28789	these	_	
138-21	28790-28798	networks	_	
138-22	28799-28803	were	_	
138-23	28804-28808	used	_	
138-24	28809-28811	as	_	
138-25	28812-28822	predictors	_	
138-26	28822-28823	.	_	

#Text=Exploring these interactions further indicated that some of these markers (more positive values in R ECN to Smoke-Food and to Smoke, more positive values in L ECN to Smoke-Food, and greater activation in SN to Food) might prove useful in treatment matching as they identify individuals more likely to respond to treatment with varenicline.
139-1	28824-28833	Exploring	_	
139-2	28834-28839	these	_	
139-3	28840-28852	interactions	_	
139-4	28853-28860	further	_	
139-5	28861-28870	indicated	_	
139-6	28871-28875	that	_	
139-7	28876-28880	some	_	
139-8	28881-28883	of	_	
139-9	28884-28889	these	_	
139-10	28890-28897	markers	_	
139-11	28898-28899	(	_	
139-12	28899-28903	more	_	
139-13	28904-28912	positive	_	
139-14	28913-28919	values	_	
139-15	28920-28922	in	_	
139-16	28923-28924	R	_	
139-17	28925-28928	ECN	_	
139-18	28929-28931	to	_	
139-19	28932-28942	Smoke-Food	_	
139-20	28943-28946	and	_	
139-21	28947-28949	to	_	
139-22	28950-28955	Smoke	_	
139-23	28955-28956	,	_	
139-24	28957-28961	more	_	
139-25	28962-28970	positive	_	
139-26	28971-28977	values	_	
139-27	28978-28980	in	_	
139-28	28981-28982	L	_	
139-29	28983-28986	ECN	_	
139-30	28987-28989	to	_	
139-31	28990-29000	Smoke-Food	_	
139-32	29000-29001	,	_	
139-33	29002-29005	and	_	
139-34	29006-29013	greater	_	
139-35	29014-29024	activation	_	
139-36	29025-29027	in	_	
139-37	29028-29030	SN	_	
139-38	29031-29033	to	_	
139-39	29034-29038	Food	_	
139-40	29038-29039	)	_	
139-41	29040-29045	might	_	
139-42	29046-29051	prove	_	
139-43	29052-29058	useful	_	
139-44	29059-29061	in	_	
139-45	29062-29071	treatment	_	
139-46	29072-29080	matching	_	
139-47	29081-29083	as	_	
139-48	29084-29088	they	_	
139-49	29089-29097	identify	_	
139-50	29098-29109	individuals	_	
139-51	29110-29114	more	_	
139-52	29115-29121	likely	_	
139-53	29122-29124	to	_	
139-54	29125-29132	respond	_	
139-55	29133-29135	to	_	
139-56	29136-29145	treatment	_	
139-57	29146-29150	with	_	
139-58	29151-29162	varenicline	_	
139-59	29162-29163	.	_	

#Text=Furthermore, more positive values of Smoke-Food for R ECN was associated with greater improvement in individuals on varenicline but not placebo.
140-1	29164-29175	Furthermore	_	
140-2	29175-29176	,	_	
140-3	29177-29181	more	_	
140-4	29182-29190	positive	_	
140-5	29191-29197	values	_	
140-6	29198-29200	of	_	
140-7	29201-29211	Smoke-Food	_	
140-8	29212-29215	for	_	
140-9	29216-29217	R	_	
140-10	29218-29221	ECN	_	
140-11	29222-29225	was	_	
140-12	29226-29236	associated	_	
140-13	29237-29241	with	_	
140-14	29242-29249	greater	_	
140-15	29250-29261	improvement	_	
140-16	29262-29264	in	_	
140-17	29265-29276	individuals	_	
140-18	29277-29279	on	_	
140-19	29280-29291	varenicline	_	
140-20	29292-29295	but	_	
140-21	29296-29299	not	_	
140-22	29300-29307	placebo	_	
140-23	29307-29308	.	_	

#Text=Previous work has shown that varenicline is associated with decreased activation to smoking cues in regions of the R ECN.
141-1	29309-29317	Previous	_	
141-2	29318-29322	work	_	
141-3	29323-29326	has	_	
141-4	29327-29332	shown	_	
141-5	29333-29337	that	_	
141-6	29338-29349	varenicline	_	
141-7	29350-29352	is	_	
141-8	29353-29363	associated	_	
141-9	29364-29368	with	_	
141-10	29369-29378	decreased	_	
141-11	29379-29389	activation	_	
141-12	29390-29392	to	_	
141-13	29393-29400	smoking	_	
141-14	29401-29405	cues	_	
141-15	29406-29408	in	_	
141-16	29409-29416	regions	_	
141-17	29417-29419	of	_	
141-18	29420-29423	the	_	
141-19	29424-29425	R	_	
141-20	29426-29429	ECN	_	
141-21	29429-29430	.	_	

#Text=In combination with our data, this might indicate that varenicline is working in this region in individuals with greater activation to Smoke and Smoke-Food by decreasing smoking cue-induced signal.
142-1	29431-29433	In	_	
142-2	29434-29445	combination	_	
142-3	29446-29450	with	_	
142-4	29451-29454	our	_	
142-5	29455-29459	data	_	
142-6	29459-29460	,	_	
142-7	29461-29465	this	_	
142-8	29466-29471	might	_	
142-9	29472-29480	indicate	_	
142-10	29481-29485	that	_	
142-11	29486-29497	varenicline	_	
142-12	29498-29500	is	_	
142-13	29501-29508	working	_	
142-14	29509-29511	in	_	
142-15	29512-29516	this	_	
142-16	29517-29523	region	_	
142-17	29524-29526	in	_	
142-18	29527-29538	individuals	_	
142-19	29539-29543	with	_	
142-20	29544-29551	greater	_	
142-21	29552-29562	activation	_	
142-22	29563-29565	to	_	
142-23	29566-29571	Smoke	_	
142-24	29572-29575	and	_	
142-25	29576-29586	Smoke-Food	_	
142-26	29587-29589	by	_	
142-27	29590-29600	decreasing	_	
142-28	29601-29608	smoking	_	
142-29	29609-29620	cue-induced	_	
142-30	29621-29627	signal	_	
142-31	29627-29628	.	_	

#Text=That the food cues were associated with greater deactivation in DMN than the smoke cues (in fact the smoke cues alone resulted in almost no mean DMN deactivation) could indicate that food cues were more appetitive; unfortunately one limitation to our study is that we did not obtain ratings of palatability.
143-1	29629-29633	That	_	
143-2	29634-29637	the	_	
143-3	29638-29642	food	_	
143-4	29643-29647	cues	_	
143-5	29648-29652	were	_	
143-6	29653-29663	associated	_	
143-7	29664-29668	with	_	
143-8	29669-29676	greater	_	
143-9	29677-29689	deactivation	_	
143-10	29690-29692	in	_	
143-11	29693-29696	DMN	_	
143-12	29697-29701	than	_	
143-13	29702-29705	the	_	
143-14	29706-29711	smoke	_	
143-15	29712-29716	cues	_	
143-16	29717-29718	(	_	
143-17	29718-29720	in	_	
143-18	29721-29725	fact	_	
143-19	29726-29729	the	_	
143-20	29730-29735	smoke	_	
143-21	29736-29740	cues	_	
143-22	29741-29746	alone	_	
143-23	29747-29755	resulted	_	
143-24	29756-29758	in	_	
143-25	29759-29765	almost	_	
143-26	29766-29768	no	_	
143-27	29769-29773	mean	_	
143-28	29774-29777	DMN	_	
143-29	29778-29790	deactivation	_	
143-30	29790-29791	)	_	
143-31	29792-29797	could	_	
143-32	29798-29806	indicate	_	
143-33	29807-29811	that	_	
143-34	29812-29816	food	_	
143-35	29817-29821	cues	_	
143-36	29822-29826	were	_	
143-37	29827-29831	more	_	
143-38	29832-29842	appetitive	_	
143-39	29842-29843	;	_	
143-40	29844-29857	unfortunately	_	
143-41	29858-29861	one	_	
143-42	29862-29872	limitation	_	
143-43	29873-29875	to	_	
143-44	29876-29879	our	_	
143-45	29880-29885	study	_	
143-46	29886-29888	is	_	
143-47	29889-29893	that	_	
143-48	29894-29896	we	_	
143-49	29897-29900	did	_	
143-50	29901-29904	not	_	
143-51	29905-29911	obtain	_	
143-52	29912-29919	ratings	_	
143-53	29920-29922	of	_	
143-54	29923-29935	palatability	_	
143-55	29935-29936	.	_	

#Text=However, even if this is true, this was not an especially striking limitation, given that the difference between these two cues was still able to predict clinical outcome.
144-1	29937-29944	However	_	
144-2	29944-29945	,	_	
144-3	29946-29950	even	_	
144-4	29951-29953	if	_	
144-5	29954-29958	this	_	
144-6	29959-29961	is	_	
144-7	29962-29966	true	_	
144-8	29966-29967	,	_	
144-9	29968-29972	this	_	
144-10	29973-29976	was	_	
144-11	29977-29980	not	_	
144-12	29981-29983	an	_	
144-13	29984-29994	especially	_	
144-14	29995-30003	striking	_	
144-15	30004-30014	limitation	_	
144-16	30014-30015	,	_	
144-17	30016-30021	given	_	
144-18	30022-30026	that	_	
144-19	30027-30030	the	_	
144-20	30031-30041	difference	_	
144-21	30042-30049	between	_	
144-22	30050-30055	these	_	
144-23	30056-30059	two	_	
144-24	30060-30064	cues	_	
144-25	30065-30068	was	_	
144-26	30069-30074	still	_	
144-27	30075-30079	able	_	
144-28	30080-30082	to	_	
144-29	30083-30090	predict	_	
144-30	30091-30099	clinical	_	
144-31	30100-30107	outcome	_	
144-32	30107-30108	.	_	

#Text=Although individuals with SUD are generally conceptualized to have increased sensitivity to drug rewards but lower sensitivity to natural rewards such as food, this is not always observed in NUD; other work has demonstrated that some individuals with NUD responded more to smoking cues relative to other pleasurable cues, and others less, and that these categories predicted smoking outcomes during NUD treatment.
145-1	30109-30117	Although	_	
145-2	30118-30129	individuals	_	
145-3	30130-30134	with	_	
145-4	30135-30138	SUD	_	
145-5	30139-30142	are	_	
145-6	30143-30152	generally	_	
145-7	30153-30167	conceptualized	_	
145-8	30168-30170	to	_	
145-9	30171-30175	have	_	
145-10	30176-30185	increased	_	
145-11	30186-30197	sensitivity	_	
145-12	30198-30200	to	_	
145-13	30201-30205	drug	_	
145-14	30206-30213	rewards	_	
145-15	30214-30217	but	_	
145-16	30218-30223	lower	_	
145-17	30224-30235	sensitivity	_	
145-18	30236-30238	to	_	
145-19	30239-30246	natural	_	
145-20	30247-30254	rewards	_	
145-21	30255-30259	such	_	
145-22	30260-30262	as	_	
145-23	30263-30267	food	_	
145-24	30267-30268	,	_	
145-25	30269-30273	this	_	
145-26	30274-30276	is	_	
145-27	30277-30280	not	_	
145-28	30281-30287	always	_	
145-29	30288-30296	observed	_	
145-30	30297-30299	in	_	
145-31	30300-30303	NUD	_	
145-32	30303-30304	;	_	
145-33	30305-30310	other	_	
145-34	30311-30315	work	_	
145-35	30316-30319	has	_	
145-36	30320-30332	demonstrated	_	
145-37	30333-30337	that	_	
145-38	30338-30342	some	_	
145-39	30343-30354	individuals	_	
145-40	30355-30359	with	_	
145-41	30360-30363	NUD	_	
145-42	30364-30373	responded	_	
145-43	30374-30378	more	_	
145-44	30379-30381	to	_	
145-45	30382-30389	smoking	_	
145-46	30390-30394	cues	_	
145-47	30395-30403	relative	_	
145-48	30404-30406	to	_	
145-49	30407-30412	other	_	
145-50	30413-30424	pleasurable	_	
145-51	30425-30429	cues	_	
145-52	30429-30430	,	_	
145-53	30431-30434	and	_	
145-54	30435-30441	others	_	
145-55	30442-30446	less	_	
145-56	30446-30447	,	_	
145-57	30448-30451	and	_	
145-58	30452-30456	that	_	
145-59	30457-30462	these	_	
145-60	30463-30473	categories	_	
145-61	30474-30483	predicted	_	
145-62	30484-30491	smoking	_	
145-63	30492-30500	outcomes	_	
145-64	30501-30507	during	_	
145-65	30508-30511	NUD	_	
145-66	30512-30521	treatment	_	
145-67	30521-30522	.	_	

#Text=Both these results and our findings demonstrate that it is the relative strength of these cues that matters clinically in NUD.
146-1	30523-30527	Both	_	
146-2	30528-30533	these	_	
146-3	30534-30541	results	_	
146-4	30542-30545	and	_	
146-5	30546-30549	our	_	
146-6	30550-30558	findings	_	
146-7	30559-30570	demonstrate	_	
146-8	30571-30575	that	_	
146-9	30576-30578	it	_	
146-10	30579-30581	is	_	
146-11	30582-30585	the	_	
146-12	30586-30594	relative	_	
146-13	30595-30603	strength	_	
146-14	30604-30606	of	_	
146-15	30607-30612	these	_	
146-16	30613-30617	cues	_	
146-17	30618-30622	that	_	
146-18	30623-30630	matters	_	
146-19	30631-30641	clinically	_	
146-20	30642-30644	in	_	
146-21	30645-30648	NUD	_	
146-22	30648-30649	.	_	

#Text=Furthermore, one could raise concerns about the validity of using food cues as a baseline, especially since an individual’s hunger levels could affect the brain’s response.
147-1	30650-30661	Furthermore	_	
147-2	30661-30662	,	_	
147-3	30663-30666	one	_	
147-4	30667-30672	could	_	
147-5	30673-30678	raise	_	
147-6	30679-30687	concerns	_	
147-7	30688-30693	about	_	
147-8	30694-30697	the	_	
147-9	30698-30706	validity	_	
147-10	30707-30709	of	_	
147-11	30710-30715	using	_	
147-12	30716-30720	food	_	
147-13	30721-30725	cues	_	
147-14	30726-30728	as	_	
147-15	30729-30730	a	_	
147-16	30731-30739	baseline	_	
147-17	30739-30740	,	_	
147-18	30741-30751	especially	_	
147-19	30752-30757	since	_	
147-20	30758-30760	an	_	
147-21	30761-30771	individual	_	
147-22	30771-30772	’	_	
147-23	30772-30773	s	_	
147-24	30774-30780	hunger	_	
147-25	30781-30787	levels	_	
147-26	30788-30793	could	_	
147-27	30794-30800	affect	_	
147-28	30801-30804	the	_	
147-29	30805-30810	brain	_	
147-30	30810-30811	’	_	
147-31	30811-30812	s	_	
147-32	30813-30821	response	_	
147-33	30821-30822	.	_	

#Text=For this reason, we included a measure of food craving [WSWS(food)] as a covariate in all relevant analyses, to control for this.
148-1	30823-30826	For	_	
148-2	30827-30831	this	_	
148-3	30832-30838	reason	_	
148-4	30838-30839	,	_	
148-5	30840-30842	we	_	
148-6	30843-30851	included	_	
148-7	30852-30853	a	_	
148-8	30854-30861	measure	_	
148-9	30862-30864	of	_	
148-10	30865-30869	food	_	
148-11	30870-30877	craving	_	
148-12	30878-30879	[	_	
148-13	30879-30883	WSWS	_	
148-14	30883-30884	(	_	
148-15	30884-30888	food	_	
148-16	30888-30889	)	_	
148-17	30889-30890	]	_	
148-18	30891-30893	as	_	
148-19	30894-30895	a	_	
148-20	30896-30905	covariate	_	
148-21	30906-30908	in	_	
148-22	30909-30912	all	_	
148-23	30913-30921	relevant	_	
148-24	30922-30930	analyses	_	
148-25	30930-30931	,	_	
148-26	30932-30934	to	_	
148-27	30935-30942	control	_	
148-28	30943-30946	for	_	
148-29	30947-30951	this	_	
148-30	30951-30952	.	_	

#Text=Finally, in some cases, results differed between the full sample (outcomes imputed to baseline) and the smaller sample with complete data (DMN Food, Table 8); when results did not replicate in both samples we did not highlight them in the discussion.
149-1	30953-30960	Finally	_	
149-2	30960-30961	,	_	
149-3	30962-30964	in	_	
149-4	30965-30969	some	_	
149-5	30970-30975	cases	_	
149-6	30975-30976	,	_	
149-7	30977-30984	results	_	
149-8	30985-30993	differed	_	
149-9	30994-31001	between	_	
149-10	31002-31005	the	_	
149-11	31006-31010	full	_	
149-12	31011-31017	sample	_	
149-13	31018-31019	(	_	
149-14	31019-31027	outcomes	_	
149-15	31028-31035	imputed	_	
149-16	31036-31038	to	_	
149-17	31039-31047	baseline	_	
149-18	31047-31048	)	_	
149-19	31049-31052	and	_	
149-20	31053-31056	the	_	
149-21	31057-31064	smaller	_	
149-22	31065-31071	sample	_	
149-23	31072-31076	with	_	
149-24	31077-31085	complete	_	
149-25	31086-31090	data	_	
149-26	31091-31092	(	_	
149-27	31092-31095	DMN	_	
149-28	31096-31100	Food	_	
149-29	31100-31101	,	_	
149-30	31102-31107	Table	_	
149-31	31108-31109	8	_	
149-32	31109-31110	)	_	
149-33	31110-31111	;	_	
149-34	31112-31116	when	_	
149-35	31117-31124	results	_	
149-36	31125-31128	did	_	
149-37	31129-31132	not	_	
149-38	31133-31142	replicate	_	
149-39	31143-31145	in	_	
149-40	31146-31150	both	_	
149-41	31151-31158	samples	_	
149-42	31159-31161	we	_	
149-43	31162-31165	did	_	
149-44	31166-31169	not	_	
149-45	31170-31179	highlight	_	
149-46	31180-31184	them	_	
149-47	31185-31187	in	_	
149-48	31188-31191	the	_	
149-49	31192-31202	discussion	_	
149-50	31202-31203	.	_	

#Text=These differences may have been driven by differences between the populations (details in Supplemental Results).
150-1	31204-31209	These	_	
150-2	31210-31221	differences	_	
150-3	31222-31225	may	_	
150-4	31226-31230	have	_	
150-5	31231-31235	been	_	
150-6	31236-31242	driven	_	
150-7	31243-31245	by	_	
150-8	31246-31257	differences	_	
150-9	31258-31265	between	_	
150-10	31266-31269	the	_	
150-11	31270-31281	populations	_	
150-12	31282-31283	(	_	
150-13	31283-31290	details	_	
150-14	31291-31293	in	_	
150-15	31294-31306	Supplemental	_	
150-16	31307-31314	Results	_	
150-17	31314-31315	)	_	
150-18	31315-31316	.	_	

#Text=In summary, these findings indicating that DMN deactivation to smoke cues relative to food cues robustly predicted clinical outcome are novel and important.
151-1	31317-31319	In	_	
151-2	31320-31327	summary	_	
151-3	31327-31328	,	_	
151-4	31329-31334	these	_	
151-5	31335-31343	findings	_	
151-6	31344-31354	indicating	_	
151-7	31355-31359	that	_	
151-8	31360-31363	DMN	_	
151-9	31364-31376	deactivation	_	
151-10	31377-31379	to	_	
151-11	31380-31385	smoke	_	
151-12	31386-31390	cues	_	
151-13	31391-31399	relative	_	
151-14	31400-31402	to	_	
151-15	31403-31407	food	_	
151-16	31408-31412	cues	_	
151-17	31413-31421	robustly	_	
151-18	31422-31431	predicted	_	
151-19	31432-31440	clinical	_	
151-20	31441-31448	outcome	_	
151-21	31449-31452	are	_	
151-22	31453-31458	novel	_	
151-23	31459-31462	and	_	
151-24	31463-31472	important	_	
151-25	31472-31473	.	_	

#Text=Notably, this is one of the first works in any SUD to directly investigate the pattern of DMN activity during the processing of palatable cues and to investigate the relationship between DMN deactivation to drug cue in relation to food cue as a marker of relapse vulnerability.
152-1	31474-31481	Notably	_	
152-2	31481-31482	,	_	
152-3	31483-31487	this	_	
152-4	31488-31490	is	_	
152-5	31491-31494	one	_	
152-6	31495-31497	of	_	
152-7	31498-31501	the	_	
152-8	31502-31507	first	_	
152-9	31508-31513	works	_	
152-10	31514-31516	in	_	
152-11	31517-31520	any	_	
152-12	31521-31524	SUD	_	
152-13	31525-31527	to	_	
152-14	31528-31536	directly	_	
152-15	31537-31548	investigate	_	
152-16	31549-31552	the	_	
152-17	31553-31560	pattern	_	
152-18	31561-31563	of	_	
152-19	31564-31567	DMN	_	
152-20	31568-31576	activity	_	
152-21	31577-31583	during	_	
152-22	31584-31587	the	_	
152-23	31588-31598	processing	_	
152-24	31599-31601	of	_	
152-25	31602-31611	palatable	_	
152-26	31612-31616	cues	_	
152-27	31617-31620	and	_	
152-28	31621-31623	to	_	
152-29	31624-31635	investigate	_	
152-30	31636-31639	the	_	
152-31	31640-31652	relationship	_	
152-32	31653-31660	between	_	
152-33	31661-31664	DMN	_	
152-34	31665-31677	deactivation	_	
152-35	31678-31680	to	_	
152-36	31681-31685	drug	_	
152-37	31686-31689	cue	_	
152-38	31690-31692	in	_	
152-39	31693-31701	relation	_	
152-40	31702-31704	to	_	
152-41	31705-31709	food	_	
152-42	31710-31713	cue	_	
152-43	31714-31716	as	_	
152-44	31717-31718	a	_	
152-45	31719-31725	marker	_	
152-46	31726-31728	of	_	
152-47	31729-31736	relapse	_	
152-48	31737-31750	vulnerability	_	
152-49	31750-31751	.	_	

#Text=Although brain activation to nicotine and other drug cues has been studied and documented and its clinical importance established in a variety of clinical populations, very little work has focused on the effects of drug and other reward cues on DMN activity and its clinical relevance.
153-1	31752-31760	Although	_	
153-2	31761-31766	brain	_	
153-3	31767-31777	activation	_	
153-4	31778-31780	to	_	
153-5	31781-31789	nicotine	_	
153-6	31790-31793	and	_	
153-7	31794-31799	other	_	
153-8	31800-31804	drug	_	
153-9	31805-31809	cues	_	
153-10	31810-31813	has	_	
153-11	31814-31818	been	_	
153-12	31819-31826	studied	_	
153-13	31827-31830	and	_	
153-14	31831-31841	documented	_	
153-15	31842-31845	and	_	
153-16	31846-31849	its	_	
153-17	31850-31858	clinical	_	
153-18	31859-31869	importance	_	
153-19	31870-31881	established	_	
153-20	31882-31884	in	_	
153-21	31885-31886	a	_	
153-22	31887-31894	variety	_	
153-23	31895-31897	of	_	
153-24	31898-31906	clinical	_	
153-25	31907-31918	populations	_	
153-26	31918-31919	,	_	
153-27	31920-31924	very	_	
153-28	31925-31931	little	_	
153-29	31932-31936	work	_	
153-30	31937-31940	has	_	
153-31	31941-31948	focused	_	
153-32	31949-31951	on	_	
153-33	31952-31955	the	_	
153-34	31956-31963	effects	_	
153-35	31964-31966	of	_	
153-36	31967-31971	drug	_	
153-37	31972-31975	and	_	
153-38	31976-31981	other	_	
153-39	31982-31988	reward	_	
153-40	31989-31993	cues	_	
153-41	31994-31996	on	_	
153-42	31997-32000	DMN	_	
153-43	32001-32009	activity	_	
153-44	32010-32013	and	_	
153-45	32014-32017	its	_	
153-46	32018-32026	clinical	_	
153-47	32027-32036	relevance	_	
153-48	32036-32037	.	_	

#Text=Future work should attempt to replicate these findings in other NUD treatment samples, as well as in other SUD, to identify whether or not this is a reliable method to predict overall treatment outcome and/or predict response to particular treatments.
154-1	32038-32044	Future	_	
154-2	32045-32049	work	_	
154-3	32050-32056	should	_	
154-4	32057-32064	attempt	_	
154-5	32065-32067	to	_	
154-6	32068-32077	replicate	_	
154-7	32078-32083	these	_	
154-8	32084-32092	findings	_	
154-9	32093-32095	in	_	
154-10	32096-32101	other	_	
154-11	32102-32105	NUD	_	
154-12	32106-32115	treatment	_	
154-13	32116-32123	samples	_	
154-14	32123-32124	,	_	
154-15	32125-32127	as	_	
154-16	32128-32132	well	_	
154-17	32133-32135	as	_	
154-18	32136-32138	in	_	
154-19	32139-32144	other	_	
154-20	32145-32148	SUD	_	
154-21	32148-32149	,	_	
154-22	32150-32152	to	_	
154-23	32153-32161	identify	_	
154-24	32162-32169	whether	_	
154-25	32170-32172	or	_	
154-26	32173-32176	not	_	
154-27	32177-32181	this	_	
154-28	32182-32184	is	_	
154-29	32185-32186	a	_	
154-30	32187-32195	reliable	_	
154-31	32196-32202	method	_	
154-32	32203-32205	to	_	
154-33	32206-32213	predict	_	
154-34	32214-32221	overall	_	
154-35	32222-32231	treatment	_	
154-36	32232-32239	outcome	_	
154-37	32240-32243	and	_	
154-38	32243-32244	/	_	
154-39	32244-32246	or	_	
154-40	32247-32254	predict	_	
154-41	32255-32263	response	_	
154-42	32264-32266	to	_	
154-43	32267-32277	particular	_	
154-44	32278-32288	treatments	_	
154-45	32288-32289	.	_	

#Text=Supplementary Material
#Text=This data was previously presented at the Organization for Human Brain Mapping, 2016, under the abstract title: “Default mode network deactivation to smoking cue predicts treatment outcome in nicotine use disorder.”
155-1	32290-32303	Supplementary	_	
155-2	32304-32312	Material	_	
155-3	32313-32317	This	_	
155-4	32318-32322	data	_	
155-5	32323-32326	was	_	
155-6	32327-32337	previously	_	
155-7	32338-32347	presented	_	
155-8	32348-32350	at	_	
155-9	32351-32354	the	_	
155-10	32355-32367	Organization	_	
155-11	32368-32371	for	_	
155-12	32372-32377	Human	_	
155-13	32378-32383	Brain	_	
155-14	32384-32391	Mapping	_	
155-15	32391-32392	,	_	
155-16	32393-32397	2016	_	
155-17	32397-32398	,	_	
155-18	32399-32404	under	_	
155-19	32405-32408	the	_	
155-20	32409-32417	abstract	_	
155-21	32418-32423	title	_	
155-22	32423-32424	:	_	
155-23	32425-32426	“	_	
155-24	32426-32433	Default	_	
155-25	32434-32438	mode	_	
155-26	32439-32446	network	_	
155-27	32447-32459	deactivation	_	
155-28	32460-32462	to	_	
155-29	32463-32470	smoking	_	
155-30	32471-32474	cue	_	
155-31	32475-32483	predicts	_	
155-32	32484-32493	treatment	_	
155-33	32494-32501	outcome	_	
155-34	32502-32504	in	_	
155-35	32505-32513	nicotine	_	
155-36	32514-32517	use	_	
155-37	32518-32526	disorder	_	
155-38	32526-32527	.	_	
155-39	32527-32528	”	_	

#Text=Financial Disclosures         
#Text=The authors have no conflicts of interest to declare.
156-1	32540-32549	Financial	_	
156-2	32550-32561	Disclosures	_	
156-3	32571-32574	The	_	
156-4	32575-32582	authors	_	
156-5	32583-32587	have	_	
156-6	32588-32590	no	_	
156-7	32591-32600	conflicts	_	
156-8	32601-32603	of	_	
156-9	32604-32612	interest	_	
156-10	32613-32615	to	_	
156-11	32616-32623	declare	_	
156-12	32623-32624	.	_	

#Text=The role of default network deactivation in cognition and disease
#Text=Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial
#Text=Does reduced smoking if you can't stop make any difference?
157-1	32626-32629	The	_	
157-2	32630-32634	role	_	
157-3	32635-32637	of	_	
157-4	32638-32645	default	_	
157-5	32646-32653	network	_	
157-6	32654-32666	deactivation	_	
157-7	32667-32669	in	_	
157-8	32670-32679	cognition	_	
157-9	32680-32683	and	_	
157-10	32684-32691	disease	_	
157-11	32692-32700	Efficacy	_	
157-12	32701-32703	of	_	
157-13	32704-32713	bupropion	_	
157-14	32714-32717	and	_	
157-15	32718-32728	predictors	_	
157-16	32729-32731	of	_	
157-17	32732-32742	successful	_	
157-18	32743-32750	outcome	_	
157-19	32751-32753	in	_	
157-20	32754-32755	a	_	
157-21	32756-32762	sample	_	
157-22	32763-32765	of	_	
157-23	32766-32772	French	_	
157-24	32773-32780	smokers	_	
157-25	32780-32781	:	_	
157-26	32782-32783	a	_	
157-27	32784-32794	randomized	_	
157-28	32795-32813	placebo-controlled	_	
157-29	32814-32819	trial	_	
157-30	32820-32824	Does	_	
157-31	32825-32832	reduced	_	
157-32	32833-32840	smoking	_	
157-33	32841-32843	if	_	
157-34	32844-32847	you	_	
157-35	32848-32853	can't	_	
157-36	32854-32858	stop	_	
157-37	32859-32863	make	_	
157-38	32864-32867	any	_	
157-39	32868-32878	difference	_	
157-40	32878-32879	?	_	

#Text=Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial
#Text=A method for making group inferences from functional MRI data using independent component analysis
#Text=Modulation of temporally coherent brain networks estimated using ICA at rest and during cognitive tasks
#Text=Long-term cigarette smoke exposure increases uncoupling protein expression but reduces energy intake
#Text=Association Between Nicotine Dependence Severity, BOLD Response to Smoking Cues, and Functional Connectivity
#Text=Neural substrates of cue reactivity: association with treatment outcomes and relapse
#Text=Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial
#Text=Neural substrates of smoking cue reactivity: a meta-analysis of fMRI studies
#Text=Comparison of multi-subject ICA methods for analysis of fMRI data
#Text=Predictors of 6-month tobacco abstinence among 1224 cigarette smokers treated for nicotine dependence
#Text=The human brain is intrinsically organized into dynamic, anticorrelated functional networks
#Text=Interrater and intermethod reliability of default mode network selection
#Text=Effects of varenicline on smoking cue-triggered neural and craving responses
#Text=Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial
#Text=Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews
#Text=Resisting the urge to smoke and craving during a smoking quit attempt on varenicline: results from a pilot fMRI study
#Text=Imputation methods for missing outcome data in meta-analysis of clinical trials
#Text=Predictors of success in smoking cessation among Italian adults motivated to quit
#Text=Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence
#Text=
#Text=Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials
#Text=Logistic Regression in Rare Events Data
#Text=Neurocircuitry of Addiction
#Text=Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders
#Text=Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function
#Text=Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial
#Text=
#Text=Automatic identification of functional clusters in FMRI data using spatial dependence
#Text=Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging
#Text=Smoking outcome by psychiatric history after behavioral and varenicline treatment
#Text=Matching high- and low-dependence smokers to self-help treatment with or without nicotine replacement
#Text=Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence
#Text=Validation of the Amsterdam Beverage Picture Set: A Controlled Picture Set for Cognitive Bias Measurement and Modification Paradigms
#Text=
#Text=Ten-year survival outcome of the nicotine transdermal patch with cognitive behavioural therapy
#Text=Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid
#Text=Delay discounting, locus of control, and cognitive impulsiveness independently predict tobacco dependence treatment outcomes in a highly dependent, lower socioeconomic group of smokers
#Text=
#Text=Satiation attenuates BOLD activity in brain regions involved in reward and increases activity in dorsolateral prefrontal cortex: an fMRI study in healthy volunteers
#Text=Overlapping patterns of brain activation to food and cocaine cues in cocaine abusers: association to striatal D2/D3 receptors
#Text=Prequit fMRI responses to pleasant cues and cigarette-related cues predict smoking cessation outcome
#Text=Addiction: decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain's control circuit
#Text=Stop smoking clinics in Malaysia: characteristics of attendees and predictors of success
#Text=The effect of Varenicline on smoking cessation in a group of young asthma patients
#Text=Psychopharmacologies for Alcohol and Drug USe Disorders
#Text=Enhanced cue reactivity and frontostriatal functional connectivity in cocaine use disorders
#Text=a.
158-1	32880-32885	Brain	_	
158-2	32886-32895	nicotinic	_	
158-3	32896-32909	acetylcholine	_	
158-4	32910-32918	receptor	_	
158-5	32919-32931	availability	_	
158-6	32932-32935	and	_	
158-7	32936-32944	response	_	
158-8	32945-32947	to	_	
158-9	32948-32955	smoking	_	
158-10	32956-32965	cessation	_	
158-11	32966-32975	treatment	_	
158-12	32975-32976	:	_	
158-13	32977-32978	a	_	
158-14	32979-32989	randomized	_	
158-15	32990-32995	trial	_	
158-16	32996-32997	A	_	
158-17	32998-33004	method	_	
158-18	33005-33008	for	_	
158-19	33009-33015	making	_	
158-20	33016-33021	group	_	
158-21	33022-33032	inferences	_	
158-22	33033-33037	from	_	
158-23	33038-33048	functional	_	
158-24	33049-33052	MRI	_	
158-25	33053-33057	data	_	
158-26	33058-33063	using	_	
158-27	33064-33075	independent	_	
158-28	33076-33085	component	_	
158-29	33086-33094	analysis	_	
158-30	33095-33105	Modulation	_	
158-31	33106-33108	of	_	
158-32	33109-33119	temporally	_	
158-33	33120-33128	coherent	_	
158-34	33129-33134	brain	_	
158-35	33135-33143	networks	_	
158-36	33144-33153	estimated	_	
158-37	33154-33159	using	_	
158-38	33160-33163	ICA	_	
158-39	33164-33166	at	_	
158-40	33167-33171	rest	_	
158-41	33172-33175	and	_	
158-42	33176-33182	during	_	
158-43	33183-33192	cognitive	_	
158-44	33193-33198	tasks	_	
158-45	33199-33208	Long-term	_	
158-46	33209-33218	cigarette	_	
158-47	33219-33224	smoke	_	
158-48	33225-33233	exposure	_	
158-49	33234-33243	increases	_	
158-50	33244-33254	uncoupling	_	
158-51	33255-33262	protein	_	
158-52	33263-33273	expression	_	
158-53	33274-33277	but	_	
158-54	33278-33285	reduces	_	
158-55	33286-33292	energy	_	
158-56	33293-33299	intake	_	
158-57	33300-33311	Association	_	
158-58	33312-33319	Between	_	
158-59	33320-33328	Nicotine	_	
158-60	33329-33339	Dependence	_	
158-61	33340-33348	Severity	_	
158-62	33348-33349	,	_	
158-63	33350-33354	BOLD	_	
158-64	33355-33363	Response	_	
158-65	33364-33366	to	_	
158-66	33367-33374	Smoking	_	
158-67	33375-33379	Cues	_	
158-68	33379-33380	,	_	
158-69	33381-33384	and	_	
158-70	33385-33395	Functional	_	
158-71	33396-33408	Connectivity	_	
158-72	33409-33415	Neural	_	
158-73	33416-33426	substrates	_	
158-74	33427-33429	of	_	
158-75	33430-33433	cue	_	
158-76	33434-33444	reactivity	_	
158-77	33444-33445	:	_	
158-78	33446-33457	association	_	
158-79	33458-33462	with	_	
158-80	33463-33472	treatment	_	
158-81	33473-33481	outcomes	_	
158-82	33482-33485	and	_	
158-83	33486-33493	relapse	_	
158-84	33494-33500	Effect	_	
158-85	33501-33503	of	_	
158-86	33504-33515	varenicline	_	
158-87	33516-33518	on	_	
158-88	33519-33526	smoking	_	
158-89	33527-33536	cessation	_	
158-90	33537-33544	through	_	
158-91	33545-33552	smoking	_	
158-92	33553-33562	reduction	_	
158-93	33562-33563	:	_	
158-94	33564-33565	a	_	
158-95	33566-33576	randomized	_	
158-96	33577-33585	clinical	_	
158-97	33586-33591	trial	_	
158-98	33592-33598	Neural	_	
158-99	33599-33609	substrates	_	
158-100	33610-33612	of	_	
158-101	33613-33620	smoking	_	
158-102	33621-33624	cue	_	
158-103	33625-33635	reactivity	_	
158-104	33635-33636	:	_	
158-105	33637-33638	a	_	
158-106	33639-33652	meta-analysis	_	
158-107	33653-33655	of	_	
158-108	33656-33660	fMRI	_	
158-109	33661-33668	studies	_	
158-110	33669-33679	Comparison	_	
158-111	33680-33682	of	_	
158-112	33683-33696	multi-subject	_	
158-113	33697-33700	ICA	_	
158-114	33701-33708	methods	_	
158-115	33709-33712	for	_	
158-116	33713-33721	analysis	_	
158-117	33722-33724	of	_	
158-118	33725-33729	fMRI	_	
158-119	33730-33734	data	_	
158-120	33735-33745	Predictors	_	
158-121	33746-33748	of	_	
158-122	33749-33750	6	_	
158-123	33750-33751	-	_	
158-124	33751-33756	month	_	
158-125	33757-33764	tobacco	_	
158-126	33765-33775	abstinence	_	
158-127	33776-33781	among	_	
158-128	33782-33786	1224	_	
158-129	33787-33796	cigarette	_	
158-130	33797-33804	smokers	_	
158-131	33805-33812	treated	_	
158-132	33813-33816	for	_	
158-133	33817-33825	nicotine	_	
158-134	33826-33836	dependence	_	
158-135	33837-33840	The	_	
158-136	33841-33846	human	_	
158-137	33847-33852	brain	_	
158-138	33853-33855	is	_	
158-139	33856-33869	intrinsically	_	
158-140	33870-33879	organized	_	
158-141	33880-33884	into	_	
158-142	33885-33892	dynamic	_	
158-143	33892-33893	,	_	
158-144	33894-33908	anticorrelated	_	
158-145	33909-33919	functional	_	
158-146	33920-33928	networks	_	
158-147	33929-33939	Interrater	_	
158-148	33940-33943	and	_	
158-149	33944-33955	intermethod	_	
158-150	33956-33967	reliability	_	
158-151	33968-33970	of	_	
158-152	33971-33978	default	_	
158-153	33979-33983	mode	_	
158-154	33984-33991	network	_	
158-155	33992-34001	selection	_	
158-156	34002-34009	Effects	_	
158-157	34010-34012	of	_	
158-158	34013-34024	varenicline	_	
158-159	34025-34027	on	_	
158-160	34028-34035	smoking	_	
158-161	34036-34049	cue-triggered	_	
158-162	34050-34056	neural	_	
158-163	34057-34060	and	_	
158-164	34061-34068	craving	_	
158-165	34069-34078	responses	_	
158-166	34079-34090	Varenicline	_	
158-167	34090-34091	,	_	
158-168	34092-34094	an	_	
158-169	34095-34106	alpha4beta2	_	
158-170	34107-34116	nicotinic	_	
158-171	34117-34130	acetylcholine	_	
158-172	34131-34139	receptor	_	
158-173	34140-34147	partial	_	
158-174	34148-34155	agonist	_	
158-175	34155-34156	,	_	
158-176	34157-34159	vs	_	
158-177	34160-34177	sustained-release	_	
158-178	34178-34187	bupropion	_	
158-179	34188-34191	and	_	
158-180	34192-34199	placebo	_	
158-181	34200-34203	for	_	
158-182	34204-34211	smoking	_	
158-183	34212-34221	cessation	_	
158-184	34221-34222	:	_	
158-185	34223-34224	a	_	
158-186	34225-34235	randomized	_	
158-187	34236-34246	controlled	_	
158-188	34247-34252	trial	_	
158-189	34253-34261	Efficacy	_	
158-190	34262-34264	of	_	
158-191	34265-34278	interventions	_	
158-192	34279-34281	to	_	
158-193	34282-34288	combat	_	
158-194	34289-34296	tobacco	_	
158-195	34297-34306	addiction	_	
158-196	34306-34307	:	_	
158-197	34308-34316	Cochrane	_	
158-198	34317-34323	update	_	
158-199	34324-34326	of	_	
158-200	34327-34331	2013	_	
158-201	34332-34339	reviews	_	
158-202	34340-34349	Resisting	_	
158-203	34350-34353	the	_	
158-204	34354-34358	urge	_	
158-205	34359-34361	to	_	
158-206	34362-34367	smoke	_	
158-207	34368-34371	and	_	
158-208	34372-34379	craving	_	
158-209	34380-34386	during	_	
158-210	34387-34388	a	_	
158-211	34389-34396	smoking	_	
158-212	34397-34401	quit	_	
158-213	34402-34409	attempt	_	
158-214	34410-34412	on	_	
158-215	34413-34424	varenicline	_	
158-216	34424-34425	:	_	
158-217	34426-34433	results	_	
158-218	34434-34438	from	_	
158-219	34439-34440	a	_	
158-220	34441-34446	pilot	_	
158-221	34447-34451	fMRI	_	
158-222	34452-34457	study	_	
158-223	34458-34468	Imputation	_	
158-224	34469-34476	methods	_	
158-225	34477-34480	for	_	
158-226	34481-34488	missing	_	
158-227	34489-34496	outcome	_	
158-228	34497-34501	data	_	
158-229	34502-34504	in	_	
158-230	34505-34518	meta-analysis	_	
158-231	34519-34521	of	_	
158-232	34522-34530	clinical	_	
158-233	34531-34537	trials	_	
158-234	34538-34548	Predictors	_	
158-235	34549-34551	of	_	
158-236	34552-34559	success	_	
158-237	34560-34562	in	_	
158-238	34563-34570	smoking	_	
158-239	34571-34580	cessation	_	
158-240	34581-34586	among	_	
158-241	34587-34594	Italian	_	
158-242	34595-34601	adults	_	
158-243	34602-34611	motivated	_	
158-244	34612-34614	to	_	
158-245	34615-34619	quit	_	
158-246	34620-34625	Brain	_	
158-247	34626-34636	reactivity	_	
158-248	34637-34639	to	_	
158-249	34640-34647	smoking	_	
158-250	34648-34652	cues	_	
158-251	34653-34658	prior	_	
158-252	34659-34661	to	_	
158-253	34662-34669	smoking	_	
158-254	34670-34679	cessation	_	
158-255	34680-34688	predicts	_	
158-256	34689-34696	ability	_	
158-257	34697-34699	to	_	
158-258	34700-34708	maintain	_	
158-259	34709-34716	tobacco	_	
158-260	34717-34727	abstinence	_	
158-261	34729-34736	Smoking	_	
158-262	34737-34746	cessation	_	
158-263	34747-34763	pharmacogenetics	_	
158-264	34763-34764	:	_	
158-265	34765-34773	analysis	_	
158-266	34774-34776	of	_	
158-267	34777-34788	varenicline	_	
158-268	34789-34792	and	_	
158-269	34793-34802	bupropion	_	
158-270	34803-34805	in	_	
158-271	34806-34824	placebo-controlled	_	
158-272	34825-34833	clinical	_	
158-273	34834-34840	trials	_	
158-274	34841-34849	Logistic	_	
158-275	34850-34860	Regression	_	
158-276	34861-34863	in	_	
158-277	34864-34868	Rare	_	
158-278	34869-34875	Events	_	
158-279	34876-34880	Data	_	
158-280	34881-34895	Neurocircuitry	_	
158-281	34896-34898	of	_	
158-282	34899-34908	Addiction	_	
158-283	34909-34919	Addictions	_	
158-284	34920-34933	Neuroclinical	_	
158-285	34934-34944	Assessment	_	
158-286	34944-34945	:	_	
158-287	34946-34947	A	_	
158-288	34948-34966	Neuroscience-Based	_	
158-289	34967-34976	Framework	_	
158-290	34977-34980	for	_	
158-291	34981-34990	Addictive	_	
158-292	34991-35000	Disorders	_	
158-293	35001-35012	Large-scale	_	
158-294	35013-35018	brain	_	
158-295	35019-35026	network	_	
158-296	35027-35035	coupling	_	
158-297	35036-35044	predicts	_	
158-298	35045-35050	acute	_	
158-299	35051-35059	nicotine	_	
158-300	35060-35070	abstinence	_	
158-301	35071-35078	effects	_	
158-302	35079-35081	on	_	
158-303	35082-35089	craving	_	
158-304	35090-35093	and	_	
158-305	35094-35103	cognitive	_	
158-306	35104-35112	function	_	
158-307	35113-35116	Use	_	
158-308	35117-35119	of	_	
158-309	35120-35123	the	_	
158-310	35124-35132	nicotine	_	
158-311	35133-35143	metabolite	_	
158-312	35144-35149	ratio	_	
158-313	35150-35152	as	_	
158-314	35153-35154	a	_	
158-315	35155-35166	genetically	_	
158-316	35167-35175	informed	_	
158-317	35176-35185	biomarker	_	
158-318	35186-35188	of	_	
158-319	35189-35197	response	_	
158-320	35198-35200	to	_	
158-321	35201-35209	nicotine	_	
158-322	35210-35215	patch	_	
158-323	35216-35218	or	_	
158-324	35219-35230	varenicline	_	
158-325	35231-35234	for	_	
158-326	35235-35242	smoking	_	
158-327	35243-35252	cessation	_	
158-328	35252-35253	:	_	
158-329	35254-35255	a	_	
158-330	35256-35266	randomised	_	
158-331	35266-35267	,	_	
158-332	35268-35280	double-blind	_	
158-333	35281-35299	placebo-controlled	_	
158-334	35300-35305	trial	_	
158-335	35307-35316	Automatic	_	
158-336	35317-35331	identification	_	
158-337	35332-35334	of	_	
158-338	35335-35345	functional	_	
158-339	35346-35354	clusters	_	
158-340	35355-35357	in	_	
158-341	35358-35362	FMRI	_	
158-342	35363-35367	data	_	
158-343	35368-35373	using	_	
158-344	35374-35381	spatial	_	
158-345	35382-35392	dependence	_	
158-346	35393-35403	Predicting	_	
158-347	35404-35414	naltrexone	_	
158-348	35415-35423	response	_	
158-349	35424-35426	in	_	
158-350	35427-35444	alcohol-dependent	_	
158-351	35445-35453	patients	_	
158-352	35453-35454	:	_	
158-353	35455-35458	the	_	
158-354	35459-35471	contribution	_	
158-355	35472-35474	of	_	
158-356	35475-35485	functional	_	
158-357	35486-35494	magnetic	_	
158-358	35495-35504	resonance	_	
158-359	35505-35512	imaging	_	
158-360	35513-35520	Smoking	_	
158-361	35521-35528	outcome	_	
158-362	35529-35531	by	_	
158-363	35532-35543	psychiatric	_	
158-364	35544-35551	history	_	
158-365	35552-35557	after	_	
158-366	35558-35568	behavioral	_	
158-367	35569-35572	and	_	
158-368	35573-35584	varenicline	_	
158-369	35585-35594	treatment	_	
158-370	35595-35603	Matching	_	
158-371	35604-35608	high	_	
158-372	35608-35609	-	_	
158-373	35610-35613	and	_	
158-374	35614-35628	low-dependence	_	
158-375	35629-35636	smokers	_	
158-376	35637-35639	to	_	
158-377	35640-35649	self-help	_	
158-378	35650-35659	treatment	_	
158-379	35660-35664	with	_	
158-380	35665-35667	or	_	
158-381	35668-35675	without	_	
158-382	35676-35684	nicotine	_	
158-383	35685-35696	replacement	_	
158-384	35697-35710	Varenicline's	_	
158-385	35711-35718	effects	_	
158-386	35719-35721	on	_	
158-387	35722-35727	acute	_	
158-388	35728-35735	smoking	_	
158-389	35736-35744	behavior	_	
158-390	35745-35748	and	_	
158-391	35749-35755	reward	_	
158-392	35756-35759	and	_	
158-393	35760-35765	their	_	
158-394	35766-35777	association	_	
158-395	35778-35782	with	_	
158-396	35783-35793	subsequent	_	
158-397	35794-35804	abstinence	_	
158-398	35805-35815	Validation	_	
158-399	35816-35818	of	_	
158-400	35819-35822	the	_	
158-401	35823-35832	Amsterdam	_	
158-402	35833-35841	Beverage	_	
158-403	35842-35849	Picture	_	
158-404	35850-35853	Set	_	
158-405	35853-35854	:	_	
158-406	35855-35856	A	_	
158-407	35857-35867	Controlled	_	
158-408	35868-35875	Picture	_	
158-409	35876-35879	Set	_	
158-410	35880-35883	for	_	
158-411	35884-35893	Cognitive	_	
158-412	35894-35898	Bias	_	
158-413	35899-35910	Measurement	_	
158-414	35911-35914	and	_	
158-415	35915-35927	Modification	_	
158-416	35928-35937	Paradigms	_	
158-417	35939-35947	Ten-year	_	
158-418	35948-35956	survival	_	
158-419	35957-35964	outcome	_	
158-420	35965-35967	of	_	
158-421	35968-35971	the	_	
158-422	35972-35980	nicotine	_	
158-423	35981-35992	transdermal	_	
158-424	35993-35998	patch	_	
158-425	35999-36003	with	_	
158-426	36004-36013	cognitive	_	
158-427	36014-36025	behavioural	_	
158-428	36026-36033	therapy	_	
158-429	36034-36049	Pharmacological	_	
158-430	36050-36057	profile	_	
158-431	36058-36060	of	_	
158-432	36061-36064	the	_	
158-433	36065-36076	alpha4beta2	_	
158-434	36077-36086	nicotinic	_	
158-435	36087-36100	acetylcholine	_	
158-436	36101-36109	receptor	_	
158-437	36110-36117	partial	_	
158-438	36118-36125	agonist	_	
158-439	36126-36137	varenicline	_	
158-440	36137-36138	,	_	
158-441	36139-36141	an	_	
158-442	36142-36151	effective	_	
158-443	36152-36159	smoking	_	
158-444	36160-36169	cessation	_	
158-445	36170-36173	aid	_	
158-446	36174-36179	Delay	_	
158-447	36180-36191	discounting	_	
158-448	36191-36192	,	_	
158-449	36193-36198	locus	_	
158-450	36199-36201	of	_	
158-451	36202-36209	control	_	
158-452	36209-36210	,	_	
158-453	36211-36214	and	_	
158-454	36215-36224	cognitive	_	
158-455	36225-36238	impulsiveness	_	
158-456	36239-36252	independently	_	
158-457	36253-36260	predict	_	
158-458	36261-36268	tobacco	_	
158-459	36269-36279	dependence	_	
158-460	36280-36289	treatment	_	
158-461	36290-36298	outcomes	_	
158-462	36299-36301	in	_	
158-463	36302-36303	a	_	
158-464	36304-36310	highly	_	
158-465	36311-36320	dependent	_	
158-466	36320-36321	,	_	
158-467	36322-36327	lower	_	
158-468	36328-36341	socioeconomic	_	
158-469	36342-36347	group	_	
158-470	36348-36350	of	_	
158-471	36351-36358	smokers	_	
158-472	36360-36369	Satiation	_	
158-473	36370-36380	attenuates	_	
158-474	36381-36385	BOLD	_	
158-475	36386-36394	activity	_	
158-476	36395-36397	in	_	
158-477	36398-36403	brain	_	
158-478	36404-36411	regions	_	
158-479	36412-36420	involved	_	
158-480	36421-36423	in	_	
158-481	36424-36430	reward	_	
158-482	36431-36434	and	_	
158-483	36435-36444	increases	_	
158-484	36445-36453	activity	_	
158-485	36454-36456	in	_	
158-486	36457-36469	dorsolateral	_	
158-487	36470-36480	prefrontal	_	
158-488	36481-36487	cortex	_	
158-489	36487-36488	:	_	
158-490	36489-36491	an	_	
158-491	36492-36496	fMRI	_	
158-492	36497-36502	study	_	
158-493	36503-36505	in	_	
158-494	36506-36513	healthy	_	
158-495	36514-36524	volunteers	_	
158-496	36525-36536	Overlapping	_	
158-497	36537-36545	patterns	_	
158-498	36546-36548	of	_	
158-499	36549-36554	brain	_	
158-500	36555-36565	activation	_	
158-501	36566-36568	to	_	
158-502	36569-36573	food	_	
158-503	36574-36577	and	_	
158-504	36578-36585	cocaine	_	
158-505	36586-36590	cues	_	
158-506	36591-36593	in	_	
158-507	36594-36601	cocaine	_	
158-508	36602-36609	abusers	_	
158-509	36609-36610	:	_	
158-510	36611-36622	association	_	
158-511	36623-36625	to	_	
158-512	36626-36634	striatal	_	
158-513	36635-36637	D2	_	
158-514	36637-36638	/	_	
158-515	36638-36640	D3	_	
158-516	36641-36650	receptors	_	
158-517	36651-36658	Prequit	_	
158-518	36659-36663	fMRI	_	
158-519	36664-36673	responses	_	
158-520	36674-36676	to	_	
158-521	36677-36685	pleasant	_	
158-522	36686-36690	cues	_	
158-523	36691-36694	and	_	
158-524	36695-36712	cigarette-related	_	
158-525	36713-36717	cues	_	
158-526	36718-36725	predict	_	
158-527	36726-36733	smoking	_	
158-528	36734-36743	cessation	_	
158-529	36744-36751	outcome	_	
158-530	36752-36761	Addiction	_	
158-531	36761-36762	:	_	
158-532	36763-36772	decreased	_	
158-533	36773-36779	reward	_	
158-534	36780-36791	sensitivity	_	
158-535	36792-36795	and	_	
158-536	36796-36805	increased	_	
158-537	36806-36817	expectation	_	
158-538	36818-36829	sensitivity	_	
158-539	36830-36838	conspire	_	
158-540	36839-36841	to	_	
158-541	36842-36851	overwhelm	_	
158-542	36852-36855	the	_	
158-543	36856-36863	brain's	_	
158-544	36864-36871	control	_	
158-545	36872-36879	circuit	_	
158-546	36880-36884	Stop	_	
158-547	36885-36892	smoking	_	
158-548	36893-36900	clinics	_	
158-549	36901-36903	in	_	
158-550	36904-36912	Malaysia	_	
158-551	36912-36913	:	_	
158-552	36914-36929	characteristics	_	
158-553	36930-36932	of	_	
158-554	36933-36942	attendees	_	
158-555	36943-36946	and	_	
158-556	36947-36957	predictors	_	
158-557	36958-36960	of	_	
158-558	36961-36968	success	_	
158-559	36969-36972	The	_	
158-560	36973-36979	effect	_	
158-561	36980-36982	of	_	
158-562	36983-36994	Varenicline	_	
158-563	36995-36997	on	_	
158-564	36998-37005	smoking	_	
158-565	37006-37015	cessation	_	
158-566	37016-37018	in	_	
158-567	37019-37020	a	_	
158-568	37021-37026	group	_	
158-569	37027-37029	of	_	
158-570	37030-37035	young	_	
158-571	37036-37042	asthma	_	
158-572	37043-37051	patients	_	
158-573	37052-37072	Psychopharmacologies	_	
158-574	37073-37076	for	_	
158-575	37077-37084	Alcohol	_	
158-576	37085-37088	and	_	
158-577	37089-37093	Drug	_	
158-578	37094-37097	USe	_	
158-579	37098-37107	Disorders	_	
158-580	37108-37116	Enhanced	_	
158-581	37117-37120	cue	_	
158-582	37121-37131	reactivity	_	
158-583	37132-37135	and	_	
158-584	37136-37150	frontostriatal	_	
158-585	37151-37161	functional	_	
158-586	37162-37174	connectivity	_	
158-587	37175-37177	in	_	
158-588	37178-37185	cocaine	_	
158-589	37186-37189	use	_	
158-590	37190-37199	disorders	_	
158-591	37200-37201	a	_	
158-592	37201-37202	.	_	

#Text=This figure shows the DMN component with each axial slice marked with a number representing the MNI z coordinate.
159-1	37203-37207	This	_	
159-2	37208-37214	figure	_	
159-3	37215-37220	shows	_	
159-4	37221-37224	the	_	
159-5	37225-37228	DMN	_	
159-6	37229-37238	component	_	
159-7	37239-37243	with	_	
159-8	37244-37248	each	_	
159-9	37249-37254	axial	_	
159-10	37255-37260	slice	_	
159-11	37261-37267	marked	_	
159-12	37268-37272	with	_	
159-13	37273-37274	a	_	
159-14	37275-37281	number	_	
159-15	37282-37294	representing	_	
159-16	37295-37298	the	_	
159-17	37299-37302	MNI	_	
159-18	37303-37304	z	_	
159-19	37305-37315	coordinate	_	
159-20	37315-37316	.	_	

#Text=Red indicates voxels which are more positively associated with the component (positive Z scores), and blue indicates voxels which are more negatively associated with this component (negative Z scores).
#Text=b.
160-1	37317-37320	Red	_	
160-2	37321-37330	indicates	_	
160-3	37331-37337	voxels	_	
160-4	37338-37343	which	_	
160-5	37344-37347	are	_	
160-6	37348-37352	more	_	
160-7	37353-37363	positively	_	
160-8	37364-37374	associated	_	
160-9	37375-37379	with	_	
160-10	37380-37383	the	_	
160-11	37384-37393	component	_	
160-12	37394-37395	(	_	
160-13	37395-37403	positive	_	
160-14	37404-37405	Z	_	
160-15	37406-37412	scores	_	
160-16	37412-37413	)	_	
160-17	37413-37414	,	_	
160-18	37415-37418	and	_	
160-19	37419-37423	blue	_	
160-20	37424-37433	indicates	_	
160-21	37434-37440	voxels	_	
160-22	37441-37446	which	_	
160-23	37447-37450	are	_	
160-24	37451-37455	more	_	
160-25	37456-37466	negatively	_	
160-26	37467-37477	associated	_	
160-27	37478-37482	with	_	
160-28	37483-37487	this	_	
160-29	37488-37497	component	_	
160-30	37498-37499	(	_	
160-31	37499-37507	negative	_	
160-32	37508-37509	Z	_	
160-33	37510-37516	scores	_	
160-34	37516-37517	)	_	
160-35	37517-37518	.	_	
160-36	37519-37520	b	_	
160-37	37520-37521	.	_	

#Text=This boxplot presents the results for the betas for the strength of the association of the DMN component with the smoke cues and the food cues separately.
161-1	37522-37526	This	_	
161-2	37527-37534	boxplot	_	
161-3	37535-37543	presents	_	
161-4	37544-37547	the	_	
161-5	37548-37555	results	_	
161-6	37556-37559	for	_	
161-7	37560-37563	the	_	
161-8	37564-37569	betas	_	
161-9	37570-37573	for	_	
161-10	37574-37577	the	_	
161-11	37578-37586	strength	_	
161-12	37587-37589	of	_	
161-13	37590-37593	the	_	
161-14	37594-37605	association	_	
161-15	37606-37608	of	_	
161-16	37609-37612	the	_	
161-17	37613-37616	DMN	_	
161-18	37617-37626	component	_	
161-19	37627-37631	with	_	
161-20	37632-37635	the	_	
161-21	37636-37641	smoke	_	
161-22	37642-37646	cues	_	
161-23	37647-37650	and	_	
161-24	37651-37654	the	_	
161-25	37655-37659	food	_	
161-26	37660-37664	cues	_	
161-27	37665-37675	separately	_	
161-28	37675-37676	.	_	

#Text=The upper and lower quartiles are represented by the box, and the median is represented by a black line within the box.
162-1	37677-37680	The	_	
162-2	37681-37686	upper	_	
162-3	37687-37690	and	_	
162-4	37691-37696	lower	_	
162-5	37697-37706	quartiles	_	
162-6	37707-37710	are	_	
162-7	37711-37722	represented	_	
162-8	37723-37725	by	_	
162-9	37726-37729	the	_	
162-10	37730-37733	box	_	
162-11	37733-37734	,	_	
162-12	37735-37738	and	_	
162-13	37739-37742	the	_	
162-14	37743-37749	median	_	
162-15	37750-37752	is	_	
162-16	37753-37764	represented	_	
162-17	37765-37767	by	_	
162-18	37768-37769	a	_	
162-19	37770-37775	black	_	
162-20	37776-37780	line	_	
162-21	37781-37787	within	_	
162-22	37788-37791	the	_	
162-23	37792-37795	box	_	
162-24	37795-37796	.	_	

#Text=The T bars extend to 1.5 times the height of the box or, if no case had a value in that range, to the minimum or maximum values.
163-1	37797-37800	The	_	
163-2	37801-37802	T	_	
163-3	37803-37807	bars	_	
163-4	37808-37814	extend	_	
163-5	37815-37817	to	_	
163-6	37818-37821	1.5	_	
163-7	37822-37827	times	_	
163-8	37828-37831	the	_	
163-9	37832-37838	height	_	
163-10	37839-37841	of	_	
163-11	37842-37845	the	_	
163-12	37846-37849	box	_	
163-13	37850-37852	or	_	
163-14	37852-37853	,	_	
163-15	37854-37856	if	_	
163-16	37857-37859	no	_	
163-17	37860-37864	case	_	
163-18	37865-37868	had	_	
163-19	37869-37870	a	_	
163-20	37871-37876	value	_	
163-21	37877-37879	in	_	
163-22	37880-37884	that	_	
163-23	37885-37890	range	_	
163-24	37890-37891	,	_	
163-25	37892-37894	to	_	
163-26	37895-37898	the	_	
163-27	37899-37906	minimum	_	
163-28	37907-37909	or	_	
163-29	37910-37917	maximum	_	
163-30	37918-37924	values	_	
163-31	37924-37925	.	_	

#Text=Circles represent outliers.
164-1	37926-37933	Circles	_	
164-2	37934-37943	represent	_	
164-3	37944-37952	outliers	_	
164-4	37952-37953	.	_	

#Text=This figure demonstrates a simple scatter plot showing the relationship between the beta for the strength of the association of the DMN component with the smoke versus food cues (Smoke - Food) and total number of cigarettes smoked in the 28 days prior to the week 6 visit (NumCig at 6 weeks).
165-1	37954-37958	This	_	
165-2	37959-37965	figure	_	
165-3	37966-37978	demonstrates	_	
165-4	37979-37980	a	_	
165-5	37981-37987	simple	_	
165-6	37988-37995	scatter	_	
165-7	37996-38000	plot	_	
165-8	38001-38008	showing	_	
165-9	38009-38012	the	_	
165-10	38013-38025	relationship	_	
165-11	38026-38033	between	_	
165-12	38034-38037	the	_	
165-13	38038-38042	beta	_	
165-14	38043-38046	for	_	
165-15	38047-38050	the	_	
165-16	38051-38059	strength	_	
165-17	38060-38062	of	_	
165-18	38063-38066	the	_	
165-19	38067-38078	association	_	
165-20	38079-38081	of	_	
165-21	38082-38085	the	_	
165-22	38086-38089	DMN	_	
165-23	38090-38099	component	_	
165-24	38100-38104	with	_	
165-25	38105-38108	the	_	
165-26	38109-38114	smoke	_	
165-27	38115-38121	versus	_	
165-28	38122-38126	food	_	
165-29	38127-38131	cues	_	
165-30	38132-38133	(	_	
165-31	38133-38138	Smoke	_	
165-32	38139-38140	-	_	
165-33	38141-38145	Food	_	
165-34	38145-38146	)	_	
165-35	38147-38150	and	_	
165-36	38151-38156	total	_	
165-37	38157-38163	number	_	
165-38	38164-38166	of	_	
165-39	38167-38177	cigarettes	_	
165-40	38178-38184	smoked	_	
165-41	38185-38187	in	_	
165-42	38188-38191	the	_	
165-43	38192-38194	28	_	
165-44	38195-38199	days	_	
165-45	38200-38205	prior	_	
165-46	38206-38208	to	_	
165-47	38209-38212	the	_	
165-48	38213-38217	week	_	
165-49	38218-38219	6	_	
165-50	38220-38225	visit	_	
165-51	38226-38227	(	_	
165-52	38227-38233	NumCig	_	
165-53	38234-38236	at	_	
165-54	38237-38238	6	_	
165-55	38239-38244	weeks	_	
165-56	38244-38245	)	_	
165-57	38245-38246	.	_	

#Text=Baseline Characteristics by Medication Group
#Text=\tVarenicline\tPlacebo\t \tNumber of males (percent)\t52 (65%)\t39 (62%)\t \tAge years (SD)\t34.3 (10.3)\t33.7 (10.0)\t \tFagerstrom Test Nicotine Dependence (SD)\t4.6 (1.9)\t4.6 (2.2)\t \tNumCig Scr (SD)\t933.7 (394.9)\t931.3 (330.6)\t \tBeta for Smoke-Food Cues\t0.26 (0.29)\t0.22 (0.28)\t \tBeta for Smoke Cues\t0.02 (0.28)\t−0.03 (0.28)\t \tBeta for Food Cues\t−0.24 (0.29)\t−0.25 (0.31)\t \tAUDIT Total Score (SD)\t5.4 (4.8)\t5.9 (5.2)\t \tBeck Anxiety Inventory Total Score (SD)\t4.4 (5.6)\t3.6 (3.8)\t \tBeck Depression Inventory Total Score (SD)\t2.6 (4.2)\t3.6 (4.6)\t \tBarratt Impulsiveness Questionnaire\t60.7 (11.1)\t63.6 (11.4)\t \tWisconsin Withdrawal Scale Score – before scan (SD)\t11.2 (3.9)\t11.9 (3.5)\t \tQuestionnaire of Smoking Urges – before scan (SD)\t41.4 (13.7)\t41.4 (15.6)\t \tHours Since Last Cigarette Smoked - at time of scan (SD)\t5.23 (4.0)\t6.09 (5.1)\t \tYears Been a Regular Smoker (SD)\t16.0 (10.4)\t17.0 (10.3)\t \tNumber Serious Quit Attempts (>12 hours abstinent) (SD)\t4.4 (5.0)\t4.9 (7.4)\t \t
#Text=Chi square tests for dichotomous variables and independent samples t tests for continuous variables demonstrated no significant difference on any measures between varenicline and placebo groups.
166-1	38247-38255	Baseline	_	
166-2	38256-38271	Characteristics	_	
166-3	38272-38274	by	_	
166-4	38275-38285	Medication	_	
166-5	38286-38291	Group	_	
166-6	38293-38304	Varenicline	_	
166-7	38305-38312	Placebo	_	
166-8	38315-38321	Number	_	
166-9	38322-38324	of	_	
166-10	38325-38330	males	_	
166-11	38331-38332	(	_	
166-12	38332-38339	percent	_	
166-13	38339-38340	)	_	
166-14	38341-38343	52	_	
166-15	38344-38345	(	_	
166-16	38345-38348	65%	_	
166-17	38348-38349	)	_	
166-18	38350-38352	39	_	
166-19	38353-38354	(	_	
166-20	38354-38357	62%	_	
166-21	38357-38358	)	_	
166-22	38361-38364	Age	_	
166-23	38365-38370	years	_	
166-24	38371-38372	(	_	
166-25	38372-38374	SD	_	
166-26	38374-38375	)	_	
166-27	38376-38380	34.3	_	
166-28	38381-38382	(	_	
166-29	38382-38386	10.3	_	
166-30	38386-38387	)	_	
166-31	38388-38392	33.7	_	
166-32	38393-38394	(	_	
166-33	38394-38398	10.0	_	
166-34	38398-38399	)	_	
166-35	38402-38412	Fagerstrom	_	
166-36	38413-38417	Test	_	
166-37	38418-38426	Nicotine	_	
166-38	38427-38437	Dependence	_	
166-39	38438-38439	(	_	
166-40	38439-38441	SD	_	
166-41	38441-38442	)	_	
166-42	38443-38446	4.6	_	
166-43	38447-38448	(	_	
166-44	38448-38451	1.9	_	
166-45	38451-38452	)	_	
166-46	38453-38456	4.6	_	
166-47	38457-38458	(	_	
166-48	38458-38461	2.2	_	
166-49	38461-38462	)	_	
166-50	38465-38471	NumCig	_	
166-51	38472-38475	Scr	_	
166-52	38476-38477	(	_	
166-53	38477-38479	SD	_	
166-54	38479-38480	)	_	
166-55	38481-38486	933.7	_	
166-56	38487-38488	(	_	
166-57	38488-38493	394.9	_	
166-58	38493-38494	)	_	
166-59	38495-38500	931.3	_	
166-60	38501-38502	(	_	
166-61	38502-38507	330.6	_	
166-62	38507-38508	)	_	
166-63	38511-38515	Beta	_	
166-64	38516-38519	for	_	
166-65	38520-38530	Smoke-Food	_	
166-66	38531-38535	Cues	_	
166-67	38536-38540	0.26	_	
166-68	38541-38542	(	_	
166-69	38542-38546	0.29	_	
166-70	38546-38547	)	_	
166-71	38548-38552	0.22	_	
166-72	38553-38554	(	_	
166-73	38554-38558	0.28	_	
166-74	38558-38559	)	_	
166-75	38562-38566	Beta	_	
166-76	38567-38570	for	_	
166-77	38571-38576	Smoke	_	
166-78	38577-38581	Cues	_	
166-79	38582-38586	0.02	_	
166-80	38587-38588	(	_	
166-81	38588-38592	0.28	_	
166-82	38592-38593	)	_	
166-83	38594-38595	−	_	
166-84	38595-38599	0.03	_	
166-85	38600-38601	(	_	
166-86	38601-38605	0.28	_	
166-87	38605-38606	)	_	
166-88	38609-38613	Beta	_	
166-89	38614-38617	for	_	
166-90	38618-38622	Food	_	
166-91	38623-38627	Cues	_	
166-92	38628-38629	−	_	
166-93	38629-38633	0.24	_	
166-94	38634-38635	(	_	
166-95	38635-38639	0.29	_	
166-96	38639-38640	)	_	
166-97	38641-38642	−	_	
166-98	38642-38646	0.25	_	
166-99	38647-38648	(	_	
166-100	38648-38652	0.31	_	
166-101	38652-38653	)	_	
166-102	38656-38661	AUDIT	_	
166-103	38662-38667	Total	_	
166-104	38668-38673	Score	_	
166-105	38674-38675	(	_	
166-106	38675-38677	SD	_	
166-107	38677-38678	)	_	
166-108	38679-38682	5.4	_	
166-109	38683-38684	(	_	
166-110	38684-38687	4.8	_	
166-111	38687-38688	)	_	
166-112	38689-38692	5.9	_	
166-113	38693-38694	(	_	
166-114	38694-38697	5.2	_	
166-115	38697-38698	)	_	
166-116	38701-38705	Beck	_	
166-117	38706-38713	Anxiety	_	
166-118	38714-38723	Inventory	_	
166-119	38724-38729	Total	_	
166-120	38730-38735	Score	_	
166-121	38736-38737	(	_	
166-122	38737-38739	SD	_	
166-123	38739-38740	)	_	
166-124	38741-38744	4.4	_	
166-125	38745-38746	(	_	
166-126	38746-38749	5.6	_	
166-127	38749-38750	)	_	
166-128	38751-38754	3.6	_	
166-129	38755-38756	(	_	
166-130	38756-38759	3.8	_	
166-131	38759-38760	)	_	
166-132	38763-38767	Beck	_	
166-133	38768-38778	Depression	_	
166-134	38779-38788	Inventory	_	
166-135	38789-38794	Total	_	
166-136	38795-38800	Score	_	
166-137	38801-38802	(	_	
166-138	38802-38804	SD	_	
166-139	38804-38805	)	_	
166-140	38806-38809	2.6	_	
166-141	38810-38811	(	_	
166-142	38811-38814	4.2	_	
166-143	38814-38815	)	_	
166-144	38816-38819	3.6	_	
166-145	38820-38821	(	_	
166-146	38821-38824	4.6	_	
166-147	38824-38825	)	_	
166-148	38828-38835	Barratt	_	
166-149	38836-38849	Impulsiveness	_	
166-150	38850-38863	Questionnaire	_	
166-151	38864-38868	60.7	_	
166-152	38869-38870	(	_	
166-153	38870-38874	11.1	_	
166-154	38874-38875	)	_	
166-155	38876-38880	63.6	_	
166-156	38881-38882	(	_	
166-157	38882-38886	11.4	_	
166-158	38886-38887	)	_	
166-159	38890-38899	Wisconsin	_	
166-160	38900-38910	Withdrawal	_	
166-161	38911-38916	Scale	_	
166-162	38917-38922	Score	_	
166-163	38923-38924	–	_	
166-164	38925-38931	before	_	
166-165	38932-38936	scan	_	
166-166	38937-38938	(	_	
166-167	38938-38940	SD	_	
166-168	38940-38941	)	_	
166-169	38942-38946	11.2	_	
166-170	38947-38948	(	_	
166-171	38948-38951	3.9	_	
166-172	38951-38952	)	_	
166-173	38953-38957	11.9	_	
166-174	38958-38959	(	_	
166-175	38959-38962	3.5	_	
166-176	38962-38963	)	_	
166-177	38966-38979	Questionnaire	_	
166-178	38980-38982	of	_	
166-179	38983-38990	Smoking	_	
166-180	38991-38996	Urges	_	
166-181	38997-38998	–	_	
166-182	38999-39005	before	_	
166-183	39006-39010	scan	_	
166-184	39011-39012	(	_	
166-185	39012-39014	SD	_	
166-186	39014-39015	)	_	
166-187	39016-39020	41.4	_	
166-188	39021-39022	(	_	
166-189	39022-39026	13.7	_	
166-190	39026-39027	)	_	
166-191	39028-39032	41.4	_	
166-192	39033-39034	(	_	
166-193	39034-39038	15.6	_	
166-194	39038-39039	)	_	
166-195	39042-39047	Hours	_	
166-196	39048-39053	Since	_	
166-197	39054-39058	Last	_	
166-198	39059-39068	Cigarette	_	
166-199	39069-39075	Smoked	_	
166-200	39076-39077	-	_	
166-201	39078-39080	at	_	
166-202	39081-39085	time	_	
166-203	39086-39088	of	_	
166-204	39089-39093	scan	_	
166-205	39094-39095	(	_	
166-206	39095-39097	SD	_	
166-207	39097-39098	)	_	
166-208	39099-39103	5.23	_	
166-209	39104-39105	(	_	
166-210	39105-39108	4.0	_	
166-211	39108-39109	)	_	
166-212	39110-39114	6.09	_	
166-213	39115-39116	(	_	
166-214	39116-39119	5.1	_	
166-215	39119-39120	)	_	
166-216	39123-39128	Years	_	
166-217	39129-39133	Been	_	
166-218	39134-39135	a	_	
166-219	39136-39143	Regular	_	
166-220	39144-39150	Smoker	_	
166-221	39151-39152	(	_	
166-222	39152-39154	SD	_	
166-223	39154-39155	)	_	
166-224	39156-39160	16.0	_	
166-225	39161-39162	(	_	
166-226	39162-39166	10.4	_	
166-227	39166-39167	)	_	
166-228	39168-39172	17.0	_	
166-229	39173-39174	(	_	
166-230	39174-39178	10.3	_	
166-231	39178-39179	)	_	
166-232	39182-39188	Number	_	
166-233	39189-39196	Serious	_	
166-234	39197-39201	Quit	_	
166-235	39202-39210	Attempts	_	
166-236	39211-39212	(	_	
166-237	39212-39213	>	_	
166-238	39213-39215	12	_	
166-239	39216-39221	hours	_	
166-240	39222-39231	abstinent	_	
166-241	39231-39232	)	_	
166-242	39233-39234	(	_	
166-243	39234-39236	SD	_	
166-244	39236-39237	)	_	
166-245	39238-39241	4.4	_	
166-246	39242-39243	(	_	
166-247	39243-39246	5.0	_	
166-248	39246-39247	)	_	
166-249	39248-39251	4.9	_	
166-250	39252-39253	(	_	
166-251	39253-39256	7.4	_	
166-252	39256-39257	)	_	
166-253	39261-39264	Chi	_	
166-254	39265-39271	square	_	
166-255	39272-39277	tests	_	
166-256	39278-39281	for	_	
166-257	39282-39293	dichotomous	_	
166-258	39294-39303	variables	_	
166-259	39304-39307	and	_	
166-260	39308-39319	independent	_	
166-261	39320-39327	samples	_	
166-262	39328-39329	t	_	
166-263	39330-39335	tests	_	
166-264	39336-39339	for	_	
166-265	39340-39350	continuous	_	
166-266	39351-39360	variables	_	
166-267	39361-39373	demonstrated	_	
166-268	39374-39376	no	_	
166-269	39377-39388	significant	_	
166-270	39389-39399	difference	_	
166-271	39400-39402	on	_	
166-272	39403-39406	any	_	
166-273	39407-39415	measures	_	
166-274	39416-39423	between	_	
166-275	39424-39435	varenicline	_	
166-276	39436-39439	and	_	
166-277	39440-39447	placebo	_	
166-278	39448-39454	groups	_	
166-279	39454-39455	.	_	

#Text=All measures were obtained prior to initiation of treatment.
167-1	39456-39459	All	_	
167-2	39460-39468	measures	_	
167-3	39469-39473	were	_	
167-4	39474-39482	obtained	_	
167-5	39483-39488	prior	_	
167-6	39489-39491	to	_	
167-7	39492-39502	initiation	_	
167-8	39503-39505	of	_	
167-9	39506-39515	treatment	_	
167-10	39515-39516	.	_	

#Text=NumCig Scr = total number of cigarettes smoked during the previous 60 days at the screen visit.
168-1	39517-39523	NumCig	_	
168-2	39524-39527	Scr	_	
168-3	39528-39529	=	_	
168-4	39530-39535	total	_	
168-5	39536-39542	number	_	
168-6	39543-39545	of	_	
168-7	39546-39556	cigarettes	_	
168-8	39557-39563	smoked	_	
168-9	39564-39570	during	_	
168-10	39571-39574	the	_	
168-11	39575-39583	previous	_	
168-12	39584-39586	60	_	
168-13	39587-39591	days	_	
168-14	39592-39594	at	_	
168-15	39595-39598	the	_	
168-16	39599-39605	screen	_	
168-17	39606-39611	visit	_	
168-18	39611-39612	.	_	

#Text=Bivariate Correlations (Spearman’s rho) Between Baseline Variables, Smoking Outcomes, and Head Motion
#Text=Age\tFTN\tScr\tQuit\tS-F\tS\tF\tAud\tBAI\tBDI\tBIQ\tWS\tWSf\tQSU\tHrs\t6wk\t12wk\trmsT\t \t1\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \t0.04\t1\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \t0.07\t0.44**\t1\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \t0.27**\t−0.05\t−0.09\t1\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \t0.06\t−0.12\t0.03\t0.02\t1\t\t\t\t\t\t\t\t\t\t\t\t\t\t \t−0.06\t0.12\t0.09\t−0.05\t0.39**\t1\t\t\t\t\t\t\t\t\t\t\t\t\t \t−0.08\t0.22**\t0.05\t−0.04\t−0.54**\t0.50**\t1\t\t\t\t\t\t\t\t\t\t\t\t \t−0.19*\t−0.17*\t−0.15\t0.02\t−0.05\t0.04\t0.05\t1\t\t\t\t\t\t\t\t\t\t\t \t−0.06\t0.07\t0.03\t0.11\t−0.06\t−0.12\t−0.02\t−0.10\t1\t\t\t\t\t\t\t\t\t\t \t0.06\t0.01\t0.03\t0.09\t−0.06\t−0.09\t−0.02\t−0.02\t0.30**\t1\t\t\t\t\t\t\t\t\t \t0.07\t−0.03\t−0.04\t0.01\t−0.20*\t−0.03\t0.12\t0.18*\t0.20*\t0.29*\t1\t\t\t\t\t\t\t\t \t−0.04\t0.25**\t−0.01\t0.12\t−0.13\t0.02\t0.14^\t0.03\t0.38**\t0.38**\t0.37**\t1\t\t\t\t\t\t\t \t0.05\t0.20*\t0.06\t0.05\t−0.15^\t−0.02\t0.13\t0.01\t0.13\t0.17*\t0.08\t0.49**\t1\t\t\t\t\t\t \t−0.05\t0.49**\t0.26**\t−0.01\t−0.03\t0.14^\t0.15^\t−0.13\t0.10\t−0.04\t0.03\t0.28**\t0.14\t1\t\t\t\t\t \t−0.02\t−0.20*\t−0.29**\t0.04\t0.01\t0.03\t0.00\t0.26**\t−0.10\t−.015\t0.01\t−0.06\t−0.08\t0.05\t1\t\t\t\t \t−0.06\t0.22**\t0.21**\t−0.15^\t−0.24**\t−0.04\t0.17*\t0.08\t−0.02\t0.14\t0.05\t0.09\t0.03\t0.13\t−0.05\t1\t\t\t \t−0.13\t0.29**\t0.25**\t−0.15^\t−0.24**\t−0.00\t0.19*\t0.09\t−0.03\t0.08\t0.09\t0.04\t−0.02\t0.17*\t−0.06\t0.84**\t1\t\t \t0.24**\t−0.02\t−0.00\t0.06\t0.06\t0.07\t0.01\t0.04\t−0.02\t0.12\t0.08\t0.10\t0.08\t0.13\t0.10\t−0.15\t−0.19*\t1\t \t0.30**\t0.02\t−0.04\t0.10\t0.07\t−0.02\t−0.09\t−0.01\t−0.08\t0.11\t0.05\t0.07\t0.06\t0.14\t0.11\t−0.14\t−0.22**\t0.82**\t \t
#Text=Significant at p <0.1
#Text=Significant at p < 0.05
#Text=Significant at p < 0.01
#Text=RxGrp = Medication Condition (varenicline = 1, placebo = 0).
169-1	39613-39622	Bivariate	_	
169-2	39623-39635	Correlations	_	
169-3	39636-39637	(	_	
169-4	39637-39645	Spearman	_	
169-5	39645-39646	’	_	
169-6	39646-39647	s	_	
169-7	39648-39651	rho	_	
169-8	39651-39652	)	_	
169-9	39653-39660	Between	_	
169-10	39661-39669	Baseline	_	
169-11	39670-39679	Variables	_	
169-12	39679-39680	,	_	
169-13	39681-39688	Smoking	_	
169-14	39689-39697	Outcomes	_	
169-15	39697-39698	,	_	
169-16	39699-39702	and	_	
169-17	39703-39707	Head	_	
169-18	39708-39714	Motion	_	
169-19	39715-39718	Age	_	
169-20	39719-39722	FTN	_	
169-21	39723-39726	Scr	_	
169-22	39727-39731	Quit	_	
169-23	39732-39735	S-F	_	
169-24	39736-39737	S	_	
169-25	39738-39739	F	_	
169-26	39740-39743	Aud	_	
169-27	39744-39747	BAI	_	
169-28	39748-39751	BDI	_	
169-29	39752-39755	BIQ	_	
169-30	39756-39758	WS	_	
169-31	39759-39762	WSf	_	
169-32	39763-39766	QSU	_	
169-33	39767-39770	Hrs	_	
169-34	39771-39774	6wk	_	
169-35	39775-39779	12wk	_	
169-36	39780-39784	rmsT	_	
169-37	39787-39788	1	_	
169-38	39808-39812	0.04	_	
169-39	39813-39814	1	_	
169-40	39833-39837	0.07	_	
169-41	39838-39842	0.44	_	
169-42	39842-39843	*	_	
169-43	39843-39844	*	_	
169-44	39845-39846	1	_	
169-45	39864-39868	0.27	_	
169-46	39868-39869	*	_	
169-47	39869-39870	*	_	
169-48	39871-39872	−	_	
169-49	39872-39876	0.05	_	
169-50	39877-39878	−	_	
169-51	39878-39882	0.09	_	
169-52	39883-39884	1	_	
169-53	39901-39905	0.06	_	
169-54	39906-39907	−	_	
169-55	39907-39911	0.12	_	
169-56	39912-39916	0.03	_	
169-57	39917-39921	0.02	_	
169-58	39922-39923	1	_	
169-59	39939-39940	−	_	
169-60	39940-39944	0.06	_	
169-61	39945-39949	0.12	_	
169-62	39950-39954	0.09	_	
169-63	39955-39956	−	_	
169-64	39956-39960	0.05	_	
169-65	39961-39965	0.39	_	
169-66	39965-39966	*	_	
169-67	39966-39967	*	_	
169-68	39968-39969	1	_	
169-69	39984-39985	−	_	
169-70	39985-39989	0.08	_	
169-71	39990-39994	0.22	_	
169-72	39994-39995	*	_	
169-73	39995-39996	*	_	
169-74	39997-40001	0.05	_	
169-75	40002-40003	−	_	
169-76	40003-40007	0.04	_	
169-77	40008-40009	−	_	
169-78	40009-40013	0.54	_	
169-79	40013-40014	*	_	
169-80	40014-40015	*	_	
169-81	40016-40020	0.50	_	
169-82	40020-40021	*	_	
169-83	40021-40022	*	_	
169-84	40023-40024	1	_	
169-85	40038-40039	−	_	
169-86	40039-40043	0.19	_	
169-87	40043-40044	*	_	
169-88	40045-40046	−	_	
169-89	40046-40050	0.17	_	
169-90	40050-40051	*	_	
169-91	40052-40053	−	_	
169-92	40053-40057	0.15	_	
169-93	40058-40062	0.02	_	
169-94	40063-40064	−	_	
169-95	40064-40068	0.05	_	
169-96	40069-40073	0.04	_	
169-97	40074-40078	0.05	_	
169-98	40079-40080	1	_	
169-99	40093-40094	−	_	
169-100	40094-40098	0.06	_	
169-101	40099-40103	0.07	_	
169-102	40104-40108	0.03	_	
169-103	40109-40113	0.11	_	
169-104	40114-40115	−	_	
169-105	40115-40119	0.06	_	
169-106	40120-40121	−	_	
169-107	40121-40125	0.12	_	
169-108	40126-40127	−	_	
169-109	40127-40131	0.02	_	
169-110	40132-40133	−	_	
169-111	40133-40137	0.10	_	
169-112	40138-40139	1	_	
169-113	40151-40155	0.06	_	
169-114	40156-40160	0.01	_	
169-115	40161-40165	0.03	_	
169-116	40166-40170	0.09	_	
169-117	40171-40172	−	_	
169-118	40172-40176	0.06	_	
169-119	40177-40178	−	_	
169-120	40178-40182	0.09	_	
169-121	40183-40184	−	_	
169-122	40184-40188	0.02	_	
169-123	40189-40190	−	_	
169-124	40190-40194	0.02	_	
169-125	40195-40199	0.30	_	
169-126	40199-40200	*	_	
169-127	40200-40201	*	_	
169-128	40202-40203	1	_	
169-129	40214-40218	0.07	_	
169-130	40219-40220	−	_	
169-131	40220-40224	0.03	_	
169-132	40225-40226	−	_	
169-133	40226-40230	0.04	_	
169-134	40231-40235	0.01	_	
169-135	40236-40237	−	_	
169-136	40237-40241	0.20	_	
169-137	40241-40242	*	_	
169-138	40243-40244	−	_	
169-139	40244-40248	0.03	_	
169-140	40249-40253	0.12	_	
169-141	40254-40258	0.18	_	
169-142	40258-40259	*	_	
169-143	40260-40264	0.20	_	
169-144	40264-40265	*	_	
169-145	40266-40270	0.29	_	
169-146	40270-40271	*	_	
169-147	40272-40273	1	_	
169-148	40283-40284	−	_	
169-149	40284-40288	0.04	_	
169-150	40289-40293	0.25	_	
169-151	40293-40294	*	_	
169-152	40294-40295	*	_	
169-153	40296-40297	−	_	
169-154	40297-40301	0.01	_	
169-155	40302-40306	0.12	_	
169-156	40307-40308	−	_	
169-157	40308-40312	0.13	_	
169-158	40313-40317	0.02	_	
169-159	40318-40322	0.14	_	
169-160	40322-40323	^	_	
169-161	40324-40328	0.03	_	
169-162	40329-40333	0.38	_	
169-163	40333-40334	*	_	
169-164	40334-40335	*	_	
169-165	40336-40340	0.38	_	
169-166	40340-40341	*	_	
169-167	40341-40342	*	_	
169-168	40343-40347	0.37	_	
169-169	40347-40348	*	_	
169-170	40348-40349	*	_	
169-171	40350-40351	1	_	
169-172	40360-40364	0.05	_	
169-173	40365-40369	0.20	_	
169-174	40369-40370	*	_	
169-175	40371-40375	0.06	_	
169-176	40376-40380	0.05	_	
169-177	40381-40382	−	_	
169-178	40382-40386	0.15	_	
169-179	40386-40387	^	_	
169-180	40388-40389	−	_	
169-181	40389-40393	0.02	_	
169-182	40394-40398	0.13	_	
169-183	40399-40403	0.01	_	
169-184	40404-40408	0.13	_	
169-185	40409-40413	0.17	_	
169-186	40413-40414	*	_	
169-187	40415-40419	0.08	_	
169-188	40420-40424	0.49	_	
169-189	40424-40425	*	_	
169-190	40425-40426	*	_	
169-191	40427-40428	1	_	
169-192	40436-40437	−	_	
169-193	40437-40441	0.05	_	
169-194	40442-40446	0.49	_	
169-195	40446-40447	*	_	
169-196	40447-40448	*	_	
169-197	40449-40453	0.26	_	
169-198	40453-40454	*	_	
169-199	40454-40455	*	_	
169-200	40456-40457	−	_	
169-201	40457-40461	0.01	_	
169-202	40462-40463	−	_	
169-203	40463-40467	0.03	_	
169-204	40468-40472	0.14	_	
169-205	40472-40473	^	_	
169-206	40474-40478	0.15	_	
169-207	40478-40479	^	_	
169-208	40480-40481	−	_	
169-209	40481-40485	0.13	_	
169-210	40486-40490	0.10	_	
169-211	40491-40492	−	_	
169-212	40492-40496	0.04	_	
169-213	40497-40501	0.03	_	
169-214	40502-40506	0.28	_	
169-215	40506-40507	*	_	
169-216	40507-40508	*	_	
169-217	40509-40513	0.14	_	
169-218	40514-40515	1	_	
169-219	40522-40523	−	_	
169-220	40523-40527	0.02	_	
169-221	40528-40529	−	_	
169-222	40529-40533	0.20	_	
169-223	40533-40534	*	_	
169-224	40535-40536	−	_	
169-225	40536-40540	0.29	_	
169-226	40540-40541	*	_	
169-227	40541-40542	*	_	
169-228	40543-40547	0.04	_	
169-229	40548-40552	0.01	_	
169-230	40553-40557	0.03	_	
169-231	40558-40562	0.00	_	
169-232	40563-40567	0.26	_	
169-233	40567-40568	*	_	
169-234	40568-40569	*	_	
169-235	40570-40571	−	_	
169-236	40571-40575	0.10	_	
169-237	40576-40577	−	_	
169-238	40577-40581	.015	_	
169-239	40582-40586	0.01	_	
169-240	40587-40588	−	_	
169-241	40588-40592	0.06	_	
169-242	40593-40594	−	_	
169-243	40594-40598	0.08	_	
169-244	40599-40603	0.05	_	
169-245	40604-40605	1	_	
169-246	40611-40612	−	_	
169-247	40612-40616	0.06	_	
169-248	40617-40621	0.22	_	
169-249	40621-40622	*	_	
169-250	40622-40623	*	_	
169-251	40624-40628	0.21	_	
169-252	40628-40629	*	_	
169-253	40629-40630	*	_	
169-254	40631-40632	−	_	
169-255	40632-40636	0.15	_	
169-256	40636-40637	^	_	
169-257	40638-40639	−	_	
169-258	40639-40643	0.24	_	
169-259	40643-40644	*	_	
169-260	40644-40645	*	_	
169-261	40646-40647	−	_	
169-262	40647-40651	0.04	_	
169-263	40652-40656	0.17	_	
169-264	40656-40657	*	_	
169-265	40658-40662	0.08	_	
169-266	40663-40664	−	_	
169-267	40664-40668	0.02	_	
169-268	40669-40673	0.14	_	
169-269	40674-40678	0.05	_	
169-270	40679-40683	0.09	_	
169-271	40684-40688	0.03	_	
169-272	40689-40693	0.13	_	
169-273	40694-40695	−	_	
169-274	40695-40699	0.05	_	
169-275	40700-40701	1	_	
169-276	40706-40707	−	_	
169-277	40707-40711	0.13	_	
169-278	40712-40716	0.29	_	
169-279	40716-40717	*	_	
169-280	40717-40718	*	_	
169-281	40719-40723	0.25	_	
169-282	40723-40724	*	_	
169-283	40724-40725	*	_	
169-284	40726-40727	−	_	
169-285	40727-40731	0.15	_	
169-286	40731-40732	^	_	
169-287	40733-40734	−	_	
169-288	40734-40738	0.24	_	
169-289	40738-40739	*	_	
169-290	40739-40740	*	_	
169-291	40741-40742	−	_	
169-292	40742-40746	0.00	_	
169-293	40747-40751	0.19	_	
169-294	40751-40752	*	_	
169-295	40753-40757	0.09	_	
169-296	40758-40759	−	_	
169-297	40759-40763	0.03	_	
169-298	40764-40768	0.08	_	
169-299	40769-40773	0.09	_	
169-300	40774-40778	0.04	_	
169-301	40779-40780	−	_	
169-302	40780-40784	0.02	_	
169-303	40785-40789	0.17	_	
169-304	40789-40790	*	_	
169-305	40791-40792	−	_	
169-306	40792-40796	0.06	_	
169-307	40797-40801	0.84	_	
169-308	40801-40802	*	_	
169-309	40802-40803	*	_	
169-310	40804-40805	1	_	
169-311	40809-40813	0.24	_	
169-312	40813-40814	*	_	
169-313	40814-40815	*	_	
169-314	40816-40817	−	_	
169-315	40817-40821	0.02	_	
169-316	40822-40823	−	_	
169-317	40823-40827	0.00	_	
169-318	40828-40832	0.06	_	
169-319	40833-40837	0.06	_	
169-320	40838-40842	0.07	_	
169-321	40843-40847	0.01	_	
169-322	40848-40852	0.04	_	
169-323	40853-40854	−	_	
169-324	40854-40858	0.02	_	
169-325	40859-40863	0.12	_	
169-326	40864-40868	0.08	_	
169-327	40869-40873	0.10	_	
169-328	40874-40878	0.08	_	
169-329	40879-40883	0.13	_	
169-330	40884-40888	0.10	_	
169-331	40889-40890	−	_	
169-332	40890-40894	0.15	_	
169-333	40895-40896	−	_	
169-334	40896-40900	0.19	_	
169-335	40900-40901	*	_	
169-336	40902-40903	1	_	
169-337	40906-40910	0.30	_	
169-338	40910-40911	*	_	
169-339	40911-40912	*	_	
169-340	40913-40917	0.02	_	
169-341	40918-40919	−	_	
169-342	40919-40923	0.04	_	
169-343	40924-40928	0.10	_	
169-344	40929-40933	0.07	_	
169-345	40934-40935	−	_	
169-346	40935-40939	0.02	_	
169-347	40940-40941	−	_	
169-348	40941-40945	0.09	_	
169-349	40946-40947	−	_	
169-350	40947-40951	0.01	_	
169-351	40952-40953	−	_	
169-352	40953-40957	0.08	_	
169-353	40958-40962	0.11	_	
169-354	40963-40967	0.05	_	
169-355	40968-40972	0.07	_	
169-356	40973-40977	0.06	_	
169-357	40978-40982	0.14	_	
169-358	40983-40987	0.11	_	
169-359	40988-40989	−	_	
169-360	40989-40993	0.14	_	
169-361	40994-40995	−	_	
169-362	40995-40999	0.22	_	
169-363	40999-41000	*	_	
169-364	41000-41001	*	_	
169-365	41002-41006	0.82	_	
169-366	41006-41007	*	_	
169-367	41007-41008	*	_	
169-368	41012-41023	Significant	_	
169-369	41024-41026	at	_	
169-370	41027-41028	p	_	
169-371	41029-41030	<	_	
169-372	41030-41033	0.1	_	
169-373	41034-41045	Significant	_	
169-374	41046-41048	at	_	
169-375	41049-41050	p	_	
169-376	41051-41052	<	_	
169-377	41053-41057	0.05	_	
169-378	41058-41069	Significant	_	
169-379	41070-41072	at	_	
169-380	41073-41074	p	_	
169-381	41075-41076	<	_	
169-382	41077-41081	0.01	_	
169-383	41082-41087	RxGrp	_	
169-384	41088-41089	=	_	
169-385	41090-41100	Medication	_	
169-386	41101-41110	Condition	_	
169-387	41111-41112	(	_	
169-388	41112-41123	varenicline	_	
169-389	41124-41125	=	_	
169-390	41126-41127	1	_	
169-391	41127-41128	,	_	
169-392	41129-41136	placebo	_	
169-393	41137-41138	=	_	
169-394	41139-41140	0	_	
169-395	41140-41141	)	_	
169-396	41141-41142	.	_	

#Text=Gen = gender (male = 1, female = 2), FTN = Fagerstrom Test for Nicotine Dependence, Scr = total number of cigarettes smoked during prior 60 days at the screen visit, Quit = number of times an attempt to quit smoking made where participant stayed off cigarettes for > 12 hrs, S-F = beta for degree of association of DMN component with smoke cues minus for food cues, S = beta for degree of association of DMN component with smoke cues, F = beta for degree of association of DMN component with food cues, Aud = AUDIT total score, BAI = Beck Anxiety Inventory Total Score, BDI = Beck Depression Inventory Total Score, BIQ = Barratt Impulsiveness Questionnaire, WS = Wisconsin Withdrawal Scale Score – pre MRI scan, WSf = sum of food-related questions only on WSWS, Hrs = Hours since last cigarette was smoked prior to the MRI scan, 6wk = total number of cigarettes smoked during prior 28 days at the 6 week follow-up visit, 12wk = total number of cigarettes smoked during prior 30 days at the 12 week follow-up visit, rmsT = root mean square translational framewise displacement, rmsR = root mean square translational framewise displacement (latter 2 variables approximate head motion during the cue task).
170-1	41143-41146	Gen	_	
170-2	41147-41148	=	_	
170-3	41149-41155	gender	_	
170-4	41156-41157	(	_	
170-5	41157-41161	male	_	
170-6	41162-41163	=	_	
170-7	41164-41165	1	_	
170-8	41165-41166	,	_	
170-9	41167-41173	female	_	
170-10	41174-41175	=	_	
170-11	41176-41177	2	_	
170-12	41177-41178	)	_	
170-13	41178-41179	,	_	
170-14	41180-41183	FTN	_	
170-15	41184-41185	=	_	
170-16	41186-41196	Fagerstrom	_	
170-17	41197-41201	Test	_	
170-18	41202-41205	for	_	
170-19	41206-41214	Nicotine	_	
170-20	41215-41225	Dependence	_	
170-21	41225-41226	,	_	
170-22	41227-41230	Scr	_	
170-23	41231-41232	=	_	
170-24	41233-41238	total	_	
170-25	41239-41245	number	_	
170-26	41246-41248	of	_	
170-27	41249-41259	cigarettes	_	
170-28	41260-41266	smoked	_	
170-29	41267-41273	during	_	
170-30	41274-41279	prior	_	
170-31	41280-41282	60	_	
170-32	41283-41287	days	_	
170-33	41288-41290	at	_	
170-34	41291-41294	the	_	
170-35	41295-41301	screen	_	
170-36	41302-41307	visit	_	
170-37	41307-41308	,	_	
170-38	41309-41313	Quit	_	
170-39	41314-41315	=	_	
170-40	41316-41322	number	_	
170-41	41323-41325	of	_	
170-42	41326-41331	times	_	
170-43	41332-41334	an	_	
170-44	41335-41342	attempt	_	
170-45	41343-41345	to	_	
170-46	41346-41350	quit	_	
170-47	41351-41358	smoking	_	
170-48	41359-41363	made	_	
170-49	41364-41369	where	_	
170-50	41370-41381	participant	_	
170-51	41382-41388	stayed	_	
170-52	41389-41392	off	_	
170-53	41393-41403	cigarettes	_	
170-54	41404-41407	for	_	
170-55	41408-41409	>	_	
170-56	41410-41412	12	_	
170-57	41413-41416	hrs	_	
170-58	41416-41417	,	_	
170-59	41418-41421	S-F	_	
170-60	41422-41423	=	_	
170-61	41424-41428	beta	_	
170-62	41429-41432	for	_	
170-63	41433-41439	degree	_	
170-64	41440-41442	of	_	
170-65	41443-41454	association	_	
170-66	41455-41457	of	_	
170-67	41458-41461	DMN	_	
170-68	41462-41471	component	_	
170-69	41472-41476	with	_	
170-70	41477-41482	smoke	_	
170-71	41483-41487	cues	_	
170-72	41488-41493	minus	_	
170-73	41494-41497	for	_	
170-74	41498-41502	food	_	
170-75	41503-41507	cues	_	
170-76	41507-41508	,	_	
170-77	41509-41510	S	_	
170-78	41511-41512	=	_	
170-79	41513-41517	beta	_	
170-80	41518-41521	for	_	
170-81	41522-41528	degree	_	
170-82	41529-41531	of	_	
170-83	41532-41543	association	_	
170-84	41544-41546	of	_	
170-85	41547-41550	DMN	_	
170-86	41551-41560	component	_	
170-87	41561-41565	with	_	
170-88	41566-41571	smoke	_	
170-89	41572-41576	cues	_	
170-90	41576-41577	,	_	
170-91	41578-41579	F	_	
170-92	41580-41581	=	_	
170-93	41582-41586	beta	_	
170-94	41587-41590	for	_	
170-95	41591-41597	degree	_	
170-96	41598-41600	of	_	
170-97	41601-41612	association	_	
170-98	41613-41615	of	_	
170-99	41616-41619	DMN	_	
170-100	41620-41629	component	_	
170-101	41630-41634	with	_	
170-102	41635-41639	food	_	
170-103	41640-41644	cues	_	
170-104	41644-41645	,	_	
170-105	41646-41649	Aud	_	
170-106	41650-41651	=	_	
170-107	41652-41657	AUDIT	_	
170-108	41658-41663	total	_	
170-109	41664-41669	score	_	
170-110	41669-41670	,	_	
170-111	41671-41674	BAI	_	
170-112	41675-41676	=	_	
170-113	41677-41681	Beck	_	
170-114	41682-41689	Anxiety	_	
170-115	41690-41699	Inventory	_	
170-116	41700-41705	Total	_	
170-117	41706-41711	Score	_	
170-118	41711-41712	,	_	
170-119	41713-41716	BDI	_	
170-120	41717-41718	=	_	
170-121	41719-41723	Beck	_	
170-122	41724-41734	Depression	_	
170-123	41735-41744	Inventory	_	
170-124	41745-41750	Total	_	
170-125	41751-41756	Score	_	
170-126	41756-41757	,	_	
170-127	41758-41761	BIQ	_	
170-128	41762-41763	=	_	
170-129	41764-41771	Barratt	_	
170-130	41772-41785	Impulsiveness	_	
170-131	41786-41799	Questionnaire	_	
170-132	41799-41800	,	_	
170-133	41801-41803	WS	_	
170-134	41804-41805	=	_	
170-135	41806-41815	Wisconsin	_	
170-136	41816-41826	Withdrawal	_	
170-137	41827-41832	Scale	_	
170-138	41833-41838	Score	_	
170-139	41839-41840	–	_	
170-140	41841-41844	pre	_	
170-141	41845-41848	MRI	_	
170-142	41849-41853	scan	_	
170-143	41853-41854	,	_	
170-144	41855-41858	WSf	_	
170-145	41859-41860	=	_	
170-146	41861-41864	sum	_	
170-147	41865-41867	of	_	
170-148	41868-41880	food-related	_	
170-149	41881-41890	questions	_	
170-150	41891-41895	only	_	
170-151	41896-41898	on	_	
170-152	41899-41903	WSWS	_	
170-153	41903-41904	,	_	
170-154	41905-41908	Hrs	_	
170-155	41909-41910	=	_	
170-156	41911-41916	Hours	_	
170-157	41917-41922	since	_	
170-158	41923-41927	last	_	
170-159	41928-41937	cigarette	_	
170-160	41938-41941	was	_	
170-161	41942-41948	smoked	_	
170-162	41949-41954	prior	_	
170-163	41955-41957	to	_	
170-164	41958-41961	the	_	
170-165	41962-41965	MRI	_	
170-166	41966-41970	scan	_	
170-167	41970-41971	,	_	
170-168	41972-41975	6wk	_	
170-169	41976-41977	=	_	
170-170	41978-41983	total	_	
170-171	41984-41990	number	_	
170-172	41991-41993	of	_	
170-173	41994-42004	cigarettes	_	
170-174	42005-42011	smoked	_	
170-175	42012-42018	during	_	
170-176	42019-42024	prior	_	
170-177	42025-42027	28	_	
170-178	42028-42032	days	_	
170-179	42033-42035	at	_	
170-180	42036-42039	the	_	
170-181	42040-42041	6	_	
170-182	42042-42046	week	_	
170-183	42047-42056	follow-up	_	
170-184	42057-42062	visit	_	
170-185	42062-42063	,	_	
170-186	42064-42068	12wk	_	
170-187	42069-42070	=	_	
170-188	42071-42076	total	_	
170-189	42077-42083	number	_	
170-190	42084-42086	of	_	
170-191	42087-42097	cigarettes	_	
170-192	42098-42104	smoked	_	
170-193	42105-42111	during	_	
170-194	42112-42117	prior	_	
170-195	42118-42120	30	_	
170-196	42121-42125	days	_	
170-197	42126-42128	at	_	
170-198	42129-42132	the	_	
170-199	42133-42135	12	_	
170-200	42136-42140	week	_	
170-201	42141-42150	follow-up	_	
170-202	42151-42156	visit	_	
170-203	42156-42157	,	_	
170-204	42158-42162	rmsT	_	
170-205	42163-42164	=	_	
170-206	42165-42169	root	_	
170-207	42170-42174	mean	_	
170-208	42175-42181	square	_	
170-209	42182-42195	translational	_	
170-210	42196-42205	framewise	_	
170-211	42206-42218	displacement	_	
170-212	42218-42219	,	_	
170-213	42220-42224	rmsR	_	
170-214	42225-42226	=	_	
170-215	42227-42231	root	_	
170-216	42232-42236	mean	_	
170-217	42237-42243	square	_	
170-218	42244-42257	translational	_	
170-219	42258-42267	framewise	_	
170-220	42268-42280	displacement	_	
170-221	42281-42282	(	_	
170-222	42282-42288	latter	_	
170-223	42289-42290	2	_	
170-224	42291-42300	variables	_	
170-225	42301-42312	approximate	_	
170-226	42313-42317	head	_	
170-227	42318-42324	motion	_	
170-228	42325-42331	during	_	
170-229	42332-42335	the	_	
170-230	42336-42339	cue	_	
170-231	42340-42344	task	_	
170-232	42344-42345	)	_	
170-233	42345-42346	.	_	

#Text=Paired T-tests comparing mean betas for Smoke vs.
171-1	42347-42353	Paired	_	
171-2	42354-42361	T-tests	_	
171-3	42362-42371	comparing	_	
171-4	42372-42376	mean	_	
171-5	42377-42382	betas	_	
171-6	42383-42386	for	_	
171-7	42387-42392	Smoke	_	
171-8	42393-42395	vs	_	
171-9	42395-42396	.	_	

#Text=Food for Primary and Exploratory Components
#Text=\tMean Smoke(SD)\tMean Food (SD)\tT\tp\t \tDMN\t−0.001 (0.28)\t−0.24 (0.30)\t9.92\t<0.001\t \tR ECN\t−0.152 (0.25)\t0.251 (0.29)\t6.153\t<0.001\t \tL ECN\t−0.005 (0.29)\t0.043 (0.33)\t2.038\t0.043\t \tSN\t0.251(0.29)\t0.258 (0.33)\t−0.316\t0.753\t \t
#Text=DMN = default mode network, ECN = Executive Control Network, SN = Salience Network, R = right, L = left, Smoke = beta for degree of association of component with smoke cues, Food = beta for degree of association of component with food cues, SD = standard deviation
#Text=Bivariate Correlations (Spearman’s rho) Between DMN Component and Exploratory (R ECN, L ECN, SN) Components
#Text=\tDMNS-F\tDMN S\tDMN F\tR ECNS-F\tR ECNS\tR ECNF\tL ECNS-F\tL ECNS\tL ECNF\t \tR ECN S-F\t0.280**\t\t\t\t\t\t\t\t\t \tR ECN S\t\t0.086\t\t\t\t\t\t\t\t \tR ECN F\t\t\t0.324**\t\t\t\t\t\t\t \tL ECN S-F\t0.142^\t\t\t0.169*\t\t\t\t\t\t \tL ECN S\t\t0.202*\t\t\t0.055\t\t\t\t\t \tL ECN F\t\t\t0.130\t\t\t0.503**\t\t\t\t \tSN S-F\t−0.270**\t\t\t0.065\t\t\t0.107\t\t\t \tSN S\t\t−0.373**\t\t\t0.011\t\t\t−0.083\t\t \tSN F\t\t\t−0.319**\t\t\t−0.076\t\t\t−0.115\t \t
#Text=Significant at p <0.1
#Text=Significant at p < 0.05
#Text=Significant at p < 0.01
#Text=DMN = default mode network, ECN = Executive Control Network, SN = Salience Network, R = right, L = left, S-F = beta for degree of association of component with smoke cues minus for food cues, S = beta for degree of association of component with smoke cues, F = beta for degree of association of component with food cues
#Text=Outcome Prediction Results Using Generalized Estimating Equations
#Text=\tBeta / Exp(B)\t \t\tSmoke - Food\tSmoke\tFood\t \tDMN\t−0.766/0.47**\t−0.102/0.72\t0.678/1.97**\t \tRxGrp\t−0.450/0.64**\t−0.467/0.63**\t0.160/1.17**\t \tGender\t0.137/1.15\t0.059/1.06\t−0.003/1.00\t \tAge\t−0.001/1.00\t−0.002/1.00\t−0.003/1.00\t \tFTND\t0.086/1.09^\t0.085/1.09*\t0.066/1.07\t \tScr\t0.001/1.00**\t0.001/1.00**\t0.001/1.00**\t \tQuit\t−0.025/0.98*\t−0.027/0.97*\t−0.027/0.97*\t \tAUDIT\t0.013/1.01\t0.015/1.02\t0.012/1.01\t \tBAI\t0.000/1.00\t0.001/1.00\t0.007/1.01\t \tBDI\t0.017/1.02\t0.023/1.02\t0.013/1.01\t \tBIQ\t0.009/1.01\t0.027/1.03\t0.005/1.01\t \tWSW\t−0.024/0.98\t−0.019/0.98\t−0.018/0.98\t \tWSWFood\t−0.005/1.00\t0.007/1.01\t−0.005/1.00\t \tQSU\t0.003/1.003\t0.002/1.00\t0.003/1.00\t \trmsRot\t−1.126/0.32^\t−1.150/0.317^\t−1.099/0.33^\t \t
#Text=p<0.1
#Text=Significant at p < 0.05
#Text=Significant at p < 0.01
#Text=Because the interaction terms (Smoke-Food × RxGrp, Smoke × RxGrp, Food × RxGrp) were not significant or trending towards significant, results without the interaction terms are presented.
172-1	42397-42401	Food	_	
172-2	42402-42405	for	_	
172-3	42406-42413	Primary	_	
172-4	42414-42417	and	_	
172-5	42418-42429	Exploratory	_	
172-6	42430-42440	Components	_	
172-7	42442-42446	Mean	_	
172-8	42447-42452	Smoke	_	
172-9	42452-42453	(	_	
172-10	42453-42455	SD	_	
172-11	42455-42456	)	_	
172-12	42457-42461	Mean	_	
172-13	42462-42466	Food	_	
172-14	42467-42468	(	_	
172-15	42468-42470	SD	_	
172-16	42470-42471	)	_	
172-17	42472-42473	T	_	
172-18	42474-42475	p	_	
172-19	42478-42481	DMN	_	
172-20	42482-42483	−	_	
172-21	42483-42488	0.001	_	
172-22	42489-42490	(	_	
172-23	42490-42494	0.28	_	
172-24	42494-42495	)	_	
172-25	42496-42497	−	_	
172-26	42497-42501	0.24	_	
172-27	42502-42503	(	_	
172-28	42503-42507	0.30	_	
172-29	42507-42508	)	_	
172-30	42509-42513	9.92	_	
172-31	42514-42515	<	_	
172-32	42515-42520	0.001	_	
172-33	42523-42524	R	_	
172-34	42525-42528	ECN	_	
172-35	42529-42530	−	_	
172-36	42530-42535	0.152	_	
172-37	42536-42537	(	_	
172-38	42537-42541	0.25	_	
172-39	42541-42542	)	_	
172-40	42543-42548	0.251	_	
172-41	42549-42550	(	_	
172-42	42550-42554	0.29	_	
172-43	42554-42555	)	_	
172-44	42556-42561	6.153	_	
172-45	42562-42563	<	_	
172-46	42563-42568	0.001	_	
172-47	42571-42572	L	_	
172-48	42573-42576	ECN	_	
172-49	42577-42578	−	_	
172-50	42578-42583	0.005	_	
172-51	42584-42585	(	_	
172-52	42585-42589	0.29	_	
172-53	42589-42590	)	_	
172-54	42591-42596	0.043	_	
172-55	42597-42598	(	_	
172-56	42598-42602	0.33	_	
172-57	42602-42603	)	_	
172-58	42604-42609	2.038	_	
172-59	42610-42615	0.043	_	
172-60	42618-42620	SN	_	
172-61	42621-42626	0.251	_	
172-62	42626-42627	(	_	
172-63	42627-42631	0.29	_	
172-64	42631-42632	)	_	
172-65	42633-42638	0.258	_	
172-66	42639-42640	(	_	
172-67	42640-42644	0.33	_	
172-68	42644-42645	)	_	
172-69	42646-42647	−	_	
172-70	42647-42652	0.316	_	
172-71	42653-42658	0.753	_	
172-72	42662-42665	DMN	_	
172-73	42666-42667	=	_	
172-74	42668-42675	default	_	
172-75	42676-42680	mode	_	
172-76	42681-42688	network	_	
172-77	42688-42689	,	_	
172-78	42690-42693	ECN	_	
172-79	42694-42695	=	_	
172-80	42696-42705	Executive	_	
172-81	42706-42713	Control	_	
172-82	42714-42721	Network	_	
172-83	42721-42722	,	_	
172-84	42723-42725	SN	_	
172-85	42726-42727	=	_	
172-86	42728-42736	Salience	_	
172-87	42737-42744	Network	_	
172-88	42744-42745	,	_	
172-89	42746-42747	R	_	
172-90	42748-42749	=	_	
172-91	42750-42755	right	_	
172-92	42755-42756	,	_	
172-93	42757-42758	L	_	
172-94	42759-42760	=	_	
172-95	42761-42765	left	_	
172-96	42765-42766	,	_	
172-97	42767-42772	Smoke	_	
172-98	42773-42774	=	_	
172-99	42775-42779	beta	_	
172-100	42780-42783	for	_	
172-101	42784-42790	degree	_	
172-102	42791-42793	of	_	
172-103	42794-42805	association	_	
172-104	42806-42808	of	_	
172-105	42809-42818	component	_	
172-106	42819-42823	with	_	
172-107	42824-42829	smoke	_	
172-108	42830-42834	cues	_	
172-109	42834-42835	,	_	
172-110	42836-42840	Food	_	
172-111	42841-42842	=	_	
172-112	42843-42847	beta	_	
172-113	42848-42851	for	_	
172-114	42852-42858	degree	_	
172-115	42859-42861	of	_	
172-116	42862-42873	association	_	
172-117	42874-42876	of	_	
172-118	42877-42886	component	_	
172-119	42887-42891	with	_	
172-120	42892-42896	food	_	
172-121	42897-42901	cues	_	
172-122	42901-42902	,	_	
172-123	42903-42905	SD	_	
172-124	42906-42907	=	_	
172-125	42908-42916	standard	_	
172-126	42917-42926	deviation	_	
172-127	42927-42936	Bivariate	_	
172-128	42937-42949	Correlations	_	
172-129	42950-42951	(	_	
172-130	42951-42959	Spearman	_	
172-131	42959-42960	’	_	
172-132	42960-42961	s	_	
172-133	42962-42965	rho	_	
172-134	42965-42966	)	_	
172-135	42967-42974	Between	_	
172-136	42975-42978	DMN	_	
172-137	42979-42988	Component	_	
172-138	42989-42992	and	_	
172-139	42993-43004	Exploratory	_	
172-140	43005-43006	(	_	
172-141	43006-43007	R	_	
172-142	43008-43011	ECN	_	
172-143	43011-43012	,	_	
172-144	43013-43014	L	_	
172-145	43015-43018	ECN	_	
172-146	43018-43019	,	_	
172-147	43020-43022	SN	_	
172-148	43022-43023	)	_	
172-149	43024-43034	Components	_	
172-150	43036-43042	DMNS-F	_	
172-151	43043-43046	DMN	_	
172-152	43047-43048	S	_	
172-153	43049-43052	DMN	_	
172-154	43053-43054	F	_	
172-155	43055-43056	R	_	
172-156	43057-43063	ECNS-F	_	
172-157	43064-43065	R	_	
172-158	43066-43070	ECNS	_	
172-159	43071-43072	R	_	
172-160	43073-43077	ECNF	_	
172-161	43078-43079	L	_	
172-162	43080-43086	ECNS-F	_	
172-163	43087-43088	L	_	
172-164	43089-43093	ECNS	_	
172-165	43094-43095	L	_	
172-166	43096-43100	ECNF	_	
172-167	43103-43104	R	_	
172-168	43105-43108	ECN	_	
172-169	43109-43112	S-F	_	
172-170	43113-43118	0.280	_	
172-171	43118-43119	*	_	
172-172	43119-43120	*	_	
172-173	43131-43132	R	_	
172-174	43133-43136	ECN	_	
172-175	43137-43138	S	_	
172-176	43140-43145	0.086	_	
172-177	43155-43156	R	_	
172-178	43157-43160	ECN	_	
172-179	43161-43162	F	_	
172-180	43165-43170	0.324	_	
172-181	43170-43171	*	_	
172-182	43171-43172	*	_	
172-183	43181-43182	L	_	
172-184	43183-43186	ECN	_	
172-185	43187-43190	S-F	_	
172-186	43191-43196	0.142	_	
172-187	43196-43197	^	_	
172-188	43200-43205	0.169	_	
172-189	43205-43206	*	_	
172-190	43214-43215	L	_	
172-191	43216-43219	ECN	_	
172-192	43220-43221	S	_	
172-193	43223-43228	0.202	_	
172-194	43228-43229	*	_	
172-195	43232-43237	0.055	_	
172-196	43244-43245	L	_	
172-197	43246-43249	ECN	_	
172-198	43250-43251	F	_	
172-199	43254-43259	0.130	_	
172-200	43262-43267	0.503	_	
172-201	43267-43268	*	_	
172-202	43268-43269	*	_	
172-203	43275-43277	SN	_	
172-204	43278-43281	S-F	_	
172-205	43282-43283	−	_	
172-206	43283-43288	0.270	_	
172-207	43288-43289	*	_	
172-208	43289-43290	*	_	
172-209	43293-43298	0.065	_	
172-210	43301-43306	0.107	_	
172-211	43311-43313	SN	_	
172-212	43314-43315	S	_	
172-213	43317-43318	−	_	
172-214	43318-43323	0.373	_	
172-215	43323-43324	*	_	
172-216	43324-43325	*	_	
172-217	43328-43333	0.011	_	
172-218	43336-43337	−	_	
172-219	43337-43342	0.083	_	
172-220	43346-43348	SN	_	
172-221	43349-43350	F	_	
172-222	43353-43354	−	_	
172-223	43354-43359	0.319	_	
172-224	43359-43360	*	_	
172-225	43360-43361	*	_	
172-226	43364-43365	−	_	
172-227	43365-43370	0.076	_	
172-228	43373-43374	−	_	
172-229	43374-43379	0.115	_	
172-230	43383-43394	Significant	_	
172-231	43395-43397	at	_	
172-232	43398-43399	p	_	
172-233	43400-43401	<	_	
172-234	43401-43404	0.1	_	
172-235	43405-43416	Significant	_	
172-236	43417-43419	at	_	
172-237	43420-43421	p	_	
172-238	43422-43423	<	_	
172-239	43424-43428	0.05	_	
172-240	43429-43440	Significant	_	
172-241	43441-43443	at	_	
172-242	43444-43445	p	_	
172-243	43446-43447	<	_	
172-244	43448-43452	0.01	_	
172-245	43453-43456	DMN	_	
172-246	43457-43458	=	_	
172-247	43459-43466	default	_	
172-248	43467-43471	mode	_	
172-249	43472-43479	network	_	
172-250	43479-43480	,	_	
172-251	43481-43484	ECN	_	
172-252	43485-43486	=	_	
172-253	43487-43496	Executive	_	
172-254	43497-43504	Control	_	
172-255	43505-43512	Network	_	
172-256	43512-43513	,	_	
172-257	43514-43516	SN	_	
172-258	43517-43518	=	_	
172-259	43519-43527	Salience	_	
172-260	43528-43535	Network	_	
172-261	43535-43536	,	_	
172-262	43537-43538	R	_	
172-263	43539-43540	=	_	
172-264	43541-43546	right	_	
172-265	43546-43547	,	_	
172-266	43548-43549	L	_	
172-267	43550-43551	=	_	
172-268	43552-43556	left	_	
172-269	43556-43557	,	_	
172-270	43558-43561	S-F	_	
172-271	43562-43563	=	_	
172-272	43564-43568	beta	_	
172-273	43569-43572	for	_	
172-274	43573-43579	degree	_	
172-275	43580-43582	of	_	
172-276	43583-43594	association	_	
172-277	43595-43597	of	_	
172-278	43598-43607	component	_	
172-279	43608-43612	with	_	
172-280	43613-43618	smoke	_	
172-281	43619-43623	cues	_	
172-282	43624-43629	minus	_	
172-283	43630-43633	for	_	
172-284	43634-43638	food	_	
172-285	43639-43643	cues	_	
172-286	43643-43644	,	_	
172-287	43645-43646	S	_	
172-288	43647-43648	=	_	
172-289	43649-43653	beta	_	
172-290	43654-43657	for	_	
172-291	43658-43664	degree	_	
172-292	43665-43667	of	_	
172-293	43668-43679	association	_	
172-294	43680-43682	of	_	
172-295	43683-43692	component	_	
172-296	43693-43697	with	_	
172-297	43698-43703	smoke	_	
172-298	43704-43708	cues	_	
172-299	43708-43709	,	_	
172-300	43710-43711	F	_	
172-301	43712-43713	=	_	
172-302	43714-43718	beta	_	
172-303	43719-43722	for	_	
172-304	43723-43729	degree	_	
172-305	43730-43732	of	_	
172-306	43733-43744	association	_	
172-307	43745-43747	of	_	
172-308	43748-43757	component	_	
172-309	43758-43762	with	_	
172-310	43763-43767	food	_	
172-311	43768-43772	cues	_	
172-312	43773-43780	Outcome	_	
172-313	43781-43791	Prediction	_	
172-314	43792-43799	Results	_	
172-315	43800-43805	Using	_	
172-316	43806-43817	Generalized	_	
172-317	43818-43828	Estimating	_	
172-318	43829-43838	Equations	_	
172-319	43840-43844	Beta	_	
172-320	43845-43846	/	_	
172-321	43847-43850	Exp	_	
172-322	43850-43851	(	_	
172-323	43851-43852	B	_	
172-324	43852-43853	)	_	
172-325	43857-43862	Smoke	_	
172-326	43863-43864	-	_	
172-327	43865-43869	Food	_	
172-328	43870-43875	Smoke	_	
172-329	43876-43880	Food	_	
172-330	43883-43886	DMN	_	
172-331	43887-43888	−	_	
172-332	43888-43893	0.766	_	
172-333	43893-43894	/	_	
172-334	43894-43898	0.47	_	
172-335	43898-43899	*	_	
172-336	43899-43900	*	_	
172-337	43901-43902	−	_	
172-338	43902-43907	0.102	_	
172-339	43907-43908	/	_	
172-340	43908-43912	0.72	_	
172-341	43913-43918	0.678	_	
172-342	43918-43919	/	_	
172-343	43919-43923	1.97	_	
172-344	43923-43924	*	_	
172-345	43924-43925	*	_	
172-346	43928-43933	RxGrp	_	
172-347	43934-43935	−	_	
172-348	43935-43940	0.450	_	
172-349	43940-43941	/	_	
172-350	43941-43945	0.64	_	
172-351	43945-43946	*	_	
172-352	43946-43947	*	_	
172-353	43948-43949	−	_	
172-354	43949-43954	0.467	_	
172-355	43954-43955	/	_	
172-356	43955-43959	0.63	_	
172-357	43959-43960	*	_	
172-358	43960-43961	*	_	
172-359	43962-43967	0.160	_	
172-360	43967-43968	/	_	
172-361	43968-43972	1.17	_	
172-362	43972-43973	*	_	
172-363	43973-43974	*	_	
172-364	43977-43983	Gender	_	
172-365	43984-43989	0.137	_	
172-366	43989-43990	/	_	
172-367	43990-43994	1.15	_	
172-368	43995-44000	0.059	_	
172-369	44000-44001	/	_	
172-370	44001-44005	1.06	_	
172-371	44006-44007	−	_	
172-372	44007-44012	0.003	_	
172-373	44012-44013	/	_	
172-374	44013-44017	1.00	_	
172-375	44020-44023	Age	_	
172-376	44024-44025	−	_	
172-377	44025-44030	0.001	_	
172-378	44030-44031	/	_	
172-379	44031-44035	1.00	_	
172-380	44036-44037	−	_	
172-381	44037-44042	0.002	_	
172-382	44042-44043	/	_	
172-383	44043-44047	1.00	_	
172-384	44048-44049	−	_	
172-385	44049-44054	0.003	_	
172-386	44054-44055	/	_	
172-387	44055-44059	1.00	_	
172-388	44062-44066	FTND	_	
172-389	44067-44072	0.086	_	
172-390	44072-44073	/	_	
172-391	44073-44077	1.09	_	
172-392	44077-44078	^	_	
172-393	44079-44084	0.085	_	
172-394	44084-44085	/	_	
172-395	44085-44089	1.09	_	
172-396	44089-44090	*	_	
172-397	44091-44096	0.066	_	
172-398	44096-44097	/	_	
172-399	44097-44101	1.07	_	
172-400	44104-44107	Scr	_	
172-401	44108-44113	0.001	_	
172-402	44113-44114	/	_	
172-403	44114-44118	1.00	_	
172-404	44118-44119	*	_	
172-405	44119-44120	*	_	
172-406	44121-44126	0.001	_	
172-407	44126-44127	/	_	
172-408	44127-44131	1.00	_	
172-409	44131-44132	*	_	
172-410	44132-44133	*	_	
172-411	44134-44139	0.001	_	
172-412	44139-44140	/	_	
172-413	44140-44144	1.00	_	
172-414	44144-44145	*	_	
172-415	44145-44146	*	_	
172-416	44149-44153	Quit	_	
172-417	44154-44155	−	_	
172-418	44155-44160	0.025	_	
172-419	44160-44161	/	_	
172-420	44161-44165	0.98	_	
172-421	44165-44166	*	_	
172-422	44167-44168	−	_	
172-423	44168-44173	0.027	_	
172-424	44173-44174	/	_	
172-425	44174-44178	0.97	_	
172-426	44178-44179	*	_	
172-427	44180-44181	−	_	
172-428	44181-44186	0.027	_	
172-429	44186-44187	/	_	
172-430	44187-44191	0.97	_	
172-431	44191-44192	*	_	
172-432	44195-44200	AUDIT	_	
172-433	44201-44206	0.013	_	
172-434	44206-44207	/	_	
172-435	44207-44211	1.01	_	
172-436	44212-44217	0.015	_	
172-437	44217-44218	/	_	
172-438	44218-44222	1.02	_	
172-439	44223-44228	0.012	_	
172-440	44228-44229	/	_	
172-441	44229-44233	1.01	_	
172-442	44236-44239	BAI	_	
172-443	44240-44245	0.000	_	
172-444	44245-44246	/	_	
172-445	44246-44250	1.00	_	
172-446	44251-44256	0.001	_	
172-447	44256-44257	/	_	
172-448	44257-44261	1.00	_	
172-449	44262-44267	0.007	_	
172-450	44267-44268	/	_	
172-451	44268-44272	1.01	_	
172-452	44275-44278	BDI	_	
172-453	44279-44284	0.017	_	
172-454	44284-44285	/	_	
172-455	44285-44289	1.02	_	
172-456	44290-44295	0.023	_	
172-457	44295-44296	/	_	
172-458	44296-44300	1.02	_	
172-459	44301-44306	0.013	_	
172-460	44306-44307	/	_	
172-461	44307-44311	1.01	_	
172-462	44314-44317	BIQ	_	
172-463	44318-44323	0.009	_	
172-464	44323-44324	/	_	
172-465	44324-44328	1.01	_	
172-466	44329-44334	0.027	_	
172-467	44334-44335	/	_	
172-468	44335-44339	1.03	_	
172-469	44340-44345	0.005	_	
172-470	44345-44346	/	_	
172-471	44346-44350	1.01	_	
172-472	44353-44356	WSW	_	
172-473	44357-44358	−	_	
172-474	44358-44363	0.024	_	
172-475	44363-44364	/	_	
172-476	44364-44368	0.98	_	
172-477	44369-44370	−	_	
172-478	44370-44375	0.019	_	
172-479	44375-44376	/	_	
172-480	44376-44380	0.98	_	
172-481	44381-44382	−	_	
172-482	44382-44387	0.018	_	
172-483	44387-44388	/	_	
172-484	44388-44392	0.98	_	
172-485	44395-44402	WSWFood	_	
172-486	44403-44404	−	_	
172-487	44404-44409	0.005	_	
172-488	44409-44410	/	_	
172-489	44410-44414	1.00	_	
172-490	44415-44420	0.007	_	
172-491	44420-44421	/	_	
172-492	44421-44425	1.01	_	
172-493	44426-44427	−	_	
172-494	44427-44432	0.005	_	
172-495	44432-44433	/	_	
172-496	44433-44437	1.00	_	
172-497	44440-44443	QSU	_	
172-498	44444-44449	0.003	_	
172-499	44449-44450	/	_	
172-500	44450-44455	1.003	_	
172-501	44456-44461	0.002	_	
172-502	44461-44462	/	_	
172-503	44462-44466	1.00	_	
172-504	44467-44472	0.003	_	
172-505	44472-44473	/	_	
172-506	44473-44477	1.00	_	
172-507	44480-44486	rmsRot	_	
172-508	44487-44488	−	_	
172-509	44488-44493	1.126	_	
172-510	44493-44494	/	_	
172-511	44494-44498	0.32	_	
172-512	44498-44499	^	_	
172-513	44500-44501	−	_	
172-514	44501-44506	1.150	_	
172-515	44506-44507	/	_	
172-516	44507-44512	0.317	_	
172-517	44512-44513	^	_	
172-518	44514-44515	−	_	
172-519	44515-44520	1.099	_	
172-520	44520-44521	/	_	
172-521	44521-44525	0.33	_	
172-522	44525-44526	^	_	
172-523	44530-44531	p	_	
172-524	44531-44532	<	_	
172-525	44532-44535	0.1	_	
172-526	44536-44547	Significant	_	
172-527	44548-44550	at	_	
172-528	44551-44552	p	_	
172-529	44553-44554	<	_	
172-530	44555-44559	0.05	_	
172-531	44560-44571	Significant	_	
172-532	44572-44574	at	_	
172-533	44575-44576	p	_	
172-534	44577-44578	<	_	
172-535	44579-44583	0.01	_	
172-536	44584-44591	Because	_	
172-537	44592-44595	the	_	
172-538	44596-44607	interaction	_	
172-539	44608-44613	terms	_	
172-540	44614-44615	(	_	
172-541	44615-44625	Smoke-Food	_	
172-542	44626-44627	×	_	
172-543	44628-44633	RxGrp	_	
172-544	44633-44634	,	_	
172-545	44635-44640	Smoke	_	
172-546	44641-44642	×	_	
172-547	44643-44648	RxGrp	_	
172-548	44648-44649	,	_	
172-549	44650-44654	Food	_	
172-550	44655-44656	×	_	
172-551	44657-44662	RxGrp	_	
172-552	44662-44663	)	_	
172-553	44664-44668	were	_	
172-554	44669-44672	not	_	
172-555	44673-44684	significant	_	
172-556	44685-44687	or	_	
172-557	44688-44696	trending	_	
172-558	44697-44704	towards	_	
172-559	44705-44716	significant	_	
172-560	44716-44717	,	_	
172-561	44718-44725	results	_	
172-562	44726-44733	without	_	
172-563	44734-44737	the	_	
172-564	44738-44749	interaction	_	
172-565	44750-44755	terms	_	
172-566	44756-44759	are	_	
172-567	44760-44769	presented	_	
172-568	44769-44770	.	_	

#Text=Exp(B) = exponential beta, DMN = default mode network, Smoke - Food = beta for degree of association of DMN component with smoke cues minus for food cues, Smoke = beta for degree of association of DMN component with smoke cues, Food = beta for degree of association of DMN component with food cues, RxGrp = Medication Condition (varenicline = 1, placebo = 0), Gender (male = 1, female = 2), FTND = Fagerstrom Test for Nicotine Dependence, Scr = number of cigarettes smoked during prior 60 days at screen, Quit = Number Serious Quit Attempts (>12 hours abstinent),,AUDIT = AUDIT Total Score, BAI = Beck Anxiety Inventory Total Score, BDI = Beck Depression Inventory Total Score, BIQ = Barratt Impulsiveness Questionnaire Total Score, WSW = Wisconsin Withdrawal Scale Score pre MRI scan, WSWFood=sum of food-related questions only on WSWS, QSU = Questionnaire of Smoking Urges, rmsRot = root mean square translational framewise displacement (head motion at time of MRI scan).
173-1	44771-44774	Exp	_	
173-2	44774-44775	(	_	
173-3	44775-44776	B	_	
173-4	44776-44777	)	_	
173-5	44778-44779	=	_	
173-6	44780-44791	exponential	_	
173-7	44792-44796	beta	_	
173-8	44796-44797	,	_	
173-9	44798-44801	DMN	_	
173-10	44802-44803	=	_	
173-11	44804-44811	default	_	
173-12	44812-44816	mode	_	
173-13	44817-44824	network	_	
173-14	44824-44825	,	_	
173-15	44826-44831	Smoke	_	
173-16	44832-44833	-	_	
173-17	44834-44838	Food	_	
173-18	44839-44840	=	_	
173-19	44841-44845	beta	_	
173-20	44846-44849	for	_	
173-21	44850-44856	degree	_	
173-22	44857-44859	of	_	
173-23	44860-44871	association	_	
173-24	44872-44874	of	_	
173-25	44875-44878	DMN	_	
173-26	44879-44888	component	_	
173-27	44889-44893	with	_	
173-28	44894-44899	smoke	_	
173-29	44900-44904	cues	_	
173-30	44905-44910	minus	_	
173-31	44911-44914	for	_	
173-32	44915-44919	food	_	
173-33	44920-44924	cues	_	
173-34	44924-44925	,	_	
173-35	44926-44931	Smoke	_	
173-36	44932-44933	=	_	
173-37	44934-44938	beta	_	
173-38	44939-44942	for	_	
173-39	44943-44949	degree	_	
173-40	44950-44952	of	_	
173-41	44953-44964	association	_	
173-42	44965-44967	of	_	
173-43	44968-44971	DMN	_	
173-44	44972-44981	component	_	
173-45	44982-44986	with	_	
173-46	44987-44992	smoke	_	
173-47	44993-44997	cues	_	
173-48	44997-44998	,	_	
173-49	44999-45003	Food	_	
173-50	45004-45005	=	_	
173-51	45006-45010	beta	_	
173-52	45011-45014	for	_	
173-53	45015-45021	degree	_	
173-54	45022-45024	of	_	
173-55	45025-45036	association	_	
173-56	45037-45039	of	_	
173-57	45040-45043	DMN	_	
173-58	45044-45053	component	_	
173-59	45054-45058	with	_	
173-60	45059-45063	food	_	
173-61	45064-45068	cues	_	
173-62	45068-45069	,	_	
173-63	45070-45075	RxGrp	_	
173-64	45076-45077	=	_	
173-65	45078-45088	Medication	_	
173-66	45089-45098	Condition	_	
173-67	45099-45100	(	_	
173-68	45100-45111	varenicline	_	
173-69	45112-45113	=	_	
173-70	45114-45115	1	_	
173-71	45115-45116	,	_	
173-72	45117-45124	placebo	_	
173-73	45125-45126	=	_	
173-74	45127-45128	0	_	
173-75	45128-45129	)	_	
173-76	45129-45130	,	_	
173-77	45131-45137	Gender	_	
173-78	45138-45139	(	_	
173-79	45139-45143	male	_	
173-80	45144-45145	=	_	
173-81	45146-45147	1	_	
173-82	45147-45148	,	_	
173-83	45149-45155	female	_	
173-84	45156-45157	=	_	
173-85	45158-45159	2	_	
173-86	45159-45160	)	_	
173-87	45160-45161	,	_	
173-88	45162-45166	FTND	_	
173-89	45167-45168	=	_	
173-90	45169-45179	Fagerstrom	_	
173-91	45180-45184	Test	_	
173-92	45185-45188	for	_	
173-93	45189-45197	Nicotine	_	
173-94	45198-45208	Dependence	_	
173-95	45208-45209	,	_	
173-96	45210-45213	Scr	_	
173-97	45214-45215	=	_	
173-98	45216-45222	number	_	
173-99	45223-45225	of	_	
173-100	45226-45236	cigarettes	_	
173-101	45237-45243	smoked	_	
173-102	45244-45250	during	_	
173-103	45251-45256	prior	_	
173-104	45257-45259	60	_	
173-105	45260-45264	days	_	
173-106	45265-45267	at	_	
173-107	45268-45274	screen	_	
173-108	45274-45275	,	_	
173-109	45276-45280	Quit	_	
173-110	45281-45282	=	_	
173-111	45283-45289	Number	_	
173-112	45290-45297	Serious	_	
173-113	45298-45302	Quit	_	
173-114	45303-45311	Attempts	_	
173-115	45312-45313	(	_	
173-116	45313-45314	>	_	
173-117	45314-45316	12	_	
173-118	45317-45322	hours	_	
173-119	45323-45332	abstinent	_	
173-120	45332-45333	)	_	
173-121	45333-45334	,	_	
173-122	45334-45335	,	_	
173-123	45335-45340	AUDIT	_	
173-124	45341-45342	=	_	
173-125	45343-45348	AUDIT	_	
173-126	45349-45354	Total	_	
173-127	45355-45360	Score	_	
173-128	45360-45361	,	_	
173-129	45362-45365	BAI	_	
173-130	45366-45367	=	_	
173-131	45368-45372	Beck	_	
173-132	45373-45380	Anxiety	_	
173-133	45381-45390	Inventory	_	
173-134	45391-45396	Total	_	
173-135	45397-45402	Score	_	
173-136	45402-45403	,	_	
173-137	45404-45407	BDI	_	
173-138	45408-45409	=	_	
173-139	45410-45414	Beck	_	
173-140	45415-45425	Depression	_	
173-141	45426-45435	Inventory	_	
173-142	45436-45441	Total	_	
173-143	45442-45447	Score	_	
173-144	45447-45448	,	_	
173-145	45449-45452	BIQ	_	
173-146	45453-45454	=	_	
173-147	45455-45462	Barratt	_	
173-148	45463-45476	Impulsiveness	_	
173-149	45477-45490	Questionnaire	_	
173-150	45491-45496	Total	_	
173-151	45497-45502	Score	_	
173-152	45502-45503	,	_	
173-153	45504-45507	WSW	_	
173-154	45508-45509	=	_	
173-155	45510-45519	Wisconsin	_	
173-156	45520-45530	Withdrawal	_	
173-157	45531-45536	Scale	_	
173-158	45537-45542	Score	_	
173-159	45543-45546	pre	_	
173-160	45547-45550	MRI	_	
173-161	45551-45555	scan	_	
173-162	45555-45556	,	_	
173-163	45557-45564	WSWFood	_	
173-164	45564-45565	=	_	
173-165	45565-45568	sum	_	
173-166	45569-45571	of	_	
173-167	45572-45584	food-related	_	
173-168	45585-45594	questions	_	
173-169	45595-45599	only	_	
173-170	45600-45602	on	_	
173-171	45603-45607	WSWS	_	
173-172	45607-45608	,	_	
173-173	45609-45612	QSU	_	
173-174	45613-45614	=	_	
173-175	45615-45628	Questionnaire	_	
173-176	45629-45631	of	_	
173-177	45632-45639	Smoking	_	
173-178	45640-45645	Urges	_	
173-179	45645-45646	,	_	
173-180	45647-45653	rmsRot	_	
173-181	45654-45655	=	_	
173-182	45656-45660	root	_	
173-183	45661-45665	mean	_	
173-184	45666-45672	square	_	
173-185	45673-45686	translational	_	
173-186	45687-45696	framewise	_	
173-187	45697-45709	displacement	_	
173-188	45710-45711	(	_	
173-189	45711-45715	head	_	
173-190	45716-45722	motion	_	
173-191	45723-45725	at	_	
173-192	45726-45730	time	_	
173-193	45731-45733	of	_	
173-194	45734-45737	MRI	_	
173-195	45738-45742	scan	_	
173-196	45742-45743	)	_	
173-197	45743-45744	.	_	

#Text=Means for neuroimaging predictor variables by abstinent versus non-abstinent subgroups for the 7 days prior to week 6 (CO confirmed), and comparisons between abstinent and non-abstinent groups (independent samples t-tests), assuming all dropouts were non-abstinent
#Text=\t\tS-F mean (SD)\tS mean (SD)\tF mean (SD)\tn\t \t7dayPP at 6 wks\tAbstinent\t0.365 (0.281)\t0.066 (0.317)\t−0.298 (0.283)\t32\t \tNon-Abstinent\t0.204 (0.283)\t−0.021 (0.268)\t−0.225 (0.304)\t111\t \t\tp value/ t statistic\t0.005/ 2.85\t0.122/ 1.56\t0.219/ −1.24\t\t \t
#Text=PP = point prevalence, CO confirmed = anyone with a CO > 10ppm at the 6 week visit were deemed Non-Abstinent regardless of self-report, SD = standard deviation, S-F = beta for degree of association of DMN component with smoke cues minus for food cues, S = beta for degree of association of DMN component with smoke cues, F = beta for degree of association of DMN component with food cues
#Text=Means for neuroimaging predictor variables by abstinent versus non-abstinent subgroups for the 30 days prior to week 12 (CO confirmed), and comparisons between abstinent and non-abstinent (independent samples t-tests), assuming all dropouts were non-abstinent
#Text=\t\tS-F mean (SD)\tS mean (SD)\tF mean (SD)\tn\t \t30dayPP at 12 wks\tAbstinent\t0.373 (0.267)\t0.045 (0.305)\t−0.329 (0.309)\t24\t \tNon-Abstinent\t0.213 (0.287)\t−0.011 (0.276)\t−0.224 (0.296)\t119\t \t\tp value/ t statistic\t0.013/ 2.53\t0.38/ 0.88\t0.117/ −1.58\t\t \t
#Text=PP = point prevalence, CO confirmed = anyone with a CO > 10ppm at the 12 week visit were deemed Non-Abstinent regardless of self-report, SD = standard deviation, S-F = beta for degree of association of DMN component with smoke cues minus for food cues, S = beta for degree of association of DMN component with smoke cues, F = beta for degree of association of DMN component with food cues
#Text=Exploring Significant Interaction Terms (Smoke-Food/Smoke/Food × RxGrp) for Exploratory Components (SN, ECN): Binning by High and Low Smoke-Food/Smoke/Food and by Placebo/Varenicline
#Text=\t\tFull Sample RxGrp Beta / Exp(B)\tNon Imputed Sample RxGrp Beta / Exp(B)\t \tR ECN\tSmoke – Food High R ECN\t−1.494/0.224**\t−1.494**/0.224**\t \t\tSmoke – Food Low R ECN\t−0.418/0.658^\t−0.453/0.636\t \t\tSmoke High R ECN\t−0.672/0.511**\t−0.898/0.408**\t \t\tSmoke Low R ECN\t−0.450/0.637*\t−0.384/0.681\t \tL ECN\tSmoke – Food High L ECN\t−0.675/0.509**\t−0.772/0.462*\t \t\tSmoke – Food Low L ECN\t−0.220/0.802\t−0.011/0.989\t \tSN\tSmoke – Food High SN\t−0.527/0.590*\t−0.669/0.512**\t \t\tSmoke – Food Low SN\t−0.502/0.605**\t−1.074/0.342**\t \t\tFood High SN\t−0.550/0.577*\t−0.987/0.373**\t \t\tFood Low SN\t−0.477/0.620*\t−0.289/0.749\t \t\t\tFull SampleComponent Beta / Exp(B)\tNon Imputed SampleComponent Beta / Exp(B)\t \tR ECN\tSmoke – Food Placebo\t0.049/1.050\t0.125/1.133\t \t\tSmoke – Food Varenicline\t−1.053/0.349**\t−1.351/0.259**\t \t\tSmoke Placebo\t0.558/1.747^\t0.554/1.740\t \t\tSmoke Varenicline\t−0.186/0.830\t0.076/1.079\t \tL ECN\tSmoke – Food Placebo\t0.039/1.039\t0.864/2.372*\t \t\tSmoke – Food Varenicline\t−0.198/0.820\t−0.410/0.664\t \tSN\tSmoke – Food Placebo\t−0.235/0.791\t−0.693/0.500^\t \t\tSmoke – Food Varenicline\t0.401/1.493\t1.082/2.952\t \t\tFood Placebo\t0.286/1.332\t0.550/1.734\t \t\tFood Varenicline\t−0.521/0.594\t−1.314/0.269*\t \t
#Text=p<0.1
#Text=Significant at p < 0.05
#Text=Significant at p < 0.01
#Text=High and Low groups for each of the components during Smoke-Food, Smoke, or Food were derived by doing a median split on the betas.
174-1	45745-45750	Means	_	
174-2	45751-45754	for	_	
174-3	45755-45767	neuroimaging	_	
174-4	45768-45777	predictor	_	
174-5	45778-45787	variables	_	
174-6	45788-45790	by	_	
174-7	45791-45800	abstinent	_	
174-8	45801-45807	versus	_	
174-9	45808-45821	non-abstinent	_	
174-10	45822-45831	subgroups	_	
174-11	45832-45835	for	_	
174-12	45836-45839	the	_	
174-13	45840-45841	7	_	
174-14	45842-45846	days	_	
174-15	45847-45852	prior	_	
174-16	45853-45855	to	_	
174-17	45856-45860	week	_	
174-18	45861-45862	6	_	
174-19	45863-45864	(	_	
174-20	45864-45866	CO	_	
174-21	45867-45876	confirmed	_	
174-22	45876-45877	)	_	
174-23	45877-45878	,	_	
174-24	45879-45882	and	_	
174-25	45883-45894	comparisons	_	
174-26	45895-45902	between	_	
174-27	45903-45912	abstinent	_	
174-28	45913-45916	and	_	
174-29	45917-45930	non-abstinent	_	
174-30	45931-45937	groups	_	
174-31	45938-45939	(	_	
174-32	45939-45950	independent	_	
174-33	45951-45958	samples	_	
174-34	45959-45966	t-tests	_	
174-35	45966-45967	)	_	
174-36	45967-45968	,	_	
174-37	45969-45977	assuming	_	
174-38	45978-45981	all	_	
174-39	45982-45990	dropouts	_	
174-40	45991-45995	were	_	
174-41	45996-46009	non-abstinent	_	
174-42	46012-46015	S-F	_	
174-43	46016-46020	mean	_	
174-44	46021-46022	(	_	
174-45	46022-46024	SD	_	
174-46	46024-46025	)	_	
174-47	46026-46027	S	_	
174-48	46028-46032	mean	_	
174-49	46033-46034	(	_	
174-50	46034-46036	SD	_	
174-51	46036-46037	)	_	
174-52	46038-46039	F	_	
174-53	46040-46044	mean	_	
174-54	46045-46046	(	_	
174-55	46046-46048	SD	_	
174-56	46048-46049	)	_	
174-57	46050-46051	n	_	
174-58	46054-46060	7dayPP	_	
174-59	46061-46063	at	_	
174-60	46064-46065	6	_	
174-61	46066-46069	wks	_	
174-62	46070-46079	Abstinent	_	
174-63	46080-46085	0.365	_	
174-64	46086-46087	(	_	
174-65	46087-46092	0.281	_	
174-66	46092-46093	)	_	
174-67	46094-46099	0.066	_	
174-68	46100-46101	(	_	
174-69	46101-46106	0.317	_	
174-70	46106-46107	)	_	
174-71	46108-46109	−	_	
174-72	46109-46114	0.298	_	
174-73	46115-46116	(	_	
174-74	46116-46121	0.283	_	
174-75	46121-46122	)	_	
174-76	46123-46125	32	_	
174-77	46128-46141	Non-Abstinent	_	
174-78	46142-46147	0.204	_	
174-79	46148-46149	(	_	
174-80	46149-46154	0.283	_	
174-81	46154-46155	)	_	
174-82	46156-46157	−	_	
174-83	46157-46162	0.021	_	
174-84	46163-46164	(	_	
174-85	46164-46169	0.268	_	
174-86	46169-46170	)	_	
174-87	46171-46172	−	_	
174-88	46172-46177	0.225	_	
174-89	46178-46179	(	_	
174-90	46179-46184	0.304	_	
174-91	46184-46185	)	_	
174-92	46186-46189	111	_	
174-93	46193-46194	p	_	
174-94	46195-46200	value	_	
174-95	46200-46201	/	_	
174-96	46202-46203	t	_	
174-97	46204-46213	statistic	_	
174-98	46214-46219	0.005	_	
174-99	46219-46220	/	_	
174-100	46221-46225	2.85	_	
174-101	46226-46231	0.122	_	
174-102	46231-46232	/	_	
174-103	46233-46237	1.56	_	
174-104	46238-46243	0.219	_	
174-105	46243-46244	/	_	
174-106	46245-46246	−	_	
174-107	46246-46250	1.24	_	
174-108	46255-46257	PP	_	
174-109	46258-46259	=	_	
174-110	46260-46265	point	_	
174-111	46266-46276	prevalence	_	
174-112	46276-46277	,	_	
174-113	46278-46280	CO	_	
174-114	46281-46290	confirmed	_	
174-115	46291-46292	=	_	
174-116	46293-46299	anyone	_	
174-117	46300-46304	with	_	
174-118	46305-46306	a	_	
174-119	46307-46309	CO	_	
174-120	46310-46311	>	_	
174-121	46312-46317	10ppm	_	
174-122	46318-46320	at	_	
174-123	46321-46324	the	_	
174-124	46325-46326	6	_	
174-125	46327-46331	week	_	
174-126	46332-46337	visit	_	
174-127	46338-46342	were	_	
174-128	46343-46349	deemed	_	
174-129	46350-46363	Non-Abstinent	_	
174-130	46364-46374	regardless	_	
174-131	46375-46377	of	_	
174-132	46378-46389	self-report	_	
174-133	46389-46390	,	_	
174-134	46391-46393	SD	_	
174-135	46394-46395	=	_	
174-136	46396-46404	standard	_	
174-137	46405-46414	deviation	_	
174-138	46414-46415	,	_	
174-139	46416-46419	S-F	_	
174-140	46420-46421	=	_	
174-141	46422-46426	beta	_	
174-142	46427-46430	for	_	
174-143	46431-46437	degree	_	
174-144	46438-46440	of	_	
174-145	46441-46452	association	_	
174-146	46453-46455	of	_	
174-147	46456-46459	DMN	_	
174-148	46460-46469	component	_	
174-149	46470-46474	with	_	
174-150	46475-46480	smoke	_	
174-151	46481-46485	cues	_	
174-152	46486-46491	minus	_	
174-153	46492-46495	for	_	
174-154	46496-46500	food	_	
174-155	46501-46505	cues	_	
174-156	46505-46506	,	_	
174-157	46507-46508	S	_	
174-158	46509-46510	=	_	
174-159	46511-46515	beta	_	
174-160	46516-46519	for	_	
174-161	46520-46526	degree	_	
174-162	46527-46529	of	_	
174-163	46530-46541	association	_	
174-164	46542-46544	of	_	
174-165	46545-46548	DMN	_	
174-166	46549-46558	component	_	
174-167	46559-46563	with	_	
174-168	46564-46569	smoke	_	
174-169	46570-46574	cues	_	
174-170	46574-46575	,	_	
174-171	46576-46577	F	_	
174-172	46578-46579	=	_	
174-173	46580-46584	beta	_	
174-174	46585-46588	for	_	
174-175	46589-46595	degree	_	
174-176	46596-46598	of	_	
174-177	46599-46610	association	_	
174-178	46611-46613	of	_	
174-179	46614-46617	DMN	_	
174-180	46618-46627	component	_	
174-181	46628-46632	with	_	
174-182	46633-46637	food	_	
174-183	46638-46642	cues	_	
174-184	46643-46648	Means	_	
174-185	46649-46652	for	_	
174-186	46653-46665	neuroimaging	_	
174-187	46666-46675	predictor	_	
174-188	46676-46685	variables	_	
174-189	46686-46688	by	_	
174-190	46689-46698	abstinent	_	
174-191	46699-46705	versus	_	
174-192	46706-46719	non-abstinent	_	
174-193	46720-46729	subgroups	_	
174-194	46730-46733	for	_	
174-195	46734-46737	the	_	
174-196	46738-46740	30	_	
174-197	46741-46745	days	_	
174-198	46746-46751	prior	_	
174-199	46752-46754	to	_	
174-200	46755-46759	week	_	
174-201	46760-46762	12	_	
174-202	46763-46764	(	_	
174-203	46764-46766	CO	_	
174-204	46767-46776	confirmed	_	
174-205	46776-46777	)	_	
174-206	46777-46778	,	_	
174-207	46779-46782	and	_	
174-208	46783-46794	comparisons	_	
174-209	46795-46802	between	_	
174-210	46803-46812	abstinent	_	
174-211	46813-46816	and	_	
174-212	46817-46830	non-abstinent	_	
174-213	46831-46832	(	_	
174-214	46832-46843	independent	_	
174-215	46844-46851	samples	_	
174-216	46852-46859	t-tests	_	
174-217	46859-46860	)	_	
174-218	46860-46861	,	_	
174-219	46862-46870	assuming	_	
174-220	46871-46874	all	_	
174-221	46875-46883	dropouts	_	
174-222	46884-46888	were	_	
174-223	46889-46902	non-abstinent	_	
174-224	46905-46908	S-F	_	
174-225	46909-46913	mean	_	
174-226	46914-46915	(	_	
174-227	46915-46917	SD	_	
174-228	46917-46918	)	_	
174-229	46919-46920	S	_	
174-230	46921-46925	mean	_	
174-231	46926-46927	(	_	
174-232	46927-46929	SD	_	
174-233	46929-46930	)	_	
174-234	46931-46932	F	_	
174-235	46933-46937	mean	_	
174-236	46938-46939	(	_	
174-237	46939-46941	SD	_	
174-238	46941-46942	)	_	
174-239	46943-46944	n	_	
174-240	46947-46954	30dayPP	_	
174-241	46955-46957	at	_	
174-242	46958-46960	12	_	
174-243	46961-46964	wks	_	
174-244	46965-46974	Abstinent	_	
174-245	46975-46980	0.373	_	
174-246	46981-46982	(	_	
174-247	46982-46987	0.267	_	
174-248	46987-46988	)	_	
174-249	46989-46994	0.045	_	
174-250	46995-46996	(	_	
174-251	46996-47001	0.305	_	
174-252	47001-47002	)	_	
174-253	47003-47004	−	_	
174-254	47004-47009	0.329	_	
174-255	47010-47011	(	_	
174-256	47011-47016	0.309	_	
174-257	47016-47017	)	_	
174-258	47018-47020	24	_	
174-259	47023-47036	Non-Abstinent	_	
174-260	47037-47042	0.213	_	
174-261	47043-47044	(	_	
174-262	47044-47049	0.287	_	
174-263	47049-47050	)	_	
174-264	47051-47052	−	_	
174-265	47052-47057	0.011	_	
174-266	47058-47059	(	_	
174-267	47059-47064	0.276	_	
174-268	47064-47065	)	_	
174-269	47066-47067	−	_	
174-270	47067-47072	0.224	_	
174-271	47073-47074	(	_	
174-272	47074-47079	0.296	_	
174-273	47079-47080	)	_	
174-274	47081-47084	119	_	
174-275	47088-47089	p	_	
174-276	47090-47095	value	_	
174-277	47095-47096	/	_	
174-278	47097-47098	t	_	
174-279	47099-47108	statistic	_	
174-280	47109-47114	0.013	_	
174-281	47114-47115	/	_	
174-282	47116-47120	2.53	_	
174-283	47121-47125	0.38	_	
174-284	47125-47126	/	_	
174-285	47127-47131	0.88	_	
174-286	47132-47137	0.117	_	
174-287	47137-47138	/	_	
174-288	47139-47140	−	_	
174-289	47140-47144	1.58	_	
174-290	47149-47151	PP	_	
174-291	47152-47153	=	_	
174-292	47154-47159	point	_	
174-293	47160-47170	prevalence	_	
174-294	47170-47171	,	_	
174-295	47172-47174	CO	_	
174-296	47175-47184	confirmed	_	
174-297	47185-47186	=	_	
174-298	47187-47193	anyone	_	
174-299	47194-47198	with	_	
174-300	47199-47200	a	_	
174-301	47201-47203	CO	_	
174-302	47204-47205	>	_	
174-303	47206-47211	10ppm	_	
174-304	47212-47214	at	_	
174-305	47215-47218	the	_	
174-306	47219-47221	12	_	
174-307	47222-47226	week	_	
174-308	47227-47232	visit	_	
174-309	47233-47237	were	_	
174-310	47238-47244	deemed	_	
174-311	47245-47258	Non-Abstinent	_	
174-312	47259-47269	regardless	_	
174-313	47270-47272	of	_	
174-314	47273-47284	self-report	_	
174-315	47284-47285	,	_	
174-316	47286-47288	SD	_	
174-317	47289-47290	=	_	
174-318	47291-47299	standard	_	
174-319	47300-47309	deviation	_	
174-320	47309-47310	,	_	
174-321	47311-47314	S-F	_	
174-322	47315-47316	=	_	
174-323	47317-47321	beta	_	
174-324	47322-47325	for	_	
174-325	47326-47332	degree	_	
174-326	47333-47335	of	_	
174-327	47336-47347	association	_	
174-328	47348-47350	of	_	
174-329	47351-47354	DMN	_	
174-330	47355-47364	component	_	
174-331	47365-47369	with	_	
174-332	47370-47375	smoke	_	
174-333	47376-47380	cues	_	
174-334	47381-47386	minus	_	
174-335	47387-47390	for	_	
174-336	47391-47395	food	_	
174-337	47396-47400	cues	_	
174-338	47400-47401	,	_	
174-339	47402-47403	S	_	
174-340	47404-47405	=	_	
174-341	47406-47410	beta	_	
174-342	47411-47414	for	_	
174-343	47415-47421	degree	_	
174-344	47422-47424	of	_	
174-345	47425-47436	association	_	
174-346	47437-47439	of	_	
174-347	47440-47443	DMN	_	
174-348	47444-47453	component	_	
174-349	47454-47458	with	_	
174-350	47459-47464	smoke	_	
174-351	47465-47469	cues	_	
174-352	47469-47470	,	_	
174-353	47471-47472	F	_	
174-354	47473-47474	=	_	
174-355	47475-47479	beta	_	
174-356	47480-47483	for	_	
174-357	47484-47490	degree	_	
174-358	47491-47493	of	_	
174-359	47494-47505	association	_	
174-360	47506-47508	of	_	
174-361	47509-47512	DMN	_	
174-362	47513-47522	component	_	
174-363	47523-47527	with	_	
174-364	47528-47532	food	_	
174-365	47533-47537	cues	_	
174-366	47538-47547	Exploring	_	
174-367	47548-47559	Significant	_	
174-368	47560-47571	Interaction	_	
174-369	47572-47577	Terms	_	
174-370	47578-47579	(	_	
174-371	47579-47589	Smoke-Food	_	
174-372	47589-47590	/	_	
174-373	47590-47595	Smoke	_	
174-374	47595-47596	/	_	
174-375	47596-47600	Food	_	
174-376	47601-47602	×	_	
174-377	47603-47608	RxGrp	_	
174-378	47608-47609	)	_	
174-379	47610-47613	for	_	
174-380	47614-47625	Exploratory	_	
174-381	47626-47636	Components	_	
174-382	47637-47638	(	_	
174-383	47638-47640	SN	_	
174-384	47640-47641	,	_	
174-385	47642-47645	ECN	_	
174-386	47645-47646	)	_	
174-387	47646-47647	:	_	
174-388	47648-47655	Binning	_	
174-389	47656-47658	by	_	
174-390	47659-47663	High	_	
174-391	47664-47667	and	_	
174-392	47668-47671	Low	_	
174-393	47672-47682	Smoke-Food	_	
174-394	47682-47683	/	_	
174-395	47683-47688	Smoke	_	
174-396	47688-47689	/	_	
174-397	47689-47693	Food	_	
174-398	47694-47697	and	_	
174-399	47698-47700	by	_	
174-400	47701-47708	Placebo	_	
174-401	47708-47709	/	_	
174-402	47709-47720	Varenicline	_	
174-403	47723-47727	Full	_	
174-404	47728-47734	Sample	_	
174-405	47735-47740	RxGrp	_	
174-406	47741-47745	Beta	_	
174-407	47746-47747	/	_	
174-408	47748-47751	Exp	_	
174-409	47751-47752	(	_	
174-410	47752-47753	B	_	
174-411	47753-47754	)	_	
174-412	47755-47758	Non	_	
174-413	47759-47766	Imputed	_	
174-414	47767-47773	Sample	_	
174-415	47774-47779	RxGrp	_	
174-416	47780-47784	Beta	_	
174-417	47785-47786	/	_	
174-418	47787-47790	Exp	_	
174-419	47790-47791	(	_	
174-420	47791-47792	B	_	
174-421	47792-47793	)	_	
174-422	47796-47797	R	_	
174-423	47798-47801	ECN	_	
174-424	47802-47807	Smoke	_	
174-425	47808-47809	–	_	
174-426	47810-47814	Food	_	
174-427	47815-47819	High	_	
174-428	47820-47821	R	_	
174-429	47822-47825	ECN	_	
174-430	47826-47827	−	_	
174-431	47827-47832	1.494	_	
174-432	47832-47833	/	_	
174-433	47833-47838	0.224	_	
174-434	47838-47839	*	_	
174-435	47839-47840	*	_	
174-436	47841-47842	−	_	
174-437	47842-47847	1.494	_	
174-438	47847-47848	*	_	
174-439	47848-47849	*	_	
174-440	47849-47850	/	_	
174-441	47850-47855	0.224	_	
174-442	47855-47856	*	_	
174-443	47856-47857	*	_	
174-444	47861-47866	Smoke	_	
174-445	47867-47868	–	_	
174-446	47869-47873	Food	_	
174-447	47874-47877	Low	_	
174-448	47878-47879	R	_	
174-449	47880-47883	ECN	_	
174-450	47884-47885	−	_	
174-451	47885-47890	0.418	_	
174-452	47890-47891	/	_	
174-453	47891-47896	0.658	_	
174-454	47896-47897	^	_	
174-455	47898-47899	−	_	
174-456	47899-47904	0.453	_	
174-457	47904-47905	/	_	
174-458	47905-47910	0.636	_	
174-459	47914-47919	Smoke	_	
174-460	47920-47924	High	_	
174-461	47925-47926	R	_	
174-462	47927-47930	ECN	_	
174-463	47931-47932	−	_	
174-464	47932-47937	0.672	_	
174-465	47937-47938	/	_	
174-466	47938-47943	0.511	_	
174-467	47943-47944	*	_	
174-468	47944-47945	*	_	
174-469	47946-47947	−	_	
174-470	47947-47952	0.898	_	
174-471	47952-47953	/	_	
174-472	47953-47958	0.408	_	
174-473	47958-47959	*	_	
174-474	47959-47960	*	_	
174-475	47964-47969	Smoke	_	
174-476	47970-47973	Low	_	
174-477	47974-47975	R	_	
174-478	47976-47979	ECN	_	
174-479	47980-47981	−	_	
174-480	47981-47986	0.450	_	
174-481	47986-47987	/	_	
174-482	47987-47992	0.637	_	
174-483	47992-47993	*	_	
174-484	47994-47995	−	_	
174-485	47995-48000	0.384	_	
174-486	48000-48001	/	_	
174-487	48001-48006	0.681	_	
174-488	48009-48010	L	_	
174-489	48011-48014	ECN	_	
174-490	48015-48020	Smoke	_	
174-491	48021-48022	–	_	
174-492	48023-48027	Food	_	
174-493	48028-48032	High	_	
174-494	48033-48034	L	_	
174-495	48035-48038	ECN	_	
174-496	48039-48040	−	_	
174-497	48040-48045	0.675	_	
174-498	48045-48046	/	_	
174-499	48046-48051	0.509	_	
174-500	48051-48052	*	_	
174-501	48052-48053	*	_	
174-502	48054-48055	−	_	
174-503	48055-48060	0.772	_	
174-504	48060-48061	/	_	
174-505	48061-48066	0.462	_	
174-506	48066-48067	*	_	
174-507	48071-48076	Smoke	_	
174-508	48077-48078	–	_	
174-509	48079-48083	Food	_	
174-510	48084-48087	Low	_	
174-511	48088-48089	L	_	
174-512	48090-48093	ECN	_	
174-513	48094-48095	−	_	
174-514	48095-48100	0.220	_	
174-515	48100-48101	/	_	
174-516	48101-48106	0.802	_	
174-517	48107-48108	−	_	
174-518	48108-48113	0.011	_	
174-519	48113-48114	/	_	
174-520	48114-48119	0.989	_	
174-521	48122-48124	SN	_	
174-522	48125-48130	Smoke	_	
174-523	48131-48132	–	_	
174-524	48133-48137	Food	_	
174-525	48138-48142	High	_	
174-526	48143-48145	SN	_	
174-527	48146-48147	−	_	
174-528	48147-48152	0.527	_	
174-529	48152-48153	/	_	
174-530	48153-48158	0.590	_	
174-531	48158-48159	*	_	
174-532	48160-48161	−	_	
174-533	48161-48166	0.669	_	
174-534	48166-48167	/	_	
174-535	48167-48172	0.512	_	
174-536	48172-48173	*	_	
174-537	48173-48174	*	_	
174-538	48178-48183	Smoke	_	
174-539	48184-48185	–	_	
174-540	48186-48190	Food	_	
174-541	48191-48194	Low	_	
174-542	48195-48197	SN	_	
174-543	48198-48199	−	_	
174-544	48199-48204	0.502	_	
174-545	48204-48205	/	_	
174-546	48205-48210	0.605	_	
174-547	48210-48211	*	_	
174-548	48211-48212	*	_	
174-549	48213-48214	−	_	
174-550	48214-48219	1.074	_	
174-551	48219-48220	/	_	
174-552	48220-48225	0.342	_	
174-553	48225-48226	*	_	
174-554	48226-48227	*	_	
174-555	48231-48235	Food	_	
174-556	48236-48240	High	_	
174-557	48241-48243	SN	_	
174-558	48244-48245	−	_	
174-559	48245-48250	0.550	_	
174-560	48250-48251	/	_	
174-561	48251-48256	0.577	_	
174-562	48256-48257	*	_	
174-563	48258-48259	−	_	
174-564	48259-48264	0.987	_	
174-565	48264-48265	/	_	
174-566	48265-48270	0.373	_	
174-567	48270-48271	*	_	
174-568	48271-48272	*	_	
174-569	48276-48280	Food	_	
174-570	48281-48284	Low	_	
174-571	48285-48287	SN	_	
174-572	48288-48289	−	_	
174-573	48289-48294	0.477	_	
174-574	48294-48295	/	_	
174-575	48295-48300	0.620	_	
174-576	48300-48301	*	_	
174-577	48302-48303	−	_	
174-578	48303-48308	0.289	_	
174-579	48308-48309	/	_	
174-580	48309-48314	0.749	_	
174-581	48319-48323	Full	_	
174-582	48324-48339	SampleComponent	_	
174-583	48340-48344	Beta	_	
174-584	48345-48346	/	_	
174-585	48347-48350	Exp	_	
174-586	48350-48351	(	_	
174-587	48351-48352	B	_	
174-588	48352-48353	)	_	
174-589	48354-48357	Non	_	
174-590	48358-48365	Imputed	_	
174-591	48366-48381	SampleComponent	_	
174-592	48382-48386	Beta	_	
174-593	48387-48388	/	_	
174-594	48389-48392	Exp	_	
174-595	48392-48393	(	_	
174-596	48393-48394	B	_	
174-597	48394-48395	)	_	
174-598	48398-48399	R	_	
174-599	48400-48403	ECN	_	
174-600	48404-48409	Smoke	_	
174-601	48410-48411	–	_	
174-602	48412-48416	Food	_	
174-603	48417-48424	Placebo	_	
174-604	48425-48430	0.049	_	
174-605	48430-48431	/	_	
174-606	48431-48436	1.050	_	
174-607	48437-48442	0.125	_	
174-608	48442-48443	/	_	
174-609	48443-48448	1.133	_	
174-610	48452-48457	Smoke	_	
174-611	48458-48459	–	_	
174-612	48460-48464	Food	_	
174-613	48465-48476	Varenicline	_	
174-614	48477-48478	−	_	
174-615	48478-48483	1.053	_	
174-616	48483-48484	/	_	
174-617	48484-48489	0.349	_	
174-618	48489-48490	*	_	
174-619	48490-48491	*	_	
174-620	48492-48493	−	_	
174-621	48493-48498	1.351	_	
174-622	48498-48499	/	_	
174-623	48499-48504	0.259	_	
174-624	48504-48505	*	_	
174-625	48505-48506	*	_	
174-626	48510-48515	Smoke	_	
174-627	48516-48523	Placebo	_	
174-628	48524-48529	0.558	_	
174-629	48529-48530	/	_	
174-630	48530-48535	1.747	_	
174-631	48535-48536	^	_	
174-632	48537-48542	0.554	_	
174-633	48542-48543	/	_	
174-634	48543-48548	1.740	_	
174-635	48552-48557	Smoke	_	
174-636	48558-48569	Varenicline	_	
174-637	48570-48571	−	_	
174-638	48571-48576	0.186	_	
174-639	48576-48577	/	_	
174-640	48577-48582	0.830	_	
174-641	48583-48588	0.076	_	
174-642	48588-48589	/	_	
174-643	48589-48594	1.079	_	
174-644	48597-48598	L	_	
174-645	48599-48602	ECN	_	
174-646	48603-48608	Smoke	_	
174-647	48609-48610	–	_	
174-648	48611-48615	Food	_	
174-649	48616-48623	Placebo	_	
174-650	48624-48629	0.039	_	
174-651	48629-48630	/	_	
174-652	48630-48635	1.039	_	
174-653	48636-48641	0.864	_	
174-654	48641-48642	/	_	
174-655	48642-48647	2.372	_	
174-656	48647-48648	*	_	
174-657	48652-48657	Smoke	_	
174-658	48658-48659	–	_	
174-659	48660-48664	Food	_	
174-660	48665-48676	Varenicline	_	
174-661	48677-48678	−	_	
174-662	48678-48683	0.198	_	
174-663	48683-48684	/	_	
174-664	48684-48689	0.820	_	
174-665	48690-48691	−	_	
174-666	48691-48696	0.410	_	
174-667	48696-48697	/	_	
174-668	48697-48702	0.664	_	
174-669	48705-48707	SN	_	
174-670	48708-48713	Smoke	_	
174-671	48714-48715	–	_	
174-672	48716-48720	Food	_	
174-673	48721-48728	Placebo	_	
174-674	48729-48730	−	_	
174-675	48730-48735	0.235	_	
174-676	48735-48736	/	_	
174-677	48736-48741	0.791	_	
174-678	48742-48743	−	_	
174-679	48743-48748	0.693	_	
174-680	48748-48749	/	_	
174-681	48749-48754	0.500	_	
174-682	48754-48755	^	_	
174-683	48759-48764	Smoke	_	
174-684	48765-48766	–	_	
174-685	48767-48771	Food	_	
174-686	48772-48783	Varenicline	_	
174-687	48784-48789	0.401	_	
174-688	48789-48790	/	_	
174-689	48790-48795	1.493	_	
174-690	48796-48801	1.082	_	
174-691	48801-48802	/	_	
174-692	48802-48807	2.952	_	
174-693	48811-48815	Food	_	
174-694	48816-48823	Placebo	_	
174-695	48824-48829	0.286	_	
174-696	48829-48830	/	_	
174-697	48830-48835	1.332	_	
174-698	48836-48841	0.550	_	
174-699	48841-48842	/	_	
174-700	48842-48847	1.734	_	
174-701	48851-48855	Food	_	
174-702	48856-48867	Varenicline	_	
174-703	48868-48869	−	_	
174-704	48869-48874	0.521	_	
174-705	48874-48875	/	_	
174-706	48875-48880	0.594	_	
174-707	48881-48882	−	_	
174-708	48882-48887	1.314	_	
174-709	48887-48888	/	_	
174-710	48888-48893	0.269	_	
174-711	48893-48894	*	_	
174-712	48898-48899	p	_	
174-713	48899-48900	<	_	
174-714	48900-48903	0.1	_	
174-715	48904-48915	Significant	_	
174-716	48916-48918	at	_	
174-717	48919-48920	p	_	
174-718	48921-48922	<	_	
174-719	48923-48927	0.05	_	
174-720	48928-48939	Significant	_	
174-721	48940-48942	at	_	
174-722	48943-48944	p	_	
174-723	48945-48946	<	_	
174-724	48947-48951	0.01	_	
174-725	48952-48956	High	_	
174-726	48957-48960	and	_	
174-727	48961-48964	Low	_	
174-728	48965-48971	groups	_	
174-729	48972-48975	for	_	
174-730	48976-48980	each	_	
174-731	48981-48983	of	_	
174-732	48984-48987	the	_	
174-733	48988-48998	components	_	
174-734	48999-49005	during	_	
174-735	49006-49016	Smoke-Food	_	
174-736	49016-49017	,	_	
174-737	49018-49023	Smoke	_	
174-738	49023-49024	,	_	
174-739	49025-49027	or	_	
174-740	49028-49032	Food	_	
174-741	49033-49037	were	_	
174-742	49038-49045	derived	_	
174-743	49046-49048	by	_	
174-744	49049-49054	doing	_	
174-745	49055-49056	a	_	
174-746	49057-49063	median	_	
174-747	49064-49069	split	_	
174-748	49070-49072	on	_	
174-749	49073-49076	the	_	
174-750	49077-49082	betas	_	
174-751	49082-49083	.	_	

#Text=Exp(B) = exponential beta, ECN = executive control network, SN = Salience Network, R = right, L = left, Smoke - Food = beta for degree of association of component with smoke cues minus for food cues, Smoke = beta for degree of association of component with smoke cues, Food = beta for degree of association of component with food cues, RxGrp = Medication Condition (varenicline = 1, placebo = 0).
175-1	49084-49087	Exp	_	
175-2	49087-49088	(	_	
175-3	49088-49089	B	_	
175-4	49089-49090	)	_	
175-5	49091-49092	=	_	
175-6	49093-49104	exponential	_	
175-7	49105-49109	beta	_	
175-8	49109-49110	,	_	
175-9	49111-49114	ECN	_	
175-10	49115-49116	=	_	
175-11	49117-49126	executive	_	
175-12	49127-49134	control	_	
175-13	49135-49142	network	_	
175-14	49142-49143	,	_	
175-15	49144-49146	SN	_	
175-16	49147-49148	=	_	
175-17	49149-49157	Salience	_	
175-18	49158-49165	Network	_	
175-19	49165-49166	,	_	
175-20	49167-49168	R	_	
175-21	49169-49170	=	_	
175-22	49171-49176	right	_	
175-23	49176-49177	,	_	
175-24	49178-49179	L	_	
175-25	49180-49181	=	_	
175-26	49182-49186	left	_	
175-27	49186-49187	,	_	
175-28	49188-49193	Smoke	_	
175-29	49194-49195	-	_	
175-30	49196-49200	Food	_	
175-31	49201-49202	=	_	
175-32	49203-49207	beta	_	
175-33	49208-49211	for	_	
175-34	49212-49218	degree	_	
175-35	49219-49221	of	_	
175-36	49222-49233	association	_	
175-37	49234-49236	of	_	
175-38	49237-49246	component	_	
175-39	49247-49251	with	_	
175-40	49252-49257	smoke	_	
175-41	49258-49262	cues	_	
175-42	49263-49268	minus	_	
175-43	49269-49272	for	_	
175-44	49273-49277	food	_	
175-45	49278-49282	cues	_	
175-46	49282-49283	,	_	
175-47	49284-49289	Smoke	_	
175-48	49290-49291	=	_	
175-49	49292-49296	beta	_	
175-50	49297-49300	for	_	
175-51	49301-49307	degree	_	
175-52	49308-49310	of	_	
175-53	49311-49322	association	_	
175-54	49323-49325	of	_	
175-55	49326-49335	component	_	
175-56	49336-49340	with	_	
175-57	49341-49346	smoke	_	
175-58	49347-49351	cues	_	
175-59	49351-49352	,	_	
175-60	49353-49357	Food	_	
175-61	49358-49359	=	_	
175-62	49360-49364	beta	_	
175-63	49365-49368	for	_	
175-64	49369-49375	degree	_	
175-65	49376-49378	of	_	
175-66	49379-49390	association	_	
175-67	49391-49393	of	_	
175-68	49394-49403	component	_	
175-69	49404-49408	with	_	
175-70	49409-49413	food	_	
175-71	49414-49418	cues	_	
175-72	49418-49419	,	_	
175-73	49420-49425	RxGrp	_	
175-74	49426-49427	=	_	
175-75	49428-49438	Medication	_	
175-76	49439-49448	Condition	_	
175-77	49449-49450	(	_	
175-78	49450-49461	varenicline	_	
175-79	49462-49463	=	_	
175-80	49464-49465	1	_	
175-81	49465-49466	,	_	
175-82	49467-49474	placebo	_	
175-83	49475-49476	=	_	
175-84	49477-49478	0	_	
175-85	49478-49479	)	_	
175-86	49479-49480	.	_	

#Text=Other predictors were included in these models (specifics in Supporting Information) but results not reported here for simplicity.
176-1	49481-49486	Other	_	
176-2	49487-49497	predictors	_	
176-3	49498-49502	were	_	
176-4	49503-49511	included	_	
176-5	49512-49514	in	_	
176-6	49515-49520	these	_	
176-7	49521-49527	models	_	
176-8	49528-49529	(	_	
176-9	49529-49538	specifics	_	
176-10	49539-49541	in	_	
176-11	49542-49552	Supporting	_	
176-12	49553-49564	Information	_	
176-13	49564-49565	)	_	
176-14	49566-49569	but	_	
176-15	49570-49577	results	_	
176-16	49578-49581	not	_	
176-17	49582-49590	reported	_	
176-18	49591-49595	here	_	
176-19	49596-49599	for	_	
176-20	49600-49610	simplicity	_	
176-21	49610-49611	.	_	
